Methods of making peptides and compositions having the same

Abstract

Provided herein are methods and compositions for providing a peptide. The methods and compositions provided herein comprise peptides with a purity of about 80% or more. The peptide compositions provided herein may be used in further cosmetic or dermatological applications.

Description

DESCRIPTION METHODS OF MAKING PEPTIDES AND COMPOSITIONS HAVING THE SAMETECHNICAL FIELD

[0001] The present disclosure relates to the synthesis of peptides with improved yields and purity. The methods involve peptide synthesis and utilize various protecting groups and coupling reagents to achieve high yields and purity. The resulting peptides find utility in a variety of fields including cosmetic composition, in particular skin, hair, nail, and / or scalp compositions.

[0002] The present disclosure also relates to methods and compositions for providing a peptide. The methods and compositions provided herein comprise peptides with a purity of 80% or more, preferably 85%. The peptide compositions provided herein may be used in further cosmetic or dermatological applications.BACKGROUND OF THE DISCLOSURE

[0003] Hair is composed of approximately 65% to 95% protein. The remaining constituents include water, lipids, pigments and trace elements. A majority of the proteins present in human hair correspond to keratin and keratin-associated proteins.

[0004] Peptides, proteins, amino acids and its derivatives have also been used in compositions for personal care products, namely hair conditioning and strengthening.

[0005] Document WO 2023 / 250104 A2 and WO 2023 / 250105 Al discloses detoxifying hair and scalp cleanser compositions that comprises peptides for cleansing and repairing hair or scalp.

[0006] Document WO 2020 / 031150 Al discloses a composition comprising a synthetic peptide for modifying the characteristics of hair.

[0007] Document WO 2015 / 056216 A2 also discloses a peptide composition for the treatment of hair.

[0008] Peptides are essential components in various fields including cosmetics. They offer a wide range of benefits, particularly in skincare, haircare, nail care, and scalp treatments. However, traditional methods for peptide synthesis often suffer from low yields and impurities, which can compromise the efficacy and safety of the final products. Therefore, there is a need for improved methods for synthesizing peptides with enhanced yields and purity.

[0009] These facts are disclosed in order to illustrate the technical problem addressed by the present disclosure.G E N ERAL DESCRI PTI ON

[0010] There is a need for improved methods of making peptides with increased yield purity and compositions comprising the same. Improved peptides can promote healthy hair with improved growth,resistance, elasticity. In an aspect, the present disclosure provides a method for providing a peptide, the method comprising: joining a first fragment of the peptide and a second fragment of the peptide, wherein 1-5 amino acids of the peptide are cysteine amino acids, and about 15% to about 50% of the amino acids of the peptide are cysteine amino acids, wherein the first fragment is represented by the Formula (l-A): (NA-A-CA)m (Formula l-A), wherein the second fragment is represented by the Formula (l-B): (NB-B-CB)p (Formula l-B), wherein: NA is the N-terminus of the first fragment, A is one or more amino acids and up to 32 amino acids, CA is the C-terminus of the first fragment, NB is the N-terminus of the second fragment, B is one or more amino acids and up to 32 amino acids, CB is the C-terminus of the second fragment, m is an integer from 1 to 32, p is an integer from 1 to 32, and the peptide is represented by the Formula (l-C') or (l-C"): NA-A-CA-NB-B-CB Formula l-C', or NB-B-CB-NA-A-CA Formula l-C", and separating the peptide, thereby providing the peptide with a purity of at least about 80% wt.[Oil] An aspect of the present disclosure relates to a method for providing a peptide wherein the method comprises the following steps: joining a first fragment of the peptide and a second fragment of the peptide in a solution or resin; wherein the first fragment is represented by the Formula (l-A):(NA-A-CAJRI(Formula l-A), wherein the second fragment is represented by the Formula (l-B):(NB-B-CB)P(Formula l-B), wherein:NA is the N-terminus of the first fragment,A is one or more amino acids and up to 32 amino acids, preferably up to 20 amino acids;CA is the C-terminus of the first fragment, NBis the N-terminus of the second fragment, B is one or more amino acids and up to 32 amino acids, preferably up to 20 amino acids;CBis the C-terminus of the second fragment, m is an integer from 1 to 32, preferably 1-10; p is an integer from 1 to 32, preferably 1-10 and; the peptide is represented by the Formula (l-C') or (l-C"):NA-A-CA-NB-B-CBFormula l-C', orNB-B-CB-NA-A-CAFormula l-C", and separating the obtained peptide from the solution, thereby providing the peptide with a purity of at least about 80% wt; wherein 1-5 amino acids of the obtained peptide are cysteine amino acids, and about 15% to about 50% of the amino acids of the peptide are cysteine amino acids; wherein the first fragment comprises a sequence of about 10% to about 90% the length of the peptide; wherein the second fragment comprises a sequence of about 10% to about 90% the length of the peptide.

[0012] Surprisingly, the method of the present disclosure provides a peptide with a purity of at least about 80% wt, namely when producing mid-length peptides (preferably 15 and 32 bases), particularly avoiding aggregation and purification issues, mitigating these problems. The obtained purity is particularly advantageous for cosmetic and skincare applications.

[0013] Unexpectedly, the disclosed method incorporates a green manufacturing approach that minimizes the use of organic solvents or environmentally harmful chemicals. This sustainable aspect is an inventive improvement over traditional chemical synthesis methods, offering both environmental and efficiency benefits.

[0014] In some embodiments, wherein the peptide comprises at least one hydrophobic amino acid residue and wherein each of the at least one hydrophobic amino acid residues is independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan.

[0015] In some embodiments, the peptide is about 1-30 amino acid residues in length. In some embodiments, the peptide is about 6-20 amino acid residues in length; more preferably wherein the peptide is about 10-15 amino acid residues in length.

[0016] In some embodiments, the peptide is about 6-22 amino acid residues in length, preferably wherein the peptide is about 7-20 amino acid residues in length.

[0017] In some embodiments, the first fragment has 3-9 amino acids, preferably wherein the first fragment has 5-7 amino acids.

[0018] In some embodiments, the second fragment has 4-13 amino acids, preferably wherein the second fragment has 4-9 amino acids.

[0019] In some embodiments, the first fragment comprises a sequence of at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% a length of the peptide. In some embodiments, the first fragment comprises a sequence of about 10% to about 90% the length of the peptide.

[0020] In some embodiments, the second fragment comprises a sequence of at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% the length of the peptide.

[0021] In some embodiments, the peptide has an amino acid content of about 25% to about 50% cysteine. In some embodiments, the peptide has 2-5 cysteines. In some embodiments, the peptide comprises atleast one hydrophobic amino acid residue. In some embodiments, the peptide has a hydrophobic amino acid content of about 5% to about 80%. In some embodiments, each of the at least one hydrophobic amino acid residues is independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan.

[0022] In some embodiments, the peptide has a general hydrophobic amino acid content of about 5% to about 80%.

[0023] In some embodiments, the peptide comprises the sequence of any one of SEQ ID NOs: 1-1368, preferably wherein the peptide comprises the sequence of SEQ. ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 23, SEQ ID NO: 98, SEQ ID NO: 230, SEQ ID NO: 450, SEQ ID NO: 467, SEQ ID NO: 506, SEQ ID NO: 691, SEQ ID NO: 718 .

[0024] In some embodiments, the peptide comprises the sequence of any one of SEQ ID NOs: 1-192 and 239-456. In some embodiments, the peptide comprises the sequence of SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 23, or a fragment thereof.

[0025] In some embodiments, the peptide has a purity of about 85% wt., about 90% wt., about 95% wt., about 97% wt., about 98% wt., about 99% wt., or about 100% wt. In some embodiments, the peptide has a purity of about 85% wt. In some embodiments, the peptide has a purity of about 90% wt. In some embodiments, the peptide has a purity of about 95% wt. In some embodiments, the peptide has a purity of about 97% wt. In some embodiments, the peptide has a purity of about 98% wt. In some embodiments, the peptide has a purity of about 99% wt. In some embodiments, the peptide has a purity of about 100% wt.

[0026] In some embodiments, the peptide comprises a protecting group. In some embodiments, an amino acid side chain of at least one of the peptide fragments comprises a protecting group. In some embodiments, the protecting group is benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tertbutyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2,2,4,6,-7-pentamethyl-2,3- dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm). In some embodiments, the protecting group is Fmoc, Cbz, Trt, or Boc.

[0027] In some embodiments, each of NA and NB comprises a protecting group, wherein each protecting group is 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butyloxycarbonyl (Boc). In some embodiments, each of CA and CB comprises a protecting group, wherein each protecting group is t-butyl (tBu), Trt, 2,4- dimethoxybenzyl (Dmb), 9-fluorenylmethyl (Fm), or benzyl (Bn). In some embodiments, the method further comprises contacting the peptide with an acidic solution to provide a deprotected peptide.

[0028] In some embodiments, the first fragment has 1-2 cysteine residues, and an amino acid content of about 10% to about 85% cysteine. In some embodiments, the first fragment has 1-5 cysteine residues, and an amino acid content of about 15% to about 45% cysteine. In some embodiments, the first fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 25-456. In some embodiments, thefirst fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 25-240. In some embodiments, the first fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 241- 456.

[0029] In some embodiments, the first fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 25-456; preferably 90% sequence identity; more preferably 95% sequence identity; even more preferably identical.

[0030] In some embodiments, the first fragment has at least 1 amino acid. In some embodiments, the first fragment has 3-9 amino acids. In some embodiments, the first fragment has at least about 70% sequence identity to any one of SEQ. ID Nos: 25-240.

[0031] In some embodiments, the first fragment comprises at least one hydrophobic amino acid residue. In some embodiments, each of the at least one hydrophobic amino acid residues is independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan. In some embodiments, about 5% to about 85% of the amino acids of the first fragment are hydrophobic amino acids.

[0032] In some embodiments, a side chain of an amino acid residue of the first fragment comprises a protecting group.

[0033] In some embodiments, the first fragment has 4 amino acids and any one of SEQ ID Nos: 217-240. In some embodiments, the first fragment has 5 amino acids and any one of SEQ ID Nos: 193-216. In some embodiments, the first fragment has 6 amino acids and any one of SEQ ID Nos: 169-192. In some embodiments, the first fragment has 7 amino acids and any one of SEQ ID Nos: 145-168. In some embodiments, the first fragment has 8 amino acids and any one of SEQ ID Nos: 121-144. In some embodiments, the first fragment has 9 amino acids and any one of SEQ ID Nos: 97-120. In some embodiments, the first fragment has 10 amino acids and any one of SEQ ID Nos: 73-96. In some embodiments, the first fragment has 11 amino acids and any one of SEQ ID Nos: 49-72. In some embodiments, the first fragment has 12 amino acids and any one of SEQ ID Nos: 25-48.

[0034] In some embodiments, the second fragment has 1 or 2 cysteine residues, and an amino acid content of about 10% to about 85% cysteine.

[0035] In some embodiments, the second fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 25-456. In some embodiments, the second fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 25-240. In some embodiments, the second fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 241-456.

[0036] In some embodiments, the second fragment has 4-13 amino acids. In some embodiments, the second fragment has 4-9 amino acids. In some embodiments, the second fragment has at least about 70% sequence identity to any one of SEQ ID Nos: 25-240.

[0037] In some embodiments, the second fragment comprises at least one hydrophobic amino acid residue. In some embodiments, each of the at least one hydrophobic amino acid residues is independentlyglycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan. In some embodiments, the second fragment has about 5% to about 85% hydrophobic amino acid content.

[0038] In some embodiments, the second fragment has 4 amino acids and any one of SEQ ID Nos: 217- 240. In some embodiments, the second fragment has 5 amino acids and any one of SEQ. ID Nos: 193-216. In some embodiments, the second fragment has 6 amino acids and any one of SEQ ID Nos: 169-192. In some embodiments, the second fragment has 7 amino acids and any one of SEQ ID Nos: 145-168. In some embodiments, the second fragment has 8 amino acids and any one of SEQ ID Nos: 121-144. In some embodiments, the second fragment has 9 amino acids and any one of SEQ ID Nos: 97-120. In some embodiments, the second fragment has 10 amino acids and any one of SEQ ID Nos: 73-96. In some embodiments, the second fragment has 11 amino acids and any one of SEQ ID Nos: 49-72. In some embodiments, the second fragment has 12 amino acids and any one of SEQ ID Nos: 25-48.

[0039] In some embodiments, the side chain of an amino acid residue of the second fragment comprises a protecting group. In some embodiments, the protecting group is benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), Boc, Fmoc, trityl (Trt), 2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm).

[0040] In some embodiments, when NA comprises a protecting group, then NB comprises a free thiol of a cysteine and CA comprises a thioether. In some embodiments, when NB comprises a protecting group, then NA comprises a free thiol of a cysteine and CB comprises a thioether.

[0041] In some embodiments, the first fragment comprises the sequence: ILA, IGV, AVP, VCC, SCG, GGV, GSC, CQPV (SEQ ID NO.: 251), GGTN (SEQ ID NO.: 252), VGAS (SEQ ID NO.: 260), GGCQ (SEQ ID NO.: 264), GSVSS (SEQ ID NO.: 266), CAPVY (SEQ ID NO.: 277), CFQPT (SEQ ID NO.: 269), CGGSG (SEQ ID NO.: 270), ASCGV (SEQ ID NO.: 273), LLGNP (SEQ ID NO.: 279), CGYGSG (SEQ ID NO.: 298), SCGCSQ (SEQ ID NO.: 305), GGVCLP (SEQ ID NO.: 306), GCISSS (SEQ ID NO.: 309), GGCQCS (SEQ ID NO.: 312), LCEPAIG (SEQ ID NO.: 316), ASECGSG (SEQ ID NO.: 320), GSCVTNP (SEQ ID NO.: 326), VCCCVPA (SEQ ID NO.: 328), GCISSSC (SEQ ID NO.: 333), GGCQCSC (SEQ ID NO.: 336), ILACAPIY (SEQ ID NO.: 337), CGYGSGCG (SEQ ID NO.: 346), SCGCSQCN (SEQ ID NO.: 353), LLCEPAIG (SEQ ID NO.: 358), GSVSSCQPS (SEQ ID NO.: 362), CAPVYCRRT (SEQ ID NO.: 363), CFQPTCVYS (SEQ ID NO.: 365), CGGSGCGGS (SEQ ID NO.: 366), IGVCGPSPP (SEQ ID NO.: 367), CQPVCPTPT (SEQ ID NO.: 371), AVPCVPSVP (SEQ ID NO.: 373), VCCCVPACS (SEQ ID NO.: 376), SCGCSQCNC (SEQ ID NO.: 377), GGVCGPSPP (SEQ ID NO.: 379), VGASCVSLL (SEQ ID NO.: 380), GSCCAPPVY (SEQ ID NO.: 383), ASCGVCLPST (SEQ ID NO.: 393), GGTNCSPRPI (SEQ ID NO.: 396), LLGNPCSTPS (SEQ ID NO.: 399), GCISSSCCPS (SEQ ID NO.: 405), GSCCAPPVYC (SEQ ID NO.: 407), LCEPAIGCEPS (SEQ ID NO.: 412), GCISSSCCPSC (SEQ ID NO.: 429), GGCQCSCCKPY (SEQ ID NO.:432), ILACAPIYCRRT (SEQ ID NO.: 433), ASECGSGCGVPV (SEQ ID NO.: 440), GGVCLPCLPAAS (SEQ ID NO.: 450), GCISSSCCPSCC (SEQ ID NO.: 453), LLCEPAIGCEPS (SEQ ID NO.: 454), or any combination thereof .

[0042] In some embodiments, the second fragment comprises the sequence: CEPAIGCEPSCG (SEQ ID NO.: 28), CCCVPACSCSVG (SEQ. ID NO.: 40), CGCSQCNCCKGG (SEQ ID NO.: 41), CGVCLPSTCPL (SEQ ID NO.: 57), CVTNPCGPIIG (SEQ ID NO.: 62), CCVPACSCSVG (SEQ ID NO.: 64), CISSSCCPSCC (SEQ ID NO.: 69), CEPAIGCEPSC (SEQ ID NO.: 70), CCAPPVYCCKL (SEQ ID NO.: 71), CQCSCCKPYCS (SEQ ID NO.: 72), CAPIYCRRTC (SEQ ID NO.: 73), CGPSPPCITS (SEQ ID NO.: 79), CGSGCGVPVC (SEQ ID NO.: 80), CVPSVPCTPG (SEQ ID NO.: 85), CVPACSCSVG (SEQ ID NO.: 88), CSQCNCCKGG (SEQ ID NO.: 89), CLPCLPAASC (SEQ ID NO.: 90), CGPSPPCITT (SEQ ID NO.: 91), CAPPVYCCKL (SEQ ID NO.: 95), CPTPTCGVG (SEQ ID NO.: 107), CSPRPICVG (SEQ ID NO.: 108), CSTPSCTTG (SEQ ID NO.: Ill), CSCCKPYCS (SEQ ID NO.: 120), CQPSCSEA (SEQ ID NO.: 122), CRRTCGGV (SEQ ID NO.: 123), CVYSCHHG (SEQ ID NO.: 125), CLPSTCPL (SEQ ID NO.: 129), CVSLLCRP (SEQ ID NO.: 140), CGCGIIL (SEQ ID NO.: 154), CNCCKGG (SEQ ID NO.: 161), CLPAASC (SEQ ID NO.: 162), CCKPYCS (SEQ ID NO.: 168), CEPSCG (SEQ ID NO.: 172), CGVPVC (SEQ ID NO.: 176), CGPIIG (SEQ ID NO.: 182), CSCSVG (SEQ ID NO.: 184), CCPSCC (SEQ ID NO.: 189), CKPYCS (SEQ ID NO.: 192), CRRTC (SEQ ID NO.: 193), CGIIL (SEQ ID NO.: 202), CCKGG (SEQ ID NO.: 209), CPSCC (SEQ ID NO.:213), CEPSC (SEQ ID NO.: 214), CSEA (SEQ ID NO.: 218), CGGV (SEQ ID NO.: 219), CHHG (SEQ ID NO.: 221), CHSL (SEQ ID NO.: 222), CITS (SEQ ID NO.: 223), CGVG (SEQ ID NO.: 227), CTPG (SEQ ID NO.: 229), CTTG (SEQ ID NO.: 231), CSVG (SEQ ID NO.: 232), CKGG (SEQ ID NO.: 233), CITT (SEQ ID NO.: 235), CCKL (SEQ ID NO.: 239), or any combination thereof.

[0043] In some embodiments, the first and the second fragment are the same or different.

[0044] In some embodiments, when NA comprises a protecting group, then CB is bound to a resin. In some embodiments, when NB comprises a protecting group, then CA is bound to a resin. In some embodiments, when NB comprises a selenocysteine, then CA comprises a thioester or selenoester. In some embodiments, when NA comprises a selenocysteine, then CB comprises a thioester or selenoester. In some embodiments, joining the first fragment and the second fragment comprises contacting the NB of the second fragment and the CA of the first fragment to provide a selenium-containing peptide. In some embodiments, joining the first fragment and the second fragment comprises contacting the NA of the first fragment and the CB of the second fragment to provide a selenium-containing peptide.

[0045] In some embodiments, the method further comprises reacting the selenium-containing peptide with a phosphine to provide a serine-containing peptide. In some embodiments, the method further comprises reacting the selenium-containing peptide with a phosphine to provide an alanine-containing peptide. In some embodiments, the method further comprises reacting the selenium-containing peptide with a phosphine and a radical initiator to provide an alanine-containing peptide. In some embodiments, the phosphine is tris(2-carboxyethyl)phosphine (TCEP).

[0046] In some embodiments, CA comprises an acyl halide. In some embodiments, CA comprises a C- terminal acyl chloride.

[0047] In some embodiments, the first fragment comprises a sequence having at least about 70% sequence identity to any one of SEQ ID NOs: 241-456.

[0048] In some embodiments, NB comprises an unprotected N-terminal amine.

[0049] In some embodiments, the second fragment comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 25-240.

[0050] In some embodiments, joining the first fragment and the second fragment comprises contacting the NB of the second fragment and the CA of the first fragment. In some embodiments, CA comprises an unprotected C-terminal carboxylate group.

[0051] In some embodiments, the first fragment comprises a sequence having at least about 70% sequence identity to any one of SEQ. ID NOs: 241-456.

[0052] In some embodiments, the method further comprises contacting the first fragment comprising the unprotected C-terminal carboxylate group with an agent to provide an activated ester. In some embodiments, the agent comprises a carbodiimide. In some embodiments, the carbodiimide comprises dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), or N,N'- diisopropylcarbodiimide (DIC), or a combination or two or more thereof. In some embodiments, the agent comprises hydroxybenzotriazole (HOBt), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N'- diisopropylcarbodiimide (DIC), l-hydroxy-7-azabenzotriazole (HOAt), or 4-dimethylaminopyridine (DMAP), or a combination of two or more thereof.

[0053] In some embodiments, NB is an unprotected N-terminal amine.

[0054] In some embodiments, the method further comprises contacting the unprotected N-terminal amine of the second fragment with the activated ester to provide the peptide. In some embodiments, the second fragment comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 25-240.

[0055] In some embodiments, joining the first fragment and the second fragment comprises contacting the NB of the second fragment and the CA of the first fragment.

[0056] In an aspect, the present disclosure provides a composition comprising a peptide, wherein the peptide is present in the composition with a purity of about 85% or more and the peptide comprises a sequence having at least about 70% sequence identity to any one of SEQ ID NOs: 1-18 and 20-456.

[0057] In some embodiments, the peptide comprises a sequence having at least about 85% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 95% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 97% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 98% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 99% sequence identity to any one of SEQ ID NOs: 1-18 and20-1368, or wherein the peptide comprises a sequence having at least about 100% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368; wherein the peptide is not SEQ ID NO: 19.

[0058] In some embodiments, the peptide is present in the composition with a purity of about 85% or more and the peptide comprises a sequence having at least about 90% sequence identity to any one of SEQ. ID NOs: 1-18 and 20-456, preferably wherein the peptide is present in the composition with a purity of about 90% or more; more preferably wherein the peptide is present in the composition with a purity of about 95% to about 100%.

[0059] In some embodiments, the peptide is present in the composition with a purity of about 90% or more. In some embodiments, the peptide is present in the composition with a purity of about 95% or more. In some embodiments, the peptide is present in the composition with a purity of about 97% or more. In some embodiments, the peptide is present in the composition with a purity of about 98% or more. In some embodiments, the peptide is present in the composition with a purity of about 99% or more. In some embodiments, the peptide is present in the composition with a purity of about 100%. In some embodiments, the peptide is present in the composition with a purity of about 85% to about 100%. In some embodiments, the peptide is present in the composition with a purity of about 90% to about 100%. In some embodiments, the peptide is present in the composition with a purity of about 95% to about 100%.

[0060] The purity may be assessed using traditional methods, namely chromatography methods, e.g., high-performance liquid chromatography (HPLC).

[0061] In some embodiments, the peptide comprises a sequence having at least about 85% sequence identity to any one of SEQ ID NOs: 1-1368. In some embodiments, the peptide comprises a sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 1-1368. In some embodiments, the peptide comprises a sequence having at least about 95% sequence identity to any one of SEQ ID NOs: 1-1368. In some embodiments, the peptide comprises a sequence having at least about 97% sequence identity to any one of SEQ ID NOs: 1-1368. In some embodiments, the peptide comprises a sequence having at least about 98% sequence identity to any one of SEQ ID NOs: 1-1368. In some embodiments, the peptide comprises a sequence having at least about 99% sequence identity to any one of SEQ ID NOs: 1-1368. In some embodiments, the peptide comprises a sequence having at least about 100% sequence identity to any one of SEQ ID NOs: 1-1368.

[0062] In some embodiments, the composition further comprises at least one excipient suitable for dermatological use. In some embodiments, at least one excipient suitable for dermatological use is selected from ethanol, benzylic alcohol, diol molecule, e.g., ethyleneglycol, propylene diol, butylenodiol, among others. In some embodiments, the composition further comprises 0-30% by weight (% wt.) ethanol; 0-3 % wt. benzylic alcohol; and / or 0-20% wt. of a diol molecule, e.g., ethyleneglycol, propylenediol or butylenodiol.

[0063] In some embodiments, the composition is for use in a cosmetic, in particular for use in hair treatment. In some embodiments, the cosmetic is a shampoo, a lotion, a serum, a cream, a conditioner, a foam, an elixir, an oil, an aerosol, or a mask. In some embodiments, a shampoo, a lotion, a serum, a cream, a conditioner, a foam, an elixir, an oil, an aerosol, or a mask comprises the composition described herein.

[0064] In an aspect, the present disclosure provides a method for providing a recombinant peptide comprising: expressing a gene encoding for the peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOs: 1-1368, and providing a composition comprising the peptide.

[0065] In an aspect, the present disclosure provides a method for providing a recombinant peptide comprising the following steps: inserting a target nucleic acid sequence encoding for the peptide having at least 70% identity to any one of SEQ. ID NOs: 1-1368 into an appropriated expression vector, phage or directly integrated in the microorganism genome or derivatives thereof in order to obtain a vector; preferably the peptide has a tag; inserting the obtained vector in a microorganism cells via heat shock transformation or electroporation, to obtain a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOs: 1-1368; wherein preferably the peptide has a tag; transforming a microorganism cell using the vector via heat shock transformation or electroporation; inoculating the transformed cells into growth media (with or without a selective marker) for several hours, wherein the transform cells express a gene encoding for the peptide having at least 70% identity to any one of SEQ ID NOs: 1-1368; preferably 80 % identity; more preferably 90% identity, even more preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical; harvesting the transformed cells and centrifuging to obtain a pellet with the peptide (if the expressed peptide is extracellular, the supernatant follows the purification process; if the peptide expression is intracellular, the cell pellets are reconstituted in buffer and lysed to release the peptide having at least 70% identity to any one of SEQ ID NOs: 1-1368); ; preferably 80 % identity; more preferably 90% identity, even more preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical; extracting and purifying (for example, by using chromatography techniques) the recombinant peptide having at least 70% identity to any one of SEQ ID NOs: 1-1368, preferably wherein the peptide has a tag and a purity level of at least 80%; preferably 80 % identity; more preferably 90% identity, even more preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical.

[0066] In some embodiments, the composition comprises a tag. In some embodiments, the tag enables purification of the peptide. In some embodiments, the tag comprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof, wherein x is an integer from 3 to 9. In some embodiments, the tag is MBP. In some embodiments, the tag is Hisx, wherein x is an integer from 3 to 9. In some embodiments, the gene comprises an expression regulating element. In some embodiments, the expression regulating element comprises a promoter. In some embodiments, the promoter comprises a prokaryotic promoter, a eukaryotic promoter, or a combination thereof. In some embodiments, the prokaryotic promoter comprises T7, Sp6, lac, araBad, trp, or Ptac, or a combination or two or more thereof. In some embodiments, the eukaryotic promoter comprises CMV, EFla, CAG, PGK, TRE, U6, or UAS, or a combination or two or more thereof. In some embodiments, the peptide is adjacent to a cleavage region, wherein the cleavage region is interspaced between the peptide and the tag. In some embodiments, the cleavage region comprises the sequence: DDDDK (SEQ ID NO: 1369), IEGR (SEQ ID NO: 1370), IDGR (SEQ ID NO: 1371), ENLYFQS (SEQ ID NO; 1372), LVPRGS (SEQ ID NO; 1373), or ETLFQGP (SEQ ID NO: 1374), or a combination or two or more thereof.

[0067] In some embodiments, the tag is adjacent to a N-terminus of the peptide. In some embodiments, the tag is adjacent to a C-terminus of the peptide. In some embodiments, the peptide comprises tag— cleavable region-peptide. In some embodiments, the peptide comprises peptide— cleavable region-tag.

[0068] In some embodiments, the cleavage region comprises at least 90% sequence identity to any one of SEQ ID NOs: 1427-1432.

[0069] In some embodiments, the peptide comprises a reporter protein.

[0070] In some embodiments, the reporter protein comprises green fluorescent protein (GFP), yellow fluorescent protein (YFP), luciferase, or a fragment thereof, or a combination thereof.

[0071] In some embodiments, the reporter protein is adjacent to the cleavable tag such that upon cleavage the reporter protein and the sequence having at least 70% identity to any one of SEQ ID NOS: 1- 24 are separated. In some embodiments, the expressing a gene encoding for a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOs: 1-24 comprises: (a) expressing a first gene encoding for a first peptide, and (b) expressing a second gene encoding for a second peptide. In some embodiments, the first peptide comprises a sequence having at least 70% identity to any one of SEQ ID NOs: 25-240. In some embodiments, the second peptide comprises a sequence having at least 70% identity to any one of SEQ ID NOs: 241-456.

[0072] In some embodiments, the first gene comprises a first region encoding a first tag. In some embodiments, the second gene comprises a second region encoding a second tag. In some embodiments, the first tag comprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof, wherein x is an integer from 3 to 9. In some embodiments, the second tagcomprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof, wherein x is an integer from 3 to 9. In some embodiments, the first tag and the second tag are the same. In some embodiments, the first tag and the second tag are different.

[0073] In some embodiments, the first gene comprises a region encoding for a first cleavable region. In some embodiments, the second gene comprises a region encoding for a second cleavable region. In some embodiments, the method further comprises joining the first peptide and the second peptide.

[0074] In some embodiments, the method comprises expressing the gene in a microorganism. In some embodiments, the microorganism is a bacterium or a yeast. In some embodiments, the bacterium is E. coli.

[0075] In some embodiments, the method further comprises transforming or transfecting a nucleic acid comprising the gene into the microorganism.

[0076] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.BRIEF DESCRIPTION OF FIGURES

[0077] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also "Figure" and "FIG." herein), of which:

[0078] Figure 1 shows a linear vector map of an expression vector comprising a promoter, the target nucleic acid sequence, linker sequence, a C-terminal affinity tag sequence, and AmpR gene and corresponding promoter according to embodiments of the disclosure.

[0079] Figure 2 shows a linear vector map of an expression vector comprising a promoter, a N-terminal affinity tag sequence, a linker sequence, the target nucleic acid sequence, and AmpR gene and corresponding promoter according to embodiments of the disclosure.DETAILED DESCRIPTION OF THE DISCLOSURE

[0080] Provided herein are methods for manufacturing peptides with improved yields and purity.Production of peptides suffers from poor yields associated with incomplete reactions, side reactions, lossof stereochemistry at the a-carbon of amino acids, among others. Solid phase peptide synthesis (SPPS) has provided an avenue for synthesizing peptides in a base-by-base basis, enabling control over peptide synthesis. However, aggregation problems associated with mid-length peptides (i.e., those shorter than 15 bases and longer than 32 bases) have presented difficulties with purification, compounded against incomplete reactions and side reactions that occur during addition of each amino acid base.

[0081] Provided herein are methods for providing peptides with higher purity by chemical and recombinant synthesis methods. Using chemical synthesis, tags may be introduced to enable better purification of the various synthesized fragments. Using recombinant methods, the high accuracy of protein expression in vivo is leveraged to provide high purity protein products. Additionally, recombinant synthesis methods are an attractive method for large-scale protein manufacturing as it is considered a green route of manufacturing for using minimal (if any) organic solvents or other chemicals considered harmful to the environment.

[0082] In some aspects, provided herein are methods of providing high purity (e.g., 80% < purity) peptides and proteins, which may be used in cosmetic or skincare products.PEPTIDES

[0083] In some aspects, provided herein are methods for providing a peptide. In some embodiments, about 1-5 amino acids of the peptide are cysteine amino acids. In some embodiments, about 15% to about 50% of the amino acids of the peptide are cysteine amino acids. In some embodiments, the first fragment is represented by the Formula (l-A): (NA-A-CA)m (Formula l-A).

[0084] In some embodiments, the second fragment is represented by the Formula (l-B): (NB-B-CB)p (Formula l-B).

[0085] In some embodiments, NA is the N-terminus of the first fragment, A is one or more amino acids and up to 32 amino acids, CA is the C-terminus of the first fragment, NB is the N-terminus of the second fragment, B is one or more amino acids and up to 32 amino acids, CB is the C-terminus of the second fragment, m is an integer from 1 to 32, p is an integer from 1 to 32. In some embodiments, the peptide is represented by the Formula (l-C') or (l-C"): NA-A-CA-NB-B-CB (Formula l-C'), or NB-B-CB-NA-A-CA (Formula l-C").

[0086] In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purity of at least about 75% wt. In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purity of at least about 80% wt. In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purity of at least about 85% wt. In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purity of at least about 90% wt. In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purity of at least about 95% wt. In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purityof at least about 99% wt. In some embodiments, the method comprises separating the peptide, thereby providing the peptide with a purity of at least about 100% wt.

[0087] In some embodiments, the peptide comprises a length (e.g., a number of amino acids in length). In some embodiments, the peptide can be at least about 1 amino acid in length, at least about 2 amino acids in length, at least about 3 amino acids in length, at least about 4 amino acids in length, at least about 5 amino acids in length, at least about 6 amino acids in length, at least about 7 amino acids in length, at least about 8 amino acids in length, at least about 9 amino acids in length, at least about 10 amino acids in length, at least about 11 amino acids in length, at least about 12 amino acids in length, at least about 13 amino acids in length, at least about 14 amino acids in length, at least about 15 amino acids in length, at least about 16 amino acids in length, at least about 17 amino acids in length, at least about 18 amino acids in length, at least about 19 amino acids in length, at least about 20 amino acids in length, at least about 21 amino acids in length, at least about 22 amino acids in length, at least about 23 amino acids in length, at least about 24 amino acids in length, at least about 25 amino acids in length, at least about 26 amino acids in length, at least about 27 amino acids in length, at least about 28 amino acids in length, at least about 29 amino acids in length, at least about 30 amino acids in length, at least about 31 amino acids in length, at least about 32 amino acids in length, at least about 33 amino acids in length, at least about 34 amino acids in length, at least about 35 amino acids in length, at least about 36 amino acids in length, at least about 37 amino acids in length, at least about 38 amino acids in length, at least about 39 amino acids in length, at least about 40 amino acids in length, at least about 45 amino acids in length, at least about 50 amino acids in length, or greater than about 50 amino acids in length. In some embodiments, the peptide can be at most about 50 amino acids in length, at most about 45 amino acids in length, at most about 40 amino acids in length, at most about 39 amino acids in length, at most about 38 amino acids in length, at most about 37 amino acids in length, at most about 36 amino acids in length, at most about 35 amino acids in length, at most about 34 amino acids in length, at most about 33 amino acids in length, at most about 32 amino acids in length, at most about 31 amino acids in length, at most about 30 amino acids in length, at most about 29 amino acids in length, at most about 28 amino acids in length, at most about 27 amino acids in length, at most about 26 amino acids in length, at most about 25 amino acids in length, at most about 24 amino acids in length, at most about 23 amino acids in length, at most about 22 amino acids in length, at most about 21 amino acids in length, at most about 20 amino acids in length, at most about 19 amino acids in length, at most about 18 amino acids in length, at most about 17 amino acids in length, at most about 16 amino acids in length, at most about 15 amino acids in length, at most about 14 amino acids in length, at most about 13 amino acids in length, at most about 12 amino acids in length, at most about 11 amino acids in length, at most about 10 amino acids in length, at most about 9 amino acids in length, at most about 8 amino acids in length, at most about 7 amino acids in length, at most about 6 amino acids in length, at most about 5 amino acids in length, at most about 4amino acids in length, at most about 3 amino acids in length, at most about 2 amino acids in length, at most about 1 amino acid in length, or at most about 1 amino acid in length.

[0088] In some embodiments, the peptide can be between about 1 amino acid in length to about 35 amino acids in length. In some embodiments, the peptide can be between about 1 amino acid in length to about 2 amino acids in length, about 1 amino acid in length to about 3 amino acids in length, about 1 amino acid in length to about 4 amino acids in length, about 1 amino acid in length to about 5 amino acids in length, about 1 amino acid in length to about 10 amino acids in length, about 1 amino acid in length to about 12 amino acids in length, about 1 amino acid in length to about 15 amino acids in length, about 1 amino acid in length to about 20 amino acids in length, about 1 amino acid in length to about 25 amino acids in length, about 1 amino acid in length to about 30 amino acids in length, about 1 amino acid in length to about 35 amino acids in length, about 2 amino acids in length to about 3 amino acids in length, about 2 amino acids in length to about 4 amino acids in length, about 2 amino acids in length to about 5 amino acids in length, about 2 amino acids in length to about 10 amino acids in length, about 2 amino acids in length to about 12 amino acids in length, about 2 amino acids in length to about 15 amino acids in length, about 2 amino acids in length to about 20 amino acids in length, about 2 amino acids in length to about 25 amino acids in length, about 2 amino acids in length to about 30 amino acids in length, about 2 amino acids in length to about 35 amino acids in length, about 3 amino acids in length to about 4 amino acids in length, about 3 amino acids in length to about 5 amino acids in length, about 3 amino acids in length to about 10 amino acids in length, about 3 amino acids in length to about 12 amino acids in length, about 3 amino acids in length to about 15 amino acids in length, about 3 amino acids in length to about 20 amino acids in length, about 3 amino acids in length to about 25 amino acids in length, about 3 amino acids in length to about 30 amino acids in length, about 3 amino acids in length to about 35 amino acids in length, about 4 amino acids in length to about 5 amino acids in length, about 4 amino acids in length to about 10 amino acids in length, about 4 amino acids in length to about 12 amino acids in length, about 4 amino acids in length to about 15 amino acids in length, about 4 amino acids in length to about 20 amino acids in length, about 4 amino acids in length to about 25 amino acids in length, about 4 amino acids in length to about 30 amino acids in length, about 4 amino acids in length to about 35 amino acids in length, about 5 amino acids in length to about 10 amino acids in length, about 5 amino acids in length to about 12 amino acids in length, about 5 amino acids in length to about 15 amino acids in length, about 5 amino acids in length to about 20 amino acids in length, about 5 amino acids in length to about 25 amino acids in length, about 5 amino acids in length to about 30 amino acids in length, about 5 amino acids in length to about 35 amino acids in length, about 10 amino acids in length to about 12 amino acids in length, about 10 amino acids in length to about 15 amino acids in length, about 10 amino acids in length to about 20 amino acids in length, about 10 amino acids in length to about 25 amino acids in length, about 10 amino acids in length to about 30 amino acids in length, about 10 amino acids in length to about 35 amino acids in length, about 12 amino acids in length to about 15 amino acids in length, about 12 amino acids in lengthto about 20 amino acids in length, about 12 amino acids in length to about 25 amino acids in length, about 12 amino acids in length to about 30 amino acids in length, about 12 amino acids in length to about 35 amino acids in length, about 15 amino acids in length to about 20 amino acids in length, about 15 amino acids in length to about 25 amino acids in length, about 15 amino acids in length to about 30 amino acids in length, about 15 amino acids in length to about 35 amino acids in length, about 20 amino acids in length to about 25 amino acids in length, about 20 amino acids in length to about 30 amino acids in length, about 20 amino acids in length to about 35 amino acids in length, about 25 amino acids in length to about 30 amino acids in length, about 25 amino acids in length to about 35 amino acids in length, or about 30 amino acids in length to about 35 amino acids in length.

[0089] In some embodiments, the first fragment comprises an amino acid sequence that is a percentage of the total length of the peptide. In some embodiments, the first fragment (e.g., (NA-A-CA)m) can be at least about 5%, at least about 10%, at least about 15%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or greater than about 90% of a length of the peptide. In some embodiments, the first fragment (e.g., (NA-A-CA)m) can be at most about 90%, at most about 80%, at most about 70%, at most about 60%, at most about 50%, at most about 45%, at most about 40%, at most about 35%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, or less than about 5% of a length of the peptide. In some embodiments, the first fragment (e.g., (NA-A-CA)m) can be between about 5% to about 90% of a length of the peptide. In some embodiments, the first fragment (e.g., (NA-A-CA)m) can be between about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 40%, about 5% to about 50%, about 5% to about 60%, about 5% to about 70%, about 5% to about 80%, about 5% to about 90%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about 10% to about 60%, about 10% to about 70%, about 10% to about 80%, about 10% to about 90%, about 15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 15% to about 40%, about 15% to about 50%, about 15% to about 60%, about 15% to about 70%, about 15% to about 80%, about 15% to about 90%, about 20% to about 25%, about 20% to about 30%, about 20% to about 40%, about 20% to about 50%, about 20% to about 60%, about 20% to about 70%, about 20% to about 80%, about 20% to about 90%, about 25% to about 30%, about 25% to about 40%, about 25% to about 50%, about 25% to about 60%, about 25% to about 70%, about 25% to about 80%, about 25% to about 90%, about 30% to about 40%, about 30% to about 50%, about 30% to about 60%, about 30% to about 70%, about 30% to about 80%, about 30% to about 90%, about 40% to about 50%, about 40% to about 60%, about 40% to about 70%, about 40% to about 80%, about 40% to about 90%, about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 60% to about 70%, about 60% to about 80%,about 60% to about 90%, about 70% to about 80%, about 70% to about 90%, or about 80% to about 90% of a length of the peptide.

[0090] In some embodiments, the second fragment comprises an amino acid sequence that is a percentage of the total length of the peptide. In some embodiments, the second fragment (e.g., (NB-B- CB)p) can be at least about 5%, at least about 10%, at least about 15%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or greater than about 90% of a length of the peptide. In some embodiments, the second fragment (e.g., (NB-B-CB)p) can be at most about 90%, at most about 80%, at most about 70%, at most about 60%, at most about 50%, at most about 45%, at most about 40%, at most about 35%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, or less than about 5% of a length of the peptide. In some embodiments, the second fragment (e.g., (NB-B-CB)p) can be between about 5% to about 90% of a length of the peptide. In some embodiments, the second fragment (e.g., (NB-B-CB)p) can be between about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 40%, about 5% to about 50%, about 5% to about 60%, about 5% to about 70%, about 5% to about 80%, about 5% to about 90%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about10% to about 60%, about 10% to about 70%, about 10% to about 80%, about 10% to about 90%, about15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 15% to about 40%, about15% to about 50%, about 15% to about 60%, about 15% to about 70%, about 15% to about 80%, about15% to about 90%, about 20% to about 25%, about 20% to about 30%, about 20% to about 40%, about20% to about 50%, about 20% to about 60%, about 20% to about 70%, about 20% to about 80%, about20% to about 90%, about 25% to about 30%, about 25% to about 40%, about 25% to about 50%, about25% to about 60%, about 25% to about 70%, about 25% to about 80%, about 25% to about 90%, about30% to about 40%, about 30% to about 50%, about 30% to about 60%, about 30% to about 70%, about30% to about 80%, about 30% to about 90%, about 40% to about 50%, about 40% to about 60%, about40% to about 70%, about 40% to about 80%, about 40% to about 90%, about 50% to about 60%, about50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 60% to about 70%, about60% to about 80%, about 60% to about 90%, about 70% to about 80%, about 70% to about 90%, or about 80% to about 90% of a length of the peptide.

[0091] Cysteine can provide benefits to hair health and / or hair growth. An increased number of cysteine residues and / or percentage of cysteine of a peptide for hair treatment may provide advantages for strength, durability, and hydration for hair. In some embodiments, the peptide comprises one cysteine residue. In some embodiments, the peptide comprises no cysteine residues (e.g., 0 cysteine residues). In some embodiments, the peptide comprises at least one cysteine residue. In some embodiments, the peptide comprises at least 2 cysteine residues, at least 3 cysteine residues, at least 4 cysteine residues, atleast 5 cysteine residues, at least 6 cysteine residues, at least 7 cysteine residues, at least 8 cysteine residues, at least 9 cysteine residues, at least 10 cysteine residues, or greater than 10 cysteine residues. In some embodiments, the peptide comprises at most 10 cysteine residues, at most 9 cysteine residues, at most 8 cysteine residues, at most 7 cysteine residues, at most 6 cysteine residues, at most 5 cysteine residues, at most 4 cysteine residues, at most 3 cysteine residues, at most 2 cysteine residues, or at most1 cysteine residue.

[0092] In some embodiments, the peptide comprises between 2 cysteine residues to 12 cysteine residues. In some embodiments, the peptide comprises between 2 cysteine residues to 3 cysteine residues, 2 cysteine residues to 4 cysteine residues, 2 cysteine residues to 5 cysteine residues, 2 cysteine residues to 6 cysteine residues, 2 cysteine residues to 7 cysteine residues, 2 cysteine residues to 8 cysteine residues,2 cysteine residues to 9 cysteine residues, 2 cysteine residues to 10 cysteine residues, 2 cysteine residues to 11 cysteine residues, 2 cysteine residues to 12 cysteine residues, 3 cysteine residues to 4 cysteine residues, 3 cysteine residues to 5 cysteine residues, 3 cysteine residues to 6 cysteine residues, 3 cysteine residues to 7 cysteine residues, 3 cysteine residues to 8 cysteine residues, 3 cysteine residues to 9 cysteine residues, 3 cysteine residues to 10 cysteine residues, 3 cysteine residues to 11 cysteine residues, 3 cysteine residues to 12 cysteine residues, 4 cysteine residues to 5 cysteine residues, 4 cysteine residues to 6 cysteine residues, 4 cysteine residues to 7 cysteine residues, 4 cysteine residues to 8 cysteine residues, 4 cysteine residues to 9 cysteine residues, 4 cysteine residues to 10 cysteine residues, 4 cysteine residues to 11 cysteine residues, 4 cysteine residues to 12 cysteine residues, 5 cysteine residues to 6 cysteine residues, 5 cysteine residues to 7 cysteine residues, 5 cysteine residues to 8 cysteine residues, 5 cysteine residues to 9 cysteine residues, 5 cysteine residues to 10 cysteine residues, 5 cysteine residues to 11 cysteine residues, 5 cysteine residues to 12 cysteine residues, 6 cysteine residues to 7 cysteine residues, 6 cysteine residues to 8 cysteine residues, 6 cysteine residues to 9 cysteine residues, 6 cysteine residues to 10 cysteine residues, 6 cysteine residues to 11 cysteine residues, 6 cysteine residues to 12 cysteine residues, 7 cysteine residues to 8 cysteine residues, 7 cysteine residues to 9 cysteine residues, 7 cysteine residues to 10 cysteine residues, 7 cysteine residues to 11 cysteine residues, 7 cysteine residues to 12 cysteine residues, 8 cysteine residues to 9 cysteine residues, 8 cysteine residues to 10 cysteine residues, 8 cysteine residues to 11 cysteine residues, 8 cysteine residues to 12 cysteine residues, 9 cysteine residues to 10 cysteine residues, 9 cysteine residues to 11 cysteine residues, 9 cysteine residues to 12 cysteine residues, 10 cysteine residues to 11 cysteine residues, 10 cysteine residues to 12 cysteine residues, or 11 cysteine residues to 12 cysteine residues.

[0093] In some embodiments, the peptide comprises a percentage of cysteine amino acid content. In some embodiments, the peptide comprises an amino acid content of at least about 5% cysteine, at least about 10% cysteine, at least about 15% cysteine, at least about 20% cysteine, at least about 25% cysteine, at least about 30% cysteine, at least about 35% cysteine, at least about 40% cysteine, at least about 45% cysteine, at least about 50% cysteine, at least about 75% cysteine, or greater than about 75% cysteine. Insome embodiments, the peptide comprises an amino acid content of at most about 75% cysteine, at most about 50% cysteine, at most about 45% cysteine, at most about 40% cysteine, at most about 35% cysteine, at most about 30% cysteine, at most about 25% cysteine, at most about 20% cysteine, at most about 15% cysteine, at most about 10% cysteine, at most about 5% cysteine, or less than about 5% cysteine.

[0094] In some embodiments, the peptide comprises an amino acid content between about 5% cysteine to about 50% cysteine. In some embodiments, the peptide comprises an amino acid content between about 5% cysteine to about 8% cysteine, about 5% cysteine to about 10% cysteine, about 5% cysteine to about 12% cysteine, about 5% cysteine to about 15% cysteine, about 5% cysteine to about 20% cysteine, about 5% cysteine to about 25% cysteine, about 5% cysteine to about 30% cysteine, about 5% cysteine to about 35% cysteine, about 5% cysteine to about 40% cysteine, about 5% cysteine to about 45% cysteine, about 5% cysteine to about 50% cysteine, about 8% cysteine to about 10% cysteine, about 8% cysteine to about 12% cysteine, about 8% cysteine to about 15% cysteine, about 8% cysteine to about 20% cysteine, about 8% cysteine to about 25% cysteine, about 8% cysteine to about 30% cysteine, about 8% cysteine to about 35% cysteine, about 8% cysteine to about 40% cysteine, about 8% cysteine to about 45% cysteine, about 8% cysteine to about 50% cysteine, about 10% cysteine to about 12% cysteine, about 10% cysteine to about 15% cysteine, about 10% cysteine to about 20% cysteine, about 10% cysteine to about 25% cysteine, about 10% cysteine to about 30% cysteine, about 10% cysteine to about 35% cysteine, about 10% cysteine to about 40% cysteine, about 10% cysteine to about 45% cysteine, about 10% cysteine to about 50% cysteine, about 12% cysteine to about 15% cysteine, about 12% cysteine to about 20% cysteine, about 12% cysteine to about 25% cysteine, about 12% cysteine to about 30% cysteine, about 12% cysteine to about 35% cysteine, about 12% cysteine to about 40% cysteine, about 12% cysteine to about 45% cysteine, about 12% cysteine to about 50% cysteine, about 15% cysteine to about 20% cysteine, about 15% cysteine to about 25% cysteine, about 15% cysteine to about 30% cysteine, about 15% cysteine to about 35% cysteine, about 15% cysteine to about 40% cysteine, about 15% cysteine to about 45% cysteine, about 15% cysteine to about 50% cysteine, about 20% cysteine to about 25% cysteine, about 20% cysteine to about 30% cysteine, about 20% cysteine to about 35% cysteine, about 20% cysteine to about 40% cysteine, about 20% cysteine to about 45% cysteine, about 20% cysteine to about 50% cysteine, about 25% cysteine to about 30% cysteine, about 25% cysteine to about 35% cysteine, about 25% cysteine to about 40% cysteine, about 25% cysteine to about 45% cysteine, about 25% cysteine to about 50% cysteine, about 30% cysteine to about 35% cysteine, about 30% cysteine to about 40% cysteine, about 30% cysteine to about 45% cysteine, about 30% cysteine to about 50% cysteine, about 35% cysteine to about 40% cysteine, about 35% cysteine to about 45% cysteine, about 35% cysteine to about 50% cysteine, about 40% cysteine to about 45% cysteine, about 40% cysteine to about 50% cysteine, or about 45% cysteine to about 50% cysteine.

[0095] In some embodiments, the peptide may comprise a number of hydrophobic residues. In some embodiments, the peptide may comprise no hydrophobic residues. A hydrophobic residue may comprisean alanine residue, a proline residue, a glycine residue, a leucine residue, a phenylalanine residue, a tyrosine residue, a valine residue, an isoleucine residue, a methionine residue, or a tryptophan residue. A peptide may comprise a combination of hydrophobic residues. The peptide described herein may comprise an alanine residue, a proline residue, a glycine residue, a leucine residue, a phenylalanine residue, a tyrosine residue, a valine residue, an isoleucine residue, a methionine residue, a tryptophan residue, or any combination thereof. In some embodiments, the at least one hydrophobic amino acid residue is glycine. In some embodiments, the at least one hydrophobic amino acid residue is alanine. In some embodiments, the at least one hydrophobic amino acid residue is valine. In some embodiments, the at least one hydrophobic amino acid residue is leucine. In some embodiments, the at least one hydrophobic amino acid residue is isoleucine. In some embodiments, the at least one hydrophobic amino acid residue is phenylalanine. In some embodiments, the at least one hydrophobic amino acid residue is tyrosine. In some embodiments, the at least one hydrophobic amino acid residue is tryptophan.

[0096] In some embodiments, the peptide may comprise at least one hydrophobic residue and the hydrophobic residue may be independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan. In some embodiments, the peptide comprises at least 1 hydrophobic residue, at least 2 hydrophobic residues, at least 3 hydrophobic residues, at least 4 hydrophobic residues, at least 5 hydrophobic residues, at least 6 hydrophobic residues, at least 7 hydrophobic residues, at least 8 hydrophobic residues, at least 9 hydrophobic residues, at least about 10 hydrophobic residues, at least about 12 hydrophobic residues, at least about 15 hydrophobic residues, at least about 18 hydrophobic residues, at least about 20 hydrophobic residues, or greater than about 20 hydrophobic residues. In some embodiments, the peptide comprises at most about 20 hydrophobic residues, at most about 18 hydrophobic residues, at most about 15 hydrophobic residues, at most about 12 hydrophobic residues, at most about 10 hydrophobic residues, at most 9 hydrophobic residues, at most 8 hydrophobic residues, at most 7 hydrophobic residues, at most 6 hydrophobic residues, at most 5 hydrophobic residues, at most 4 hydrophobic residues, at most 3 hydrophobic residues, at most 2 hydrophobic residues, or at most 1 hydrophobic residue.

[0097] In some embodiments, the peptide comprises between about 1 hydrophobic residue to about 15 hydrophobic residues. In some embodiments, the peptide comprises between about 1 hydrophobic residue to about 2 hydrophobic residues, about 1 hydrophobic residue to about 3 hydrophobic residues, about 1 hydrophobic residue to about 4 hydrophobic residues, about 1 hydrophobic residue to about 5 hydrophobic residues, about 1 hydrophobic residue to about 6 hydrophobic residues, about 1 hydrophobic residue to about 7 hydrophobic residues, about 1 hydrophobic residue to about 8 hydrophobic residues, about 1 hydrophobic residue to about 9 hydrophobic residues, about 1 hydrophobic residue to about 10 hydrophobic residues, about 1 hydrophobic residue to about 12 hydrophobic residues, about 1 hydrophobic residue to about 15 hydrophobic residues, about 2 hydrophobic residues to about 3 hydrophobic residues, about 2 hydrophobic residues to about 4hydrophobic residues, about 2 hydrophobic residues to about 5 hydrophobic residues, about 2 hydrophobic residues to about 6 hydrophobic residues, about 2 hydrophobic residues to about 7 hydrophobic residues, about 2 hydrophobic residues to about 8 hydrophobic residues, about 2 hydrophobic residues to about 9 hydrophobic residues, about 2 hydrophobic residues to about 10 hydrophobic residues, about 2 hydrophobic residues to about 12 hydrophobic residues, about 2 hydrophobic residues to about 15 hydrophobic residues, about 3 hydrophobic residues to about 4 hydrophobic residues, about 3 hydrophobic residues to about 5 hydrophobic residues, about 3 hydrophobic residues to about 6 hydrophobic residues, about 3 hydrophobic residues to about 7 hydrophobic residues, about 3 hydrophobic residues to about 8 hydrophobic residues, about 3 hydrophobic residues to about 9 hydrophobic residues, about 3 hydrophobic residues to about 10 hydrophobic residues, about 3 hydrophobic residues to about 12 hydrophobic residues, about 3 hydrophobic residues to about 15 hydrophobic residues, about 4 hydrophobic residues to about 5 hydrophobic residues, about 4 hydrophobic residues to about 6 hydrophobic residues, about 4 hydrophobic residues to about 7 hydrophobic residues, about 4 hydrophobic residues to about 8 hydrophobic residues, about 4 hydrophobic residues to about 9 hydrophobic residues, about 4 hydrophobic residues to about 10 hydrophobic residues, about 4 hydrophobic residues to about 12 hydrophobic residues, about 4 hydrophobic residues to about 15 hydrophobic residues, about 5 hydrophobic residues to about 6 hydrophobic residues, about 5 hydrophobic residues to about 7 hydrophobic residues, about 5 hydrophobic residues to about 8 hydrophobic residues, about 5 hydrophobic residues to about 9 hydrophobic residues, about 5 hydrophobic residues to about 10 hydrophobic residues, about 5 hydrophobic residues to about 12 hydrophobic residues, about 5 hydrophobic residues to about 15 hydrophobic residues, about 6 hydrophobic residues to about 7 hydrophobic residues, about 6 hydrophobic residues to about 8 hydrophobic residues, about 6 hydrophobic residues to about 9 hydrophobic residues, about 6 hydrophobic residues to about 10 hydrophobic residues, about 6 hydrophobic residues to about 12 hydrophobic residues, about 6 hydrophobic residues to about 15 hydrophobic residues, about 7 hydrophobic residues to about 8 hydrophobic residues, about 7 hydrophobic residues to about 9 hydrophobic residues, about 7 hydrophobic residues to about 10 hydrophobic residues, about 7 hydrophobic residues to about 12 hydrophobic residues, about 7 hydrophobic residues to about 15 hydrophobic residues, about 8 hydrophobic residues to about 9 hydrophobic residues, about 8 hydrophobic residues to about 10 hydrophobic residues, about 8 hydrophobic residues to about 12 hydrophobic residues, about 8 hydrophobic residues to about 15 hydrophobic residues, about 9 hydrophobic residues to about 10 hydrophobic residues, about 9 hydrophobic residues to about 12 hydrophobic residues, about 9 hydrophobic residues to about 15 hydrophobic residues, about 10 hydrophobic residues to about 12 hydrophobic residues, about 10 hydrophobic residues to about 15 hydrophobic residues, or about 12 hydrophobic residues to about 15 hydrophobic residues.

[0098] In some embodiments, a total amino acid composition of a peptide described herein may comprise a percentage of hydrophobic amino acids (e.g., a hydrophobic amino acid content). In some embodiments, the peptide may have a hydrophobic amino acid content of at least about 2%, at least about 5%, at least about 8%, at least about 10%, at least about 12%, at least about 15%, at least about18%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or greater than about 90%. In some embodiments, the peptide may have a hydrophobic amino acid content of at most about 90%, at most about 80%, at most about 70%, at most about 60%, at most about 50%, at most about 45%, at most about 40%, at most about 35%, at most about 30%, at most about25%, at most about 20%, at most about 18%, at most about 15%, at most about 12%, at most about 10%, at most about 8%, at most about 5%, at most about 2%, or less than about 2%.

[0099] In some embodiments, the peptide has a hydrophobic amino acid content of about 5% to about90%, about 5% to about 85%, about 5% to about 80%, about 5% to about 75%, about 5% to about 70%, about 5% to about 65%, about 5% to about 60%, about 5% to about 55%, about 5% to about 50%, about5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 5% to about 10%, about 10% to about90%, about 10% to about 85%, about 10% to about 80%, about 10% to about 75%, about 10% to about70%, about 10% to about 65%, about 10% to about 60%, about 10% to about 55%, about 10% to about50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about30%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, about 15% to about90%, about 15% to about 85%, about 15% to about 80%, about 15% to about 75%, about 15% to about70%, about 15% to about 65%, about 15% to about 60%, about 15% to about 55%, about 15% to about50%, about 15% to about 45%, about 15% to about 40%, about 15% to about 35%, about 15% to about30%, about 15% to about 25%, about 15% to about 20%, about 20% to about 90%, about 20% to about85%, about 20% to about 80%, about 20% to about 75%, about 20% to about 70%, about 20% to about65%, about 20% to about 60%, about 20% to about 55%, about 20% to about 50%, about 20% to about45%, about 20% to about 40%, about 20% to about 35%, about 20% to about 30%, or about 20% to about25%. In some embodiments, the peptide has about 5% to about 90% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 85% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 80% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 75% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 70% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 65% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 60% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 55% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 50% hydrophobic amino acid content. In someembodiments, the peptide has about 5% to about 45% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 40% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 35% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 30% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 25% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 20% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 15% hydrophobic amino acid content. In some embodiments, the peptide has about 5% to about 10% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 90% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 85% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 80% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 75% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 70% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 65% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 60% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 55% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 50% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 45% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 40% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 35% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 30% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 25% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 20% hydrophobic amino acid content. In some embodiments, the peptide has about 10% to about 15% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 90% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 85% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 80% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 75% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 70% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 65% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 60% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 55% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 50% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 45% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 40% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 35% hydrophobic amino acid content. In someembodiments, the peptide has about 15% to about 30% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 25% hydrophobic amino acid content. In some embodiments, the peptide has about 15% to about 20% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 90% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 85% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 80% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 75% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 70% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 65% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 60% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 55% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 50% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 45% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 40% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 35% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 30% hydrophobic amino acid content. In some embodiments, the peptide has about 20% to about 25% hydrophobic amino acid content.

[0100] In some embodiments, the peptide comprises a sequence of any one of the sequences of Table 2.

[0101] In some embodiments, the peptide comprises an amino acid sequence as set forth in any one ofSEQ ID NOs: 1-1368. In some embodiments, the peptide comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1-24, SEQ ID NOs: 25-48, SEQ ID NOs: 49-72, SEQ ID NOs: 73-96, SEQ ID NOs:97-120, SEQ ID NOs: 121-144, SEQ ID NOs: 145-168, SEQ ID NOs: 169-192, SEQ ID NOs: 193-216, SEQ IDNOs: 217-240, SEQ ID NOs: 241-264, SEQ ID NOs: 265-288, SEQ ID NOs: 289-312, SEQ ID NOs: 313-336, SEQ ID NOs: 337-360, SEQ ID NOs: 361-384, SEQ ID NOs: 385-408, SEQ ID NOs: 409-432, SEQ ID NOs: 433- 456, SEQ ID NOs: 457-480, SEQ ID NOs: 481-504, SEQ ID NOs: 505-528, SEQ ID NOs: 529-552, SEQ ID NOs: 553-576, SEQ ID NOs: 577-600, SEQ ID NOs: 601-624, SEQ ID NOs: 625-648, SEQ ID NOs: 649-672, SEQ ID NOs: 673-696, SEQ ID NOs: 697-720, SEQ ID NOs: 721-744, SEQ ID NOs: 745-768, SEQ ID NOs: 769-792, SEQ ID NOs: 793-816, SEQ ID NOs: 817-840, SEQ ID NOs: 841-864, SEQ ID NOs: 865-888, SEQ ID NOs: 889- 912, SEQ ID NOs: 913-936, SEQ ID NOs: 937-960, SEQ ID NOs: 961-984, SEQ ID NOs: 985-1008, SEQ ID NOs: 1009-1032, SEQ ID NOs: 1033-1056, SEQ ID NOs: 1057-1080, SEQ ID NOs: 1081-1104, SEQ ID NOs: 1105- 1028, SEQ ID NOs: 1129-1152, SEQ ID NOs: 1053-1176, SEQ ID NOs: 1177-1200, SEQ ID NOs: 1201-1224, SEQ ID NOs: 1225-1248, SEQ ID NOs: 1249-1272, SEQ ID NOs: 1273-1296, SEQ ID NOs: 1297-1320, SEQ ID NOs: 1321-1344, or SEQ ID NOs: 1345-1368.

[0102] In some embodiments, the peptide comprises a sequence of at least about 90% sequence identity, at least about 91% sequence identity, at least about 92% sequence identity, at least about 93% sequence identity, at least about 94% sequence identity, at least about 95% sequence identity, at least about 96%sequence identity, at least about 97% sequence identity, at least about 98% sequence identity, at least about 98.5% sequence identity, at least about 99% sequence identity, at least about 99.5% sequence identity, at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-1368.

[0103] In some embodiments, the peptide comprises a sequence of at least about 90% sequence identity, at least about 91% sequence identity, at least about 92% sequence identity, at least about 93% sequence identity, at least about 94% sequence identity, at least about 95% sequence identity, at least about 96% sequence identity, at least about 97% sequence identity, at least about 98% sequence identity, at least about 98.5% sequence identity, at least about 99% sequence identity, at least about 99.5% sequence identity, at least about 99.9% sequence identity to an amino acid sequence as set forth in the amino acid sequence of SEQ. ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 23, or any fragment thereof.

[0104] In some embodiments, the peptide comprises a sequence as set forth in the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 23, or any fragment thereof, or any combination of two or more thereof.

[0105] In some embodiments, the N-terminus or C-terminus of the peptide is covalently bound to a tag. In some instances, the tag enables purification of the peptide. In some embodiments, the tag comprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof. In some embodiments, the tag is MBP. In some embodiments, the tag is a (His)x. In some embodiments, x is an integer from 1 to 10. In some embodiments, x is 1. In some embodiments, x is 2. In some embodiments, x is 3. In some embodiments, x is 4. In some embodiments, x is 5. In some embodiments, x is 6. In some embodiments, x is 7. In some embodiments, x is 8. In some embodiments, x is 9. In some embodiments, x is lOln some embodiments, the tag is a glutathione S-transferase (GST). In some embodiments, the tag is a chitin binding protein (CBP). In some embodiments, the tag is a ubiquitin. In some embodiments, the tag is a small ubiquitin-like modifier (SUMO). In some embodiments, the tag is a flag-acidic target tag (FATT).

[0106] In some embodiments, a cleavage region is interspaced between the tag and the N-terminus or the C-terminus of the peptide. In some instances, the cleavage region enables cleavage of the cleavage region itself and the tag, thereby providing the peptide. In some embodiments, the cleavage region comprises the sequence DDDDK (SEQ ID NO: 1369), IEGR (SEQ ID NO: 1370), IDGR (SEQ ID NO: 1371), ENLYFQS (SEQ ID NO: 1372), LVPRGS (SEQ ID NO: 1373), or ETLFQGP (SEQ ID NO: 1374), or a combination or two or more thereof. In some embodiments, the cleavage region comprises a sequence from Table 1.Table 1. Cleavage Region Sequences

[0107] In some embodiments, the methods provided herein may provide a peptide with a specific purity. In some embodiments, the peptide has a purity of at least about 75% wt. In some embodiments, the peptide has a purity of at least about 70% wt, at least about 75% wt, at least about 80% wt, at least about 85% wt, at least about 86% wt, at least about 87% wt, at least about 88% wt, at least about 89% wt, at least about 90% wt, at least about 91% wt, at least about 92% wt, at least about 93% wt, at least about 94% wt, at least about 95% wt, at least about 96% wt, at least about 97% wt, at least about 97.5% wt, at least about 98% wt, at least about 98.5% wt, at least about 99% wt, at least about 99.5% wt, at least about 99.9% wt, or greater than about 99.9% wt. In some embodiments, the peptide has a purity of at most about 99.9% wt, at most about 99.5% wt, at most about 99% wt, at most about 98.5% wt, at most about 98% wt, at most about 97.5% wt, at most about 97% wt, at most about 96% wt, at most about 95% wt, at most about 94% wt, at most about 93% wt, at most about 92% wt, at most about 91% wt, at most about 90% wt, at most about 89% wt, at most about 88% wt, at most about 87% wt, at most about 86% wt, at most about 85% wt, at most about 80% wt, at most about 75% wt, at most about 70% wt, or less than about 70% wt.

[0108] In some embodiments, the peptide has a purity between about 70% wt to about 99% wt. In some embodiments, the peptide has a purity between about 70% wt to about 75% wt, about 70% wt to about 80% wt, about 70% wt to about 85% wt, about 70% wt to about 90% wt, about 70% wt to about 92% wt, about 70% wt to about 94% wt, about 70% wt to about 96% wt, about 70% wt to about 98% wt, about 70% wt to about 99% wt, about 75% wt to about 80% wt, about 75% wt to about 85% wt, about 75% wt to about 90% wt, about 75% wt to about 92% wt, about 75% wt to about 94% wt, about 75% wt to about 96% wt, about 75% wt to about 98% wt, about 75% wt to about 99% wt, about 80% wt to about 85% wt, about 80% wt to about 90% wt, about 80% wt to about 92% wt, about 80% wt to about 94% wt, about 80% wt to about 96% wt, about 80% wt to about 98% wt, about 80% wt to about 99% wt, about 85% wt to about 90% wt, about 85% wt to about 92% wt, about 85% wt to about 94% wt, about 85% wt to about 96% wt, about 85% wt to about 98% wt, about 85% wt to about 99% wt, about 90% wt to about 92% wt, about 90% wt to about 94% wt, about 90% wt to about 96% wt, about 90% wt to about 98% wt, about 90% wt to about 99% wt, about 92% wt to about 94% wt, about 92% wt to about 96% wt, about 92% wt to about 98% wt, about 92% wt to about 99% wt, about 94% wt to about 96% wt, about 94% wt to about 98% wt, about 94% wt to about 99% wt, about 96% wt to about 98% wt, about 96% wt to about 99% wt, or about 98% wt to about 99% wt. In some embodiments, the peptide has a purity of 100% wt.

[0109] In some embodiments, the peptide comprises a protecting group. In some embodiments, the peptide comprises at least one protecting group. In some embodiments, an amino acid side chain of apeptide fragment of the peptide comprises a protecting group. In some embodiments, an amino acid side chain of a first peptide fragment of the peptide comprises a protecting group. In some embodiments, an amino acid side chain of a first peptide fragment of the peptide comprises at least one protecting group. In some embodiments, an amino acid side chain of a second peptide fragment of the peptide comprises a protecting group. In some embodiments, an amino acid side chain of a second peptide fragment of the peptide comprises at least one protecting group. In some embodiments, both an amino acid side chain of the first peptide fragment and an amino acid side chain of the second peptide fragment comprise at least one protecting group.

[0110] In some embodiments, a protecting group can comprise benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tert-butyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2, 2,4,6, -7- pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm). In some embodiments, a peptide described herein may comprise benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tert-butyloxycarbonyl (Boc), 9- Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2,2,4,6,-7-pentamethyl-2,3-dihydrobenzofuran-5- sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm), or any combination thereof.

[0111] In some embodiments, the protecting group covalently bound to the amino acid side chain depends on the amino acid side chain. When the amino acid is asparagine (Asn), the protecting group covalently bound to the amino acid side chain is Trt. When the amino acid is aspartate (Asp), the protecting group covalently bound to the amino acid side chain is OtBu. When the amino acid is cysteine (Cys), the protecting group covalently bound to the S atom of the side chain is Acm, Bzl, pMeBzl, pMeOBzl, tBu, Trt, Acm, Bzl, Mmt, pMeBzl, pMeOBzl, or tBu. When the amino acid is glutamine (Gin), the protecting group covalently bound to the amino acid side chain is Trt. When the amino acid is serine (Ser), the protecting group covalently bound to the amino acid side chain is tBu. When the amino acid is glutamine (Thr), the protecting group covalently bound to the amino acid side chain is tBu. When the amino acid is tryptophan (Trp), the protecting group covalently bound to the amino acid side chain is Boc. When the amino acid is tyrosine (Tyr), the protecting group covalently bound to the amino acid side chain is tBu.

[0112] In some embodiments, NA of the first peptide fragment, (NA-A-CA)m, comprises a protecting group. In some embodiments, NB of the second peptide fragment, (NB-B-CB)p, comprises a protecting group. In some embodiments, both of NA and NB comprise a protecting group. In some embodiments, each of NA and NB comprise a protecting group of 9-fluorenylmethoxycarbonyl (Fmoc) or tertbutyloxycarbonyl (Boc). In some embodiments, each of NA and NB comprise the same protecting group. In some embodiments, each of NA and NB comprise a different protecting group. In some embodiments, CA of the first peptide fragment, (NA-A-CA)m, comprises a protecting group. In some embodiments, CBT1of the second peptide fragment, (NB-B-CB)p, comprises a protecting group. In some embodiments, both of CA and CB comprise a protecting group. In some embodiments, each of CA and CB comprise a protecting group of t-butyl (tBu), Trt, 2,4-dimethoxybenzyl (Dmb), 9-fluorenylmethyl (Fm), or benzyl (Bn). In some embodiments, each of CA and CB comprise the same protecting group. In some embodiments, each of CA and CB comprise a different protecting group.

[0113] In some embodiments, the methods described herein may comprise contacting a peptide with an acidic solution. In some embodiments, contacting a peptide with an acidic solution provides a deprotected peptide.First Fragment of Peptide

[0114] In some embodiments, the first fragment, represented by the Formula (l-A), comprises a number of cysteine residues. In some embodiments, the first fragment, represented by the Formula (l-A), comprises a percentage of cysteine in an amino acid content. In some embodiments, a first fragment of a peptide described herein comprises no cysteine residues (e.g., 0 cysteine residues). In some embodiments, a first fragment of a peptide described herein comprises at least one cysteine residue. In some embodiments, a first fragment of a peptide described herein comprises at least 1 cysteine residue, at least 2 cysteine residues, at least 3 cysteine residues, at least 4 cysteine residues, at least 5 cysteine residues, at least 6 cysteine residues, at least 7 cysteine residues, at least 8 cysteine residues, at least 9 cysteine residues, at least 10 cysteine residues, or greater than 10 cysteine residues. In some embodiments, the peptide comprises at most 10 cysteine residues, at most 9 cysteine residues, at most 8 cysteine residues, at most 7 cysteine residues, at most 6 cysteine residues, at most 5 cysteine residues, at most 4 cysteine residues, at most 3 cysteine residues, at most 2 cysteine residues, or at most 1 cysteine residue.

[0115] In some embodiments, a first fragment of a peptide described herein comprises between about 1 cysteine residue to about 10 cysteine residues. In some embodiments, a first fragment of a peptide described herein comprises between about 1 cysteine residue to about 2 cysteine residues, about 1 cysteine residue to about 3 cysteine residues, about 1 cysteine residue to about 4 cysteine residues, about 1 cysteine residue to about 5 cysteine residues, about 1 cysteine residue to about 6 cysteine residues, about 1 cysteine residue to about 7 cysteine residues, about 1 cysteine residue to about 8 cysteine residues, about 1 cysteine residue to about 9 cysteine residues, about 1 cysteine residue to about 10 cysteine residues, about 2 cysteine residues to about 3 cysteine residues, about 2 cysteine residues to about 4 cysteine residues, about 2 cysteine residues to about 5 cysteine residues, about 2 cysteine residues to about 6 cysteine residues, about 2 cysteine residues to about 7 cysteine residues, about 2 cysteine residues to about 8 cysteine residues, about 2 cysteine residues to about 9 cysteine residues, about 2 cysteine residues to about 10 cysteine residues, about 3 cysteine residues to about 4 cysteine residues, about 3 cysteine residues to about 5 cysteine residues, about 3 cysteine residues to about 6 cysteine residues, about 3 cysteine residues to about 7 cysteine residues, about 3 cysteine residues toabout 8 cysteine residues, about 3 cysteine residues to about 9 cysteine residues, about 3 cysteine residues to about 10 cysteine residues, about 4 cysteine residues to about 5 cysteine residues, about 4 cysteine residues to about 6 cysteine residues, about 4 cysteine residues to about 7 cysteine residues, about 4 cysteine residues to about 8 cysteine residues, about 4 cysteine residues to about 9 cysteine residues, about 4 cysteine residues to about 10 cysteine residues, about 5 cysteine residues to about 6 cysteine residues, about 5 cysteine residues to about 7 cysteine residues, about 5 cysteine residues to about 8 cysteine residues, about 5 cysteine residues to about 9 cysteine residues, about 5 cysteine residues to about 10 cysteine residues, about 6 cysteine residues to about 7 cysteine residues, about 6 cysteine residues to about 8 cysteine residues, about 6 cysteine residues to about 9 cysteine residues, about 6 cysteine residues to about 10 cysteine residues, about 7 cysteine residues to about 8 cysteine residues, about 7 cysteine residues to about 9 cysteine residues, about 7 cysteine residues to about 10 cysteine residues, about 8 cysteine residues to about 9 cysteine residues, about 8 cysteine residues to about 10 cysteine residues, or about 9 cysteine residues to about 10 cysteine residues.

[0116] In some embodiments, a first fragment of a peptide described herein comprises an amino acid content of at least about 5% cysteine, at least about 10% cysteine, at least about 15% cysteine, at least about 20% cysteine, at least about 25% cysteine, at least about 30% cysteine, at least about 35% cysteine, at least about 40% cysteine, at least about 45% cysteine, at least about 50% cysteine, at least about 60% cysteine, at least about 70% cysteine, at least about 80%, at least about 85% cysteine, or greater than about 85% cysteine. In some embodiments, a first fragment of a peptide described herein comprises an amino acid content of at most about 85% cysteine, at most about 80% cysteine, at most about 70% cysteine, at most about 60% cysteine, at most about 50% cysteine, at most about 45% cysteine, at most about 40% cysteine, at most about 35% cysteine, at most about 30% cysteine, at most about 25% cysteine, at most about 20% cysteine, at most about 15% cysteine, at most about 10% cysteine, at most about 5% cysteine, or less than about 5% cysteine.

[0117] In some embodiments, a first fragment of a peptide described herein comprises an amino acid content between about 5% cysteine to about 90% cysteine. In some embodiments, a first fragment of a peptide described herein comprises an amino acid content of at least about 5% cysteine. In some embodiments, a first fragment of a peptide described herein comprises an amino acid content of at most about 90% cysteine. In some embodiments, a first fragment of a peptide described herein comprises an amino acid content between about 5% cysteine to about 10% cysteine, about 5% cysteine to about 15% cysteine, about 5% cysteine to about 20% cysteine, about 5% cysteine to about 25% cysteine, about 5% cysteine to about 30% cysteine, about 5% cysteine to about 40% cysteine, about 5% cysteine to about 50% cysteine, about 5% cysteine to about 60% cysteine, about 5% cysteine to about 70% cysteine, about 5% cysteine to about 80% cysteine, about 5% cysteine to about 90% cysteine, about 10% cysteine to about 15% cysteine, about 10% cysteine to about 20% cysteine, about 10% cysteine to about 25% cysteine, about 10% cysteine to about 30% cysteine, about 10% cysteine to about 40% cysteine, about 10% cysteineto about 50% cysteine, about 10% cysteine to about 60% cysteine, about 10% cysteine to about 70% cysteine, about 10% cysteine to about 80% cysteine, about 10% cysteine to about 90% cysteine, about 15% cysteine to about 20% cysteine, about 15% cysteine to about 25% cysteine, about 15% cysteine to about 30% cysteine, about 15% cysteine to about 40% cysteine, about 15% cysteine to about 50% cysteine, about 15% cysteine to about 60% cysteine, about 15% cysteine to about 70% cysteine, about 15% cysteine to about 80% cysteine, about 15% cysteine to about 90% cysteine, about 20% cysteine to about 25% cysteine, about 20% cysteine to about 30% cysteine, about 20% cysteine to about 40% cysteine, about 20% cysteine to about 50% cysteine, about 20% cysteine to about 60% cysteine, about 20% cysteine to about 70% cysteine, about 20% cysteine to about 80% cysteine, about 20% cysteine to about 90% cysteine, about 25% cysteine to about 30% cysteine, about 25% cysteine to about 40% cysteine, about 25% cysteine to about 50% cysteine, about 25% cysteine to about 60% cysteine, about 25% cysteine to about 70% cysteine, about 25% cysteine to about 80% cysteine, about 25% cysteine to about 90% cysteine, about 30% cysteine to about 40% cysteine, about 30% cysteine to about 50% cysteine, about 30% cysteine to about 60% cysteine, about 30% cysteine to about 70% cysteine, about 30% cysteine to about 80% cysteine, about 30% cysteine to about 90% cysteine, about 40% cysteine to about 50% cysteine, about 40% cysteine to about 60% cysteine, about 40% cysteine to about 70% cysteine, about 40% cysteine to about 80% cysteine, about 40% cysteine to about 90% cysteine, about 50% cysteine to about 60% cysteine, about 50% cysteine to about 70% cysteine, about 50% cysteine to about 80% cysteine, about 50% cysteine to about 90% cysteine, about 60% cysteine to about 70% cysteine, about 60% cysteine to about 80% cysteine, about 60% cysteine to about 90% cysteine, about 70% cysteine to about 80% cysteine, about 70% cysteine to about 90% cysteine, or about 80% cysteine to about 90% cysteine.

[0118] In some embodiments, a first fragment of a peptide described herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to any one of SEQ ID NOs: 25-1368. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 25- 1368.

[0119] In some embodiments, a first fragment of a peptide described herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to any one of SEQ ID NOs: 25-240 or 457-912. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence as set forth in any one of SEQID NOs: 25-240 or 457-912.

[0120] In some embodiments, a first fragment of a peptide described herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to any one of SEQ ID NOs: 241-456 or 913-1368. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 241-456 or 913-1368.

[0121] In some embodiments, a first fragment of a peptide described herein comprises a length of amino acids. In some embodiments, the first fragment of a peptide described herein can be at least about 1 amino acid in length, at least about 2 amino acids in length, at least about 3 amino acids in length, at least about 4 amino acids in length, at least about 5 amino acids in length, at least about 6 amino acids in length, at least about 7 amino acids in length, at least about 8 amino acids in length, at least about 9 amino acids in length, at least about 10 amino acids in length, at least about 11 amino acids in length, at least about 12 amino acids in length, at least about 13 amino acids in length, at least about 14 amino acids in length, at least about 15 amino acids in length, at least about 16 amino acids in length, at least about 17 amino acids in length, at least about 18 amino acids in length, at least about 19 amino acids in length, at least about 20 amino acids in length, at least about 21 amino acids in length, at least about 22 amino acids in length, at least about 23 amino acids in length, at least about 24 amino acids in length, at least about 25 amino acids in length, at least about 26 amino acids in length, at least about 27 amino acids in length, at least about 28 amino acids in length, at least about 29 amino acids in length, at least about 30 amino acids in length, at least about 31 amino acids in length, at least about 32 amino acids in length, at least about 33 amino acids in length, at least about 34 amino acids in length, at least about 35 amino acids in length, or greater than about 35 amino acids in length. In some embodiments, the first fragment of a peptide described herein can be at most about 35 amino acids in length, at most about 34 amino acids in length, at most about 33 amino acids in length, at most about 32 amino acids in length, at most about 31 amino acids in length, at most about 30 amino acids in length, at most about 29 amino acids in length, at most about 28 amino acids in length, at most about 27 amino acids in length, at most about 26 amino acids in length, at most about 25 amino acids in length, at most about 24 amino acids in length, at most about 23 amino acids in length, at most about 22 amino acids in length, at most about 21 amino acids in length, at most about 20 amino acids in length, at most about 19 amino acids in length, at most about 18 amino acids in length, at most about 17 amino acids in length, at most about 16 amino acids in length, at most about 15 amino acids in length, at most about 14 amino acids in length, at most about 13 amino acids in length, at most about 12 amino acids in length, at most about 11 amino acids in length, at most about 10 amino acids in length, at most about 9 amino acids in length, at most about 8 amino acids in length, at most about 7 amino acids in length, at most about 6 amino acids in length, at most about 5 amino acidsin length, at most about 4 amino acids in length, at most about 3 amino acids in length, at most about 2 amino acids in length, at most about 1 amino acid in length, or at most about 1 amino acid in length.

[0122] In some embodiments, the first fragment of a peptide described herein can be between about 1 amino acid to about 15 amino acids. In some embodiments, the first fragment of a peptide described herein can be between at least about 1 amino acid. In some embodiments, the first fragment of a peptide described herein can be between at most about 15 amino acids. In some embodiments, the first fragment of a peptide described herein can be between about 1 amino acid to about 2 amino acids, about 1 amino acid to about 3 amino acids, about 1 amino acid to about 4 amino acids, about 1 amino acid to about 5 amino acids, about 1 amino acid to about 6 amino acids, about 1 amino acid to about 7 amino acids, about1 amino acid to about 8 amino acids, about 1 amino acid to about 9 amino acids, about 1 amino acid to about 10 amino acids, about 1 amino acid to about 12 amino acids, about 1 amino acid to about 15 amino acids, about 2 amino acids to about 3 amino acids, about 2 amino acids to about 4 amino acids, about 2 amino acids to about 5 amino acids, about 2 amino acids to about 6 amino acids, about 2 amino acids to about 7 amino acids, about 2 amino acids to about 8 amino acids, about 2 amino acids to about 9 amino acids, about 2 amino acids to about 10 amino acids, about 2 amino acids to about 12 amino acids, about2 amino acids to about 15 amino acids, about 3 amino acids to about 4 amino acids, about 3 amino acids to about 5 amino acids, about 3 amino acids to about 6 amino acids, about 3 amino acids to about 7 amino acids, about 3 amino acids to about 8 amino acids, about 3 amino acids to about 9 amino acids, about 3 amino acids to about 10 amino acids, about 3 amino acids to about 12 amino acids, about 3 amino acids to about 15 amino acids, about 4 amino acids to about 5 amino acids, about 4 amino acids to about 6 amino acids, about 4 amino acids to about 7 amino acids, about 4 amino acids to about 8 amino acids, about 4 amino acids to about 9 amino acids, about 4 amino acids to about 10 amino acids, about 4 amino acids to about 12 amino acids, about 4 amino acids to about 15 amino acids, about 5 amino acids to about6 amino acids, about 5 amino acids to about 7 amino acids, about 5 amino acids to about 8 amino acids, about 5 amino acids to about 9 amino acids, about 5 amino acids to about 10 amino acids, about 5 amino acids to about 12 amino acids, about 5 amino acids to about 15 amino acids, about 6 amino acids to about7 amino acids, about 6 amino acids to about 8 amino acids, about 6 amino acids to about 9 amino acids, about 6 amino acids to about 10 amino acids, about 6 amino acids to about 12 amino acids, about 6 amino acids to about 15 amino acids, about 7 amino acids to about 8 amino acids, about 7 amino acids to about9 amino acids, about 7 amino acids to about 10 amino acids, about 7 amino acids to about 12 amino acids, about 7 amino acids to about 15 amino acids, about 8 amino acids to about 9 amino acids, about 8 amino acids to about 10 amino acids, about 8 amino acids to about 12 amino acids, about 8 amino acids to about 15 amino acids, about 9 amino acids to about 10 amino acids, about 9 amino acids to about 12 amino acids, about 9 amino acids to about 15 amino acids, about 10 amino acids to about 12 amino acids, about10 amino acids to about 15 amino acids, or about 12 amino acids to about 15 amino acids.

[0123] In some embodiments, the first fragment of a peptide described herein may comprise a number of hydrophobic residues. In some embodiments, the first fragment of a peptide described herein may comprise no hydrophobic residues. A first fragment of a peptide described herein may comprise a combination of hydrophobic residues. A first fragment of a peptide described herein may comprise at least one hydrophobic residue and the hydrophobic residue may be independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan. In some embodiments, the first fragment of a peptide described herein comprises at least 1 hydrophobic residue, at least 2 hydrophobic residues, at least 3 hydrophobic residues, at least 4 hydrophobic residues, at least 5 hydrophobic residues, at least 6 hydrophobic residues, at least 7 hydrophobic residues, at least 8 hydrophobic residues, at least 9 hydrophobic residues, at least about 10 hydrophobic residues, at least about 12 hydrophobic residues, at least about 15 hydrophobic residues, at least about 18 hydrophobic residues, at least about 20 hydrophobic residues, or greater than about 20 hydrophobic residues. In some embodiments, the first fragment of a peptide described herein comprises at most about 20 hydrophobic residues, at most about 18 hydrophobic residues, at most about 15 hydrophobic residues, at most about 12 hydrophobic residues, at most about 10 hydrophobic residues, at most 9 hydrophobic residues, at most 8 hydrophobic residues, at most 7 hydrophobic residues, at most 6 hydrophobic residues, at most 5 hydrophobic residues, at most 4 hydrophobic residues, at most 3 hydrophobic residues, at most 2 hydrophobic residues, or at most 1 hydrophobic residue.

[0124] In some embodiments, the first fragment of a peptide described herein may have a hydrophobic amino acid content of at least about 2%, at least about 5%, at least about 8%, at least about 10%, at least about 12%, at least about 15%, at least about 18%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or greater than about 90%. In some embodiments, the first fragment of a peptide described herein may have a hydrophobic amino acid content of at most about 90%, at most about 80%, at most about 70%, at most about 60%, at most about 50%, at most about 45%, at most about 40%, at most about 35%, at most about 30%, at most about 25%, at most about 20%, at most about 18%, at most about 15%, at most about 12%, at most about 10%, at most about 8%, at most about 5%, at most about 2%, or less than about 2%.

[0125] In some embodiments, a side chain of the first fragment of a peptide described herein comprises a protecting group. In some embodiments, a protecting group of a side chain of a first fragment of a peptide described herein can comprise benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tertbutyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2,2,4,6,-7-pentamethyl-2,3- dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm). In some embodiments, a peptide described herein may comprise benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tert-butyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt),2,2,4,6,-7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p- methylbenzyl (Meb), or acetoamidomethyl (Acm), or any combination thereof.

[0126] In some embodiments, the first fragment of a peptide described herein has 4 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 217-240. In some embodiments, the first fragment of a peptide described herein has 4 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 217-240.

[0127] In some embodiments, the first fragment of a peptide described herein has 5 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 193-216. In some embodiments, the first fragment of a peptide described herein has 5 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 193-216.

[0128] In some embodiments, the first fragment of a peptide described herein has 6 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 169-192. In some embodiments, the first fragment of a peptide described herein has 6 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 169-192.

[0129] In some embodiments, the first fragment of a peptide described herein has 7 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 145-168. In some embodiments, the first fragment of a peptide described herein has 7 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 145-168.

[0130] In some embodiments, the first fragment of a peptide described herein has 8 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 121-144. In some embodiments, the first fragment of a peptide described herein has 8 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 121-144.

[0131] In some embodiments, the first fragment of a peptide described herein has 9 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 97-120. In some embodiments, the first fragment of a peptide described herein has 9 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 97-120.

[0132] In some embodiments, the first fragment of a peptide described herein has 10 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 73-96. In some embodiments, the first fragment of a peptide described herein has 10 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 73-96.

[0133] In some embodiments, the first fragment of a peptide described herein has 11 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 49-72. In some embodiments, the first fragment of a peptide described herein has 11 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 49-72.

[0134] In some embodiments, the first fragment of a peptide described herein has 12 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 25-48. In some embodiments, the first fragment of a peptide described herein has 12 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 25-48.

[0135] In some embodiments, the first fragment of a peptide described herein has 14 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 457-480. In some embodiments, the first fragment of a peptide described herein has 14 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 457-480.

[0136] In some embodiments, the first fragment of a peptide described herein has 15 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 481-504. In some embodiments, the first fragment of a peptide described herein has 15 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 481-504.

[0137] In some embodiments, the first fragment of a peptide described herein has 16 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 505-528. In some embodiments, the first fragment of a peptide described herein has 16 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 505-528.

[0138] In some embodiments, the first fragment of a peptide described herein has 17 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 529-552. In some embodiments, the first fragment of a peptide described herein has 17 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 529-552.

[0139] In some embodiments, the first fragment of a peptide described herein has 18 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 553-576. In some embodiments, the first fragment of a peptide described herein has 18 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 553-576.

[0140] In some embodiments, the first fragment of a peptide described herein has 19 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 577-600. In some embodiments, the first fragment of a peptide described herein has 19 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 577-600.

[0141] In some embodiments, the first fragment of a peptide described herein has 20 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 601-624. In some embodiments, the first fragment of a peptide described herein has 20 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 601-624.

[0142] In some embodiments, the first fragment of a peptide described herein has 21 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 625-648. In some embodiments, the first fragment of a peptide described herein has 21 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 625-648.

[0143] In some embodiments, the first fragment of a peptide described herein has 22 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 649-672. In some embodiments, the first fragment of a peptide described herein has 22 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 649-672.

[0144] In some embodiments, the first fragment of a peptide described herein has 23 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 673-696. In some embodiments, the first fragment of a peptide described herein has 23 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 673-696.

[0145] In some embodiments, the first fragment of a peptide described herein has 24 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 697-720. In some embodiments, the first fragment of a peptide described herein has 24 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 697-720.

[0146] In some embodiments, the first fragment of a peptide described herein has 25 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 721-744. In some embodiments, the first fragment of a peptide described herein has 25 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 721-744.

[0147] In some embodiments, the first fragment of a peptide described herein has 26 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 745-768. In some embodiments, the first fragment of a peptide described herein has 26 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 745-768.

[0148] In some embodiments, the first fragment of a peptide described herein has 27 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 769-792. In some embodiments, the first fragment of a peptide described herein has 27 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 769-792.

[0149] In some embodiments, the first fragment of a peptide described herein has 28 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 793-816. In some embodiments, the first fragment of a peptide described herein has 28 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 793-816.

[0150] In some embodiments, the first fragment of a peptide described herein has 29 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 817-840. In some embodiments, the first fragment of a peptide described herein has 29 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 817-840.

[0151] In some embodiments, the first fragment of a peptide described herein has 31 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 865-888. In some embodiments, the first fragment of a peptide described herein has 31 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 865-888.

[0152] In some embodiments, the first fragment of a peptide described herein has 32 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 889-912. In some embodiments, the first fragment of a peptide described herein has 32 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 889-912.

[0153] In some embodiments, the first fragment of a peptide described herein has 4 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 241-264. In some embodiments, the first fragment of a peptide described herein has 4 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 241-264.

[0154] In some embodiments, the first fragment of a peptide described herein has 5 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 265-288. In some embodiments, the first fragment of a peptide described herein has 5 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 265-288.

[0155] In some embodiments, the first fragment of a peptide described herein has 6 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 289-312. In some embodiments, the first fragment of a peptide described herein has 6 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 289-312.

[0156] In some embodiments, the first fragment of a peptide described herein has 7 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 313-336. In some embodiments, the first fragment of a peptide described herein has 7 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 313-336.

[0157] In some embodiments, the first fragment of a peptide described herein has 8 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 337-360. In some embodiments, the first fragment of a peptide described herein has 8 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 337-360.

[0158] In some embodiments, the first fragment of a peptide described herein has 9 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 361-384. In some embodiments, the first fragment of a peptide described herein has 9 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 361-384.

[0159] In some embodiments, the first fragment of a peptide described herein has 10 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 385-408. In some embodiments, the first fragment of a peptide described herein has 10 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 385-408.

[0160] In some embodiments, the first fragment of a peptide described herein has 11 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 409-432. In some embodiments, the first fragment of a peptide described herein has 11 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 409-432.

[0161] In some embodiments, the first fragment of a peptide described herein has 12 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 433-456. In some embodiments, the first fragment of a peptide described herein has 12 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 433-456.

[0162] In some embodiments, the first fragment of a peptide described herein has 14 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 913-936. In some embodiments, the first fragment of a peptide described herein has 14 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 913-936.

[0163] In some embodiments, the first fragment of a peptide described herein has 15 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 937-960. In some embodiments, the first fragment of a peptide described herein has 15 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 937-960.

[0164] In some embodiments, the first fragment of a peptide described herein has 16 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 961-984. In some embodiments, the first fragment of a peptide described herein has 16 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 961-984.

[0165] In some embodiments, the first fragment of a peptide described herein has 17 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 985-1008. In some embodiments, the first fragment of a peptide described herein has 17 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 985-1008.

[0166] In some embodiments, the first fragment of a peptide described herein has 18 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1009-1032. In some embodiments, the first fragment of a peptide described herein has 18 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1009-1032.

[0167] In some embodiments, the first fragment of a peptide described herein has 19 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 1033-1056. In some embodiments, the first fragment of a peptide described herein has 19 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1033-1056.

[0168] In some embodiments, the first fragment of a peptide described herein has 20 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1057-1080. In some embodiments, the first fragment of a peptide described herein has 20 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1057-1080.

[0169] In some embodiments, the first fragment of a peptide described herein has 21 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1081-1104. In some embodiments, the first fragment of a peptide described herein has 21 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1081-1104.

[0170] In some embodiments, the first fragment of a peptide described herein has 22 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1105-1128. In some embodiments, the first fragment of a peptide described herein has 22 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1105-1128.

[0171] In some embodiments, the first fragment of a peptide described herein has 23 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1129-1152. In some embodiments, the first fragment of a peptide described herein has 23 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1129-1152.

[0172] In some embodiments, the first fragment of a peptide described herein has 24 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1153-1176. In some embodiments, the first fragment of a peptide described herein has 24 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1153-1176.

[0173] In some embodiments, the first fragment of a peptide described herein has 25 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 1177-1200. In some embodiments, the first fragment of a peptide described herein has 25 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1177-1200.

[0174] In some embodiments, the first fragment of a peptide described herein has 26 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1201-1224. In some embodiments, the first fragment of a peptide described herein has 26 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1201-1224.

[0175] In some embodiments, the first fragment of a peptide described herein has 27 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1225-1248. In some embodiments, the first fragment of a peptide described herein has 27 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1225-1248.

[0176] In some embodiments, the first fragment of a peptide described herein has 28 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1249-1272. In some embodiments, the first fragment of a peptide described herein has 28 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1249-1272.

[0177] In some embodiments, the first fragment of a peptide described herein has 29 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1273-1296. In some embodiments, the first fragment of a peptide described herein has 29 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1273-1296.

[0178] In some embodiments, the first fragment of a peptide described herein has 30 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1297-1320. In some embodiments, the first fragment of a peptide described herein has 30 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1297-1320.

[0179] In some embodiments, the first fragment of a peptide described herein has 31 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acidsequence as set forth in any one of SEQ ID NOs: 1321-1344. In some embodiments, the first fragment of a peptide described herein has 31 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1321-1344.

[0180] In some embodiments, the first fragment of a peptide described herein has 32 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1345-1368. In some embodiments, the first fragment of a peptide described herein has 32 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1345-1368.

[0181] Second Fragment of Peptide

[0182] In some embodiments, the second fragment, represented by the Formula (l-B), comprises a number of cysteine residues. In some embodiments, the second fragment, represented by the Formula (l-B), comprises a percentage of cysteine in an amino acid content. In some embodiments, a second fragment of a peptide described herein comprises no cysteine residues (e.g., 0 cysteine residues). In some embodiments, a second fragment of a peptide described herein comprises at least one cysteine residue. In some embodiments, a second fragment of a peptide described herein comprises at least 1 cysteine residue, at least 2 cysteine residues, at least 3 cysteine residues, at least 4 cysteine residues, at least 5 cysteine residues, at least 6 cysteine residues, at least 7 cysteine residues, at least 8 cysteine residues, at least 9 cysteine residues, at least 10 cysteine residues, or greater than 10 cysteine residues. In some embodiments, the peptide comprises at most 10 cysteine residues, at most 9 cysteine residues, at most 8 cysteine residues, at most 7 cysteine residues, at most 6 cysteine residues, at most 5 cysteine residues, at most 4 cysteine residues, at most 3 cysteine residues, at most 2 cysteine residues, or at most 1 cysteine residue.

[0183] In some embodiments, a second fragment of a peptide described herein comprises between about 1 cysteine residue to about 10 cysteine residues. In some embodiments, a second fragment of a peptide described herein comprises between about 1 cysteine residue to about 2 cysteine residues, about 1 cysteine residue to about 3 cysteine residues, about 1 cysteine residue to about 4 cysteine residues, about 1 cysteine residue to about 5 cysteine residues, about 1 cysteine residue to about 6 cysteine residues, about 1 cysteine residue to about 7 cysteine residues, about 1 cysteine residue to about 8 cysteine residues, about 1 cysteine residue to about 9 cysteine residues, about 1 cysteine residue to about 10 cysteine residues, about 2 cysteine residues to about 3 cysteine residues, about 2 cysteine residues to about 4 cysteine residues, about 2 cysteine residues to about 5 cysteine residues, about 2 cysteine residues to about 6 cysteine residues, about 2 cysteine residues to about 7 cysteine residues, about 2 cysteine residues to about 8 cysteine residues, about 2 cysteine residues to about 9 cysteine residues, about 2 cysteine residues to about 10 cysteine residues, about 3 cysteine residues to about 4 cysteine residues, about 3 cysteine residues to about 5 cysteine residues, about 3 cysteine residues to about 6cysteine residues, about 3 cysteine residues to about 7 cysteine residues, about 3 cysteine residues to about 8 cysteine residues, about 3 cysteine residues to about 9 cysteine residues, about 3 cysteine residues to about 10 cysteine residues, about 4 cysteine residues to about 5 cysteine residues, about 4 cysteine residues to about 6 cysteine residues, about 4 cysteine residues to about 7 cysteine residues, about 4 cysteine residues to about 8 cysteine residues, about 4 cysteine residues to about 9 cysteine residues, about 4 cysteine residues to about 10 cysteine residues, about 5 cysteine residues to about 6 cysteine residues, about 5 cysteine residues to about 7 cysteine residues, about 5 cysteine residues to about 8 cysteine residues, about 5 cysteine residues to about 9 cysteine residues, about 5 cysteine residues to about 10 cysteine residues, about 6 cysteine residues to about 7 cysteine residues, about 6 cysteine residues to about 8 cysteine residues, about 6 cysteine residues to about 9 cysteine residues, about 6 cysteine residues to about 10 cysteine residues, about 7 cysteine residues to about 8 cysteine residues, about 7 cysteine residues to about 9 cysteine residues, about 7 cysteine residues to about 10 cysteine residues, about 8 cysteine residues to about 9 cysteine residues, about 8 cysteine residues to about 10 cysteine residues, or about 9 cysteine residues to about 10 cysteine residues.

[0184] In some embodiments, a second fragment of a peptide described herein comprises an amino acid content of at least about 5% cysteine, at least about 10% cysteine, at least about 15% cysteine, at least about 20% cysteine, at least about 25% cysteine, at least about 30% cysteine, at least about 35% cysteine, at least about 40% cysteine, at least about 45% cysteine, at least about 50% cysteine, at least about 60% cysteine, at least about 70% cysteine, at least about 80%, at least about 85% cysteine, or greater than about 85% cysteine. In some embodiments, a second fragment of a peptide described herein comprises an amino acid content of at most about 85% cysteine, at most about 80% cysteine, at most about 70% cysteine, at most about 60% cysteine, at most about 50% cysteine, at most about 45% cysteine, at most about 40% cysteine, at most about 35% cysteine, at most about 30% cysteine, at most about 25% cysteine, at most about 20% cysteine, at most about 15% cysteine, at most about 10% cysteine, at most about 5% cysteine, or less than about 5% cysteine.

[0185] In some embodiments, a second fragment of a peptide described herein comprises an amino acid content between about 5% cysteine to about 90% cysteine. In some embodiments, a second fragment of a peptide described herein comprises an amino acid content between at least about 5% cysteine. In some embodiments, a second fragment of a peptide described herein comprises an amino acid content between at most about 90% cysteine. In some embodiments, a second fragment of a peptide described herein comprises an amino acid content between about 5% cysteine to about 10% cysteine, about 5% cysteine to about 15% cysteine, about 5% cysteine to about 20% cysteine, about 5% cysteine to about 25% cysteine, about 5% cysteine to about 30% cysteine, about 5% cysteine to about 40% cysteine, about 5% cysteine to about 50% cysteine, about 5% cysteine to about 60% cysteine, about 5% cysteine to about 70% cysteine, about 5% cysteine to about 80% cysteine, about 5% cysteine to about 90% cysteine, about 10% cysteine to about 15% cysteine, about 10% cysteine to about 20% cysteine, about 10% cysteine toabout 25% cysteine, about 10% cysteine to about 30% cysteine, about 10% cysteine to about 40% cysteine, about 10% cysteine to about 50% cysteine, about 10% cysteine to about 60% cysteine, about 10% cysteine to about 70% cysteine, about 10% cysteine to about 80% cysteine, about 10% cysteine to about 90% cysteine, about 15% cysteine to about 20% cysteine, about 15% cysteine to about 25% cysteine, about 15% cysteine to about 30% cysteine, about 15% cysteine to about 40% cysteine, about 15% cysteine to about 50% cysteine, about 15% cysteine to about 60% cysteine, about 15% cysteine to about 70% cysteine, about 15% cysteine to about 80% cysteine, about 15% cysteine to about 90% cysteine, about 20% cysteine to about 25% cysteine, about 20% cysteine to about 30% cysteine, about 20% cysteine to about 40% cysteine, about 20% cysteine to about 50% cysteine, about 20% cysteine to about 60% cysteine, about 20% cysteine to about 70% cysteine, about 20% cysteine to about 80% cysteine, about 20% cysteine to about 90% cysteine, about 25% cysteine to about 30% cysteine, about 25% cysteine to about 40% cysteine, about 25% cysteine to about 50% cysteine, about 25% cysteine to about 60% cysteine, about 25% cysteine to about 70% cysteine, about 25% cysteine to about 80% cysteine, about 25% cysteine to about 90% cysteine, about 30% cysteine to about 40% cysteine, about 30% cysteine to about 50% cysteine, about 30% cysteine to about 60% cysteine, about 30% cysteine to about 70% cysteine, about 30% cysteine to about 80% cysteine, about 30% cysteine to about 90% cysteine, about 40% cysteine to about 50% cysteine, about 40% cysteine to about 60% cysteine, about 40% cysteine to about 70% cysteine, about 40% cysteine to about 80% cysteine, about 40% cysteine to about 90% cysteine, about 50% cysteine to about 60% cysteine, about 50% cysteine to about 70% cysteine, about 50% cysteine to about 80% cysteine, about 50% cysteine to about 90% cysteine, about 60% cysteine to about 70% cysteine, about 60% cysteine to about 80% cysteine, about 60% cysteine to about 90% cysteine, about 70% cysteine to about 80% cysteine, about 70% cysteine to about 90% cysteine, or about 80% cysteine to about 90% cysteine.

[0186] In some embodiments, a second fragment of a peptide described herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to any one of SEQ ID NOs: 25-1368. In some embodiments, a second fragment of a peptide described herein comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 25-1368.

[0187] In some embodiments, a second fragment of a peptide described herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to any one of SEQ ID NOs: 25-240 or 457-912. In some embodiments, a second fragment of a peptide described herein comprises an amino acid sequence as set forth in any one of SEQID NOs: 25-240 or 457-912.

[0188] In some embodiments, a second fragment of a peptide described herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to any one of SEQ ID NOs: 241-456 or 913-1368. In some embodiments, a second fragment of a peptide described herein comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 241-456 or 913-1368.

[0189] In some embodiments, a second fragment of a peptide described herein comprises a length of amino acids. In some embodiments, the second fragment of a peptide described herein can be at least about 1 amino acid in length, at least about 2 amino acids in length, at least about 3 amino acids in length, at least about 4 amino acids in length, at least about 5 amino acids in length, at least about 6 amino acids in length, at least about 7 amino acids in length, at least about 8 amino acids in length, at least about 9 amino acids in length, at least about 10 amino acids in length, at least about 11 amino acids in length, at least about 12 amino acids in length, at least about 13 amino acids in length, at least about 14 amino acids in length, at least about 15 amino acids in length, at least about 16 amino acids in length, at least about 17 amino acids in length, at least about 18 amino acids in length, at least about 19 amino acids in length, at least about 20 amino acids in length, at least about 21 amino acids in length, at least about 22 amino acids in length, at least about 23 amino acids in length, at least about 24 amino acids in length, at least about 25 amino acids in length, at least about 26 amino acids in length, at least about 27 amino acids in length, at least about 28 amino acids in length, at least about 29 amino acids in length, at least about 30 amino acids in length, at least about 31 amino acids in length, at least about 32 amino acids in length, at least about 33 amino acids in length, at least about 34 amino acids in length, at least about 35 amino acids in length, or greater than about 35 amino acids in length. In some embodiments, the second fragment of a peptide described herein can be at most about 35 amino acids in length, at most about 34 amino acids in length, at most about 33 amino acids in length, at most about 32 amino acids in length, at most about 31 amino acids in length, at most about 30 amino acids in length, at most about 29 amino acids in length, at most about 28 amino acids in length, at most about 27 amino acids in length, at most about 26 amino acids in length, at most about 25 amino acids in length, at most about 24 amino acids in length, at most about 23 amino acids in length, at most about 22 amino acids in length, at most about 21 amino acids in length, at most about 20 amino acids in length, at most about 19 amino acids in length, at most about 18 amino acids in length, at most about 17 amino acids in length, at most about 16 amino acids in length, at most about 15 amino acids in length, at most about 14 amino acids in length, at most about 13 amino acids in length, at most about 12 amino acids in length, at most about 11 amino acids in length, at most about 10 amino acids in length, at most about 9 amino acids in length, at most about 8 amino acids in length, at most about 7 amino acids in length, at most about 6 amino acids in length, at most about 5 amino acids in length, at most about 4 amino acids in length, at most about 3 amino acids in length, atmost about 2 amino acids in length, at most about 1 amino acid in length, or at most about 1 amino acid in length.

[0190] In some embodiments, the second fragment of a peptide described herein can be between about 1 amino acid to about 15 amino acids. In some embodiments, the second fragment of a peptide described herein can be between at least about 1 amino acid. In some embodiments, the second fragment of a peptide described herein can be between at most about 15 amino acids. In some embodiments, the second fragment of a peptide described herein can be between about 1 amino acid to about 2 amino acids, about 1 amino acid to about 3 amino acids, about 1 amino acid to about 4 amino acids, about 1 amino acid to about 5 amino acids, about 1 amino acid to about 6 amino acids, about 1 amino acid to about 7 amino acids, about 1 amino acid to about 8 amino acids, about 1 amino acid to about 9 amino acids, about 1 amino acid to about 10 amino acids, about 1 amino acid to about 12 amino acids, about 1 amino acid to about 15 amino acids, about 2 amino acids to about 3 amino acids, about 2 amino acids to about 4 amino acids, about 2 amino acids to about 5 amino acids, about 2 amino acids to about 6 amino acids, about 2 amino acids to about 7 amino acids, about 2 amino acids to about 8 amino acids, about 2 amino acids to about 9 amino acids, about 2 amino acids to about 10 amino acids, about 2 amino acids to about 12 amino acids, about 2 amino acids to about 15 amino acids, about 3 amino acids to about 4 amino acids, about 3 amino acids to about 5 amino acids, about 3 amino acids to about 6 amino acids, about 3 amino acids to about 7 amino acids, about 3 amino acids to about 8 amino acids, about 3 amino acids to about 9 amino acids, about 3 amino acids to about 10 amino acids, about 3 amino acids to about 12 amino acids, about 3 amino acids to about 15 amino acids, about 4 amino acids to about 5 amino acids, about 4 amino acids to about 6 amino acids, about 4 amino acids to about 7 amino acids, about 4 amino acids to about 8 amino acids, about 4 amino acids to about 9 amino acids, about 4 amino acids to about 10 amino acids, about 4 amino acids to about 12 amino acids, about 4 amino acids to about 15 amino acids, about 5 amino acids to about 6 amino acids, about 5 amino acids to about 7 amino acids, about 5 amino acids to about 8 amino acids, about 5 amino acids to about 9 amino acids, about 5 amino acids to about 10 amino acids, about 5 amino acids to about 12 amino acids, about 5 amino acids to about 15 amino acids, about 6 amino acids to about 7 amino acids, about 6 amino acids to about 8 amino acids, about 6 amino acids to about 9 amino acids, about 6 amino acids to about 10 amino acids, about 6 amino acids to about 12 amino acids, about 6 amino acids to about 15 amino acids, about 7 amino acids to about 8 amino acids, about 7 amino acids to about 9 amino acids, about 7 amino acids to about 10 amino acids, about 7 amino acids to about 12 amino acids, about 7 amino acids to about 15 amino acids, about 8 amino acids to about 9 amino acids, about 8 amino acids to about 10 amino acids, about 8 amino acids to about 12 amino acids, about 8 amino acids to about 15 amino acids, about 9 amino acids to about 10 amino acids, about 9 amino acids to about 12 amino acids, about 9 amino acids to about 15 amino acids, about 10 amino acids to about 12 amino acids, about 10 amino acids to about 15 amino acids, or about 12 amino acids to about15 amino acids.

[0191] In some embodiments, the second fragment of a peptide described herein may comprise a number of hydrophobic residues. In some embodiments, the second fragment of a peptide described herein may comprise no hydrophobic residues. A second fragment of a peptide described herein may comprise a combination of hydrophobic residues. A second fragment of a peptide described herein may comprise at least one hydrophobic residue and the hydrophobic residue may be independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan. In some embodiments, the second fragment of a peptide described herein comprises at least 1 hydrophobic residue, at least 2 hydrophobic residues, at least 3 hydrophobic residues, at least 4 hydrophobic residues, at least 5 hydrophobic residues, at least 6 hydrophobic residues, at least 7 hydrophobic residues, at least 8 hydrophobic residues, at least 9 hydrophobic residues, at least about 10 hydrophobic residues, at least about 12 hydrophobic residues, at least about 15 hydrophobic residues, at least about 18 hydrophobic residues, at least about 20 hydrophobic residues, or greater than about 20 hydrophobic residues. In some embodiments, the second fragment of a peptide described herein comprises at most about 20 hydrophobic residues, at most about 18 hydrophobic residues, at most about 15 hydrophobic residues, at most about 12 hydrophobic residues, at most about 10 hydrophobic residues, at most 9 hydrophobic residues, at most 8 hydrophobic residues, at most 7 hydrophobic residues, at most 6 hydrophobic residues, at most 5 hydrophobic residues, at most 4 hydrophobic residues, at most 3 hydrophobic residues, at most 2 hydrophobic residues, or at most 1 hydrophobic residue.

[0192] In some embodiments, the second fragment of a peptide described herein may have a hydrophobic amino acid content of at least about 2%, at least about 5%, at least about 8%, at least about 10%, at least about 12%, at least about 15%, at least about 18%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or greater than about 90%. In some embodiments, the second fragment of a peptide described herein may have a hydrophobic amino acid content of at most about 90%, at most about 80%, at most about 70%, at most about 60%, at most about 50%, at most about 45%, at most about 40%, at most about 35%, at most about 30%, at most about 25%, at most about 20%, at most about 18%, at most about 15%, at most about 12%, at most about 10%, at most about 8%, at most about 5%, at most about 2%, or less than about 2%.

[0193] In some embodiments, a side chain of the second fragment of a peptide described herein comprises a protecting group. In some embodiments, a protecting group of a side chain of a second fragment of a peptide described herein can comprise benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tert-butyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2,2,4,6,-7-pentamethyl- 2,3-dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm). In some embodiments, a peptide described herein may comprise benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), tert-butyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2,2,4,6,-7-pentamethyl-2,3-dihydrobenzofuran-5- sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm), or any combination thereof.

[0194] In some embodiments, the second fragment of a peptide described herein has 4 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 217-240. In some embodiments, the second fragment of a peptide described herein has 4 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 217-240.

[0195] In some embodiments, the second fragment of a peptide described herein has 5 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 193-216. In some embodiments, the second fragment of a peptide described herein has 5 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 193-216.

[0196] In some embodiments, the second fragment of a peptide described herein has 6 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 169-192. In some embodiments, the second fragment of a peptide described herein has 6 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 169-192.

[0197] In some embodiments, the second fragment of a peptide described herein has 7 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 145-168. In some embodiments, the second fragment of a peptide described herein has 7 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 145-168.

[0198] In some embodiments, the second fragment of a peptide described herein has 8 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 121-144. In some embodiments, the second fragment of a peptide described herein has 8 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 121-144.

[0199] In some embodiments, the second fragment of a peptide described herein has 9 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%,at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 97-120. In some embodiments, the second fragment of a peptide described herein has 9 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 97-120.

[0200] In some embodiments, the second fragment of a peptide described herein has 10 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 73-96. In some embodiments, the second fragment of a peptide described herein has 10 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 73-96.

[0201] In some embodiments, the second fragment of a peptide described herein has 11 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 49-72. In some embodiments, the second fragment of a peptide described herein has 11 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 49-72.

[0202] In some embodiments, the second fragment of a peptide described herein has 12 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 25-48. In some embodiments, the second fragment of a peptide described herein has 12 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 25-48.

[0203] In some embodiments, the second fragment of a peptide described herein has 14 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 457-480. In some embodiments, the second fragment of a peptide described herein has 14 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 457-480.

[0204] In some embodiments, the second fragment of a peptide described herein has 15 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 481-504. In some embodiments, the second fragment of a peptide described herein has 15 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 481-504.

[0205] In some embodiments, the second fragment of a peptide described herein has 16 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 505-528. In some embodiments, the second fragment of a peptide described herein has 16 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 505-528.

[0206] In some embodiments, the second fragment of a peptide described herein has 17 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 529-552. In some embodiments, the second fragment of a peptide described herein has 17 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 529-552.

[0207] In some embodiments, the second fragment of a peptide described herein has 18 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 553-576. In some embodiments, the second fragment of a peptide described herein has 18 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 553-576.

[0208] In some embodiments, the second fragment of a peptide described herein has 19 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 577-600. In some embodiments, the second fragment of a peptide described herein has 19 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 577-600.

[0209] In some embodiments, the second fragment of a peptide described herein has 20 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 601-624. In some embodiments, the second fragment of a peptide described herein has 20 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 601-624.

[0210] In some embodiments, the second fragment of a peptide described herein has 21 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 625-648. In some embodiments, the second fragment of a peptide described herein has 21 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 625-648.

[0211] In some embodiments, the second fragment of a peptide described herein has 22 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 649-672. In some embodiments, the second fragment of a peptide described herein has 22 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 649-672.

[0212] In some embodiments, the second fragment of a peptide described herein has 23 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 673-696. In some embodiments, the second fragment of a peptide described herein has 23 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 673-696.

[0213] In some embodiments, the second fragment of a peptide described herein has 24 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 697-720. In some embodiments, the second fragment of a peptide described herein has 24 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 697-720.

[0214] In some embodiments, the second fragment of a peptide described herein has 25 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 721-744. In some embodiments, the second fragment of a peptide described herein has 25 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 721-744.

[0215] In some embodiments, the second fragment of a peptide described herein has 26 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 745-768. In some embodiments, the second fragment of a peptide described herein has 26 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 745-768.

[0216] In some embodiments, the second fragment of a peptide described herein has 27 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 769-792. In some embodiments, the second fragment of a peptide described herein has 27 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 769-792.

[0217] In some embodiments, the second fragment of a peptide described herein has 28 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 793-816. In some embodiments, the second fragment of a peptide described herein has 28 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 793-816.

[0218] In some embodiments, the second fragment of a peptide described herein has 29 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 817-840. In some embodiments, the second fragment of a peptide described herein has 29 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 817-840.

[0219] In some embodiments, the second fragment of a peptide described herein has 30 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 841-864. In some embodiments, the second fragment of a peptide described herein has 30 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 841-864.

[0220] In some embodiments, the second fragment of a peptide described herein has 31 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 865-888. In some embodiments, the second fragment of a peptide described herein has 31 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 865-888.

[0221] In some embodiments, the second fragment of a peptide described herein has 32 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 889-912. In some embodiments, the second fragment of a peptide described herein has 32 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 889-912.

[0222] In some embodiments, the second fragment of a peptide described herein has 4 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 241-264. In some embodiments, the second fragment of a peptide described herein has 4 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 241-264.

[0223] In some embodiments, the second fragment of a peptide described herein has 5 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%,at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 265-288. In some embodiments, the second fragment of a peptide described herein has 5 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 265-288.

[0224] In some embodiments, the second fragment of a peptide described herein has 6 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 289-312. In some embodiments, the second fragment of a peptide described herein has 6 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 289-312.

[0225] In some embodiments, the second fragment of a peptide described herein has 7 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 313-336. In some embodiments, the second fragment of a peptide described herein has 7 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 313-336.

[0226] In some embodiments, the second fragment of a peptide described herein has 8 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 337-360. In some embodiments, the second fragment of a peptide described herein has 8 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 337-360.

[0227] In some embodiments, the second fragment of a peptide described herein has 9 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 361-384. In some embodiments, the second fragment of a peptide described herein has 9 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 361-384.

[0228] In some embodiments, the second fragment of a peptide described herein has 10 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 385-408. In some embodiments, the second fragment of a peptide described herein has 10 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 385-408.

[0229] In some embodiments, the second fragment of a peptide described herein has 11 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 409-432. In some embodiments, the second fragment of a peptide described herein has 11 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 409-432.

[0230] In some embodiments, the second fragment of a peptide described herein has 12 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 433-456. In some embodiments, the second fragment of a peptide described herein has 12 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 433-456.

[0231] In some embodiments, the second fragment of a peptide described herein has 14 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 913-936. In some embodiments, the second fragment of a peptide described herein has 14 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 913-936.

[0232] In some embodiments, the second fragment of a peptide described herein has 15 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 937-960. In some embodiments, the second fragment of a peptide described herein has 15 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 937-960.

[0233] In some embodiments, the second fragment of a peptide described herein has 16 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 961-984. In some embodiments, the second fragment of a peptide described herein has 16 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 961-984.

[0234] In some embodiments, the second fragment of a peptide described herein has 17 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 985-1008. In some embodiments, the second fragment of a peptide described herein has 17 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 985-1008.

[0235] In some embodiments, the second fragment of a peptide described herein has 18 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1009-1032. In some embodiments, the second fragment of a peptide described herein has 18 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1009-1032.

[0236] In some embodiments, the second fragment of a peptide described herein has 19 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1033-1056. In some embodiments, the second fragment of a peptide described herein has 19 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1033-1056.

[0237] In some embodiments, the second fragment of a peptide described herein has 20 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1057-1080. In some embodiments, the second fragment of a peptide described herein has 20 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1057-1080.

[0238] In some embodiments, the second fragment of a peptide described herein has 21 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1081-1104. In some embodiments, the second fragment of a peptide described herein has 21 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1081-1104.

[0239] In some embodiments, the second fragment of a peptide described herein has 22 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1105-1128. In some embodiments, the second fragment of a peptide described herein has 22 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1105-1128.

[0240] In some embodiments, the second fragment of a peptide described herein has 23 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1129-1152. In some embodiments, the second fragment of a peptide described herein has 23 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1129-1152.

[0241] In some embodiments, the second fragment of a peptide described herein has 24 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1153-1176. In some embodiments, the second fragment of a peptide described herein has 24 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1153-1176.

[0242] In some embodiments, the second fragment of a peptide described herein has 25 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1177-1200. In some embodiments, the second fragment of a peptide described herein has 25 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1177-1200.

[0243] In some embodiments, the second fragment of a peptide described herein has 26 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1201-1224. In some embodiments, the second fragment of a peptide described herein has 26 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1201-1224.

[0244] In some embodiments, the second fragment of a peptide described herein has 27 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1225-1248. In some embodiments, the second fragment of a peptide described herein has 27 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1225-1248.

[0245] In some embodiments, the second fragment of a peptide described herein has 28 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1249-1272. In some embodiments, the second fragment of a peptide described herein has 28 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1249-1272.

[0246] In some embodiments, the second fragment of a peptide described herein has 29 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1273-1296. In some embodiments, the second fragment of a peptide described herein has 29 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1273-1296.

[0247] In some embodiments, the second fragment of a peptide described herein has 30 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1297-1320. In some embodiments, the second fragment of a peptide described herein has 30 amino acids and comprises an amino acid sequence as set forth in any one of SEQ. ID NOs: 1297-1320.

[0248] In some embodiments, the second fragment of a peptide described herein has 31 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1321-1344. In some embodiments, the second fragment of a peptide described herein has 31 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1321-1344.

[0249] In some embodiments, the second fragment of a peptide described herein has 32 amino acids and comprises a sequence with at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% sequence identity to an amino acid sequence as set forth in any one of SEQ ID NOs: 1345-1368. In some embodiments, the second fragment of a peptide described herein has 32 amino acids and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1345-1368.

[0250] In some embodiments, a method described herein comprises providing a peptide with a modification to a N-terminus, a C-terminus, or a combination thereof. In some embodiments, a terminus (e.g., N-terminal and / or C-terminal) of the peptide may comprise a peptide modification. In some embodiments, a terminus (e.g., N-terminal and / or C-terminal) of a first fragment and / or a second fragment of a peptide may comprise a peptide modification.

[0251] In some embodiments, a N-terminal of a first fragment (e.g., NA) comprises a protecting group or a free thiol of a cysteine. In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises a protecting group or a free thiol of a cysteine. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises a protecting group. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises a free thiol of a cysteine. In some embodiments, a N-terminal of a first fragment comprises a protecting group and a N-terminal of a second fragment comprises a free thiol of a cysteine. In some embodiments, a N-terminal of a first fragment comprises a free thiol of a cysteine and a N-terminal of a second fragment comprises a protecting group. In some embodiments, a C-terminal of a first fragment (e.g., CA) comprises a thioether. In some embodiments, a C-terminal of a second fragment (e.g., CB) comprises a thioether.

[0252] In some embodiments, a N-terminal of a first fragment (e.g., NA) comprises a protecting group or a free thiol of a cysteine and a C-terminal of a first fragment (e.g., CA) comprises a thioether. In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises a protecting group or a free thiol of a cysteine and a C-terminal of a second fragment (e.g., CB) comprises a thioether. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises aprotecting group and a C-terminal of a first fragment comprises a thioether. In some embodiments, a N- terminal of a first fragment and a N-terminal of a second fragment comprises a protecting group and a C- terminal of a second fragment comprises a thioether. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises a free thiol of a cysteine and a C-terminal of a first fragment comprises a thioether. In some embodiments, a N-terminal of a first fragment and a N- terminal of a second fragment comprises a free thiol of a cysteine and a C-terminal of a second fragment comprises a thioether. In some embodiments, a N-terminal of a first fragment comprises a protecting group, a N-terminal of a second fragment comprises a free thiol of a cysteine, and a C-terminal of a first fragment comprises a thioether. In some embodiments, a N-terminal of a first fragment comprises a protecting group, a N-terminal of a second fragment comprises a free thiol of a cysteine, and a C-terminal of a second fragment comprises a thioether. In some embodiments, a N-terminal of a first fragment comprises a free thiol of a cysteine, a N-terminal of a second fragment comprises a protecting group, and a C-terminal of a first fragment comprises a thioether. In some embodiments, a N-terminal of a first fragment comprises a free thiol of a cysteine, a N-terminal of a second fragment comprises a protecting group, and a C-terminal of a second fragment comprises a thioether.

[0253] In some embodiments, a N-terminal of a first fragment (e.g., NA) comprises a protecting group or a free thiol of a cysteine and a C-terminal of a first fragment (e.g., CA) may be bound to a resin. In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises a protecting group or a free thiol of a cysteine and a C-terminal of a second fragment (e.g., CB) may be bound to a resin. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises a protecting group and a C-terminal of a first fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises a protecting group and a C-terminal of a second fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment and a N-terminal of a second fragment comprises a free thiol of a cysteine and a C-terminal of a first fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment and a N- terminal of a second fragment comprises a free thiol of a cysteine and a C-terminal of a second fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment comprises a protecting group, a N-terminal of a second fragment comprises a free thiol of a cysteine, and a C-terminal of a first fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment comprises a protecting group, a N-terminal of a second fragment comprises a free thiol of a cysteine, and a C-terminal of a second fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment comprises a free thiol of a cysteine, a N-terminal of a second fragment comprises a protecting group, and a C-terminal of a first fragment may be bound to a resin. In some embodiments, a N-terminal of a first fragment comprises a free thiol of a cysteine, a N-terminal of a second fragment comprises a protecting group, and a C-terminal of a second fragment may be bound to a resin.

[0254] Selenium and selenoproteins can be beneficial for keratinocyte function or improving hair qualities (e.g., strength, elasticity, shine). In some embodiments, the peptide described herein, a first fragment of a peptide described herein, a second fragment of a peptide described herein, or a combination thereof may comprise a selenocysteine, a thioester, or a selenoester. In some embodiments, a N-terminal of a first fragment (e.g., NA) comprises a selenocysteine. In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises a selenocysteine. In some embodiments, a C-terminal of a first fragment (e.g., CA) comprises a thioether or a selenoester. In some embodiments, when the C-terminus of the first fragment (e.g., CA) comprises a thioether or a selenoester, NB-B-CB comprises a thiol of a cysteine. In some embodiments, a C-terminal of a second fragment (e.g., CB) comprises a thioether or a selenoester. In some embodiments, a N-terminal of a first fragment (e.g., NA) comprises a selenocysteine and a C-terminal of a first fragment (e.g., CA) comprises a thioether or a selenoester. In some embodiments, a N-terminal of a first fragment (e.g., NA) comprises a selenocysteine and a C-terminal of a second fragment (e.g., CB) comprises a thioether or a selenoester. In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises a selenocysteine and a C-terminal of a first fragment (e.g., CA) comprises a thioether or a selenoester. In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises a selenocysteine and a C-terminal of a second fragment (e.g., CB) comprises a thioether or a selenoester.

[0255] In some embodiments, a configuration of a peptide described herein comprises joining a first fragment and a second fragment. In some embodiments, joining the first fragment and the second fragment comprises contacting a N-terminal of a second fragment (e.g., NB) to a C-terminal of a first fragment (e.g., CA). In some embodiments, joining the first fragment and the second fragment comprises contacting a N-terminal of a second fragment (e.g., NB) to a C-terminal of a first fragment (e.g., CA) to provide a selenium-containing peptide. In some embodiments, joining the first fragment and the second fragment comprises contacting a N-terminal of a second fragment (e.g., NB) to a C-terminal of a first fragment (e.g., CA) to provide a peptide with a configuration set forth in Formula l-C'.

[0256] In some embodiments, joining the first fragment and the second fragment comprises contacting a N-terminal of a first fragment (e.g., NA) to a C-terminal of a second fragment (e.g., CB). In some embodiments, joining the first fragment and the second fragment comprises contacting a N-terminal of a first fragment (e.g., NA) to a C-terminal of a second fragment (e.g., CB) to provide a selenium-containing peptide. In some embodiments, joining the first fragment and the second fragment comprises contacting a N-terminal of a first fragment (e.g., NA) to a C-terminal of a second fragment (e.g., CB) to provide a peptide with a configuration set forth in Formula l-C".

[0257] In some embodiments, the selenium-containing peptide reacts with a phosphine. In some embodiments, the selenium-containing peptide reacts with a phosphine to provide a serine-containing peptide. In some embodiments, the peptide comprises at least one serine residue. In some embodiments, the selenium-containing peptide reacts with a phosphine to provide an alanine-containing peptide. Insome embodiments, the peptide comprises at least one alanine residue. In some embodiments, the selenium-containing peptide reacts with a phosphine to provide a glycine-containing peptide. In some embodiments, the peptide comprises at least one glycine residue. In some embodiments, the selenium- containing peptide reacts with a phosphine to provide a threonine-containing peptide. In some embodiments, the peptide comprises at least one threonine residue. In some embodiments, the selenium-containing peptide reacts with a phosphine to provide an isoleucine-containing peptide. In some embodiments, the peptide comprises at least one isoleucine residue. In some embodiments, the selenium-containing peptide reacts with a phosphine to provide a leucine-containing peptide. In some embodiments, the peptide comprises at least one leucine residue. In some embodiments, the selenium- containing peptide reacts with a phosphine to provide a valine-containing peptide. In some embodiments, the peptide comprises at least one valine residue.

[0258] In some embodiments, the selenium-containing peptide reacts with a phosphine and a radical initiator to provide an alanine-containing peptide. In some embodiments, the selenium-containing peptide reacts with a phosphine and a radical initiator to provide a glycine-containing peptide. In some embodiments, the selenium-containing peptide reacts with a phosphine and a radical initiator to provide an isoleucine-containing peptide. In some embodiments, the selenium-containing peptide reacts with a phosphine and a radical initiator to provide a leucine-containing peptide. In some embodiments, the selenium-containing peptide reacts with a phosphine and a radical initiator to provide a valine-containing peptide. In some embodiments, the selenium-containing peptide reacts with a phosphine and a radical initiator to provide an threonine-containing peptide. The controlled radical initiators can be bis- dithiocarbamate or bis-dithiocarbonate compounds with a single carbon atom between the two dithiocarbamate or dithiocarbonate groups. The controlled radical initiators can be referred to as photoinitiators or photoiniferters because the controlled radical polymerization reaction can be photolytical ly induced. Without wishing to be bound by theory, the combination of a radical initiator and a reducing agent (e.g., TCEP) may control a rate of reaction.

[0259] In some embodiments, the phosphine can be a homoleptic phosphine, a heteroleptic phosphine, and / or an asymmetric phosphine. In some embodiments, the phosphine can be tris-(hydroxymethyl) phosphine (THMP), tris-(carboxyethyl)phosphine (TCEP), tris-(3-hydroxypropyl)phosphine (THPP), or any combination thereof.

[0260] In some embodiments, the radical initiator can be 2,2'-Azobis[2-(2-imidazolin-2-yl)-propane] dihydrochloride, tert-butyl hydroperoxide (TBHP), cumene hydroperoxide, acetophenone, (±)- camphorquinone, 4'-hydroxyacetophenone, 3'-hydroxyacetophenone, benzophenone, 3- methylbenzophenone, 2-methylbenzophenone, 3,4-dimethylbenzophenone, 3-hydroxybenzophenone, 4-hydroxybenzophenone, benzoin, anisoin, benzoin methyl ether, benzoin ethyl ether, benzoin isopropyl ether, 2,2-diethoxyacetophenone, benzil dimethylketal, 2-isonitrosopropiophenone, anthraquinone, 2-ethylanthraquinone, sodium anthraquinone2-sulfonate monohydrate, 2-chlorothioxanthone, 2- isopropylthioxanthone, 2,7-dimethoxythioxanthone, or any combination thereof.

[0261] In some embodiments, a C-terminal of a first fragment (e.g., CA) comprises an acyl halide. In some embodiments, a C-terminal of a first fragment (e.g., CA) comprises an acyl chloride. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to a sequence as set forth in SEQ ID NOs: 241-456 or 913-1368. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence having about one (e.g., 0, 1) amino acid substitution in an amino acid sequence as set forth in SEQ. ID NOs: 241- 456 or 913-1368.

[0262] In some embodiments, a N-terminal of a second fragment (e.g., NB) comprises an unprotected N- terminal amine. In some embodiments, a second fragment of a peptide described herein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to a sequence as set forth in SEQ ID NOs: 25-240 or 457-912. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence having about one (e.g., 0, 1) amino acid substitution in an amino acid sequence as set forth in SEQ ID NOs: 25-240 or 457-912.

[0263] In some embodiments, a first fragment and a second fragment of the peptide are joined. In some embodiments, joining the first fragment to the second fragment comprises contacting the N-terminal of the second fragment (e.g., NB) with the C terminal of the first fragment (e.g., CA). In some embodiments, joining the first fragment to the second fragment comprises contacting the N-terminal of the first fragment (e.g., NA) with the C-terminal of the second fragment (e.g., CB).

[0264] In some embodiments, a C-terminal of a first fragment comprises an unprotected C-terminal carboxylate group. In some embodiments, a first fragment of a peptide described herein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to a sequence as set forth in SEQ ID NOs: 241-456 or 913-1368. In some embodiments, a method for providing a peptide as described herein comprises contacting the first peptide fragment comprising the unprotected C-terminal carboxylate group with an agent. In some embodiments, contacting the first peptide fragment comprising the unprotected C-terminal carboxylate group with an agent provides an activated ester. Without wishingto be bound by theory, the activated ester may be susceptible towards nucleophilic attack. The agent may comprise a carbodiimide. The carbodiimide may comprise dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC), or N,N'-diisopropylcarbodiimide (DIC), or a combination or two or more thereof. In some embodiments, the carbodiimide comprises DCC. In some embodiments, the carbodiimide comprises EDC. In some embodiments, the carbodiimide comprises DIC.

[0265] The agent can comprise a peptide coupling agent. In some embodiments, the agent is selected from the group consisting of benzotriazole-l-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), [(l-(Cyano-2-ethoxy-2-oxoethylideneaminooxy) dimethylaminomorpholino)] uronium hexafluorophosphate (COMU), hexafluorophosphate azabenzotriazole tetramethyl uranium (HATU), 2-(lH-Benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HBTU), O-(lH-6-Chlorobenzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HCTU), (7-Azabenzotriazol-l-yloxy)trispyrrolidinophosphonium hexafluorophosphate (PyAOP®), Benzotriazole-l-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP®), PyClock6-Chloro-benzotriazole-l-yloxy-tris-pyrrolidinophosphonium, 1- Cyano-2-ethoxy-2-oxoethylideneaminooxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyOxim), O-[(Ethoxycarbonyl)cyanomethylenamino]-N,N,N / E,N / E -tetramethyl uronium tetrafluoroborate (TOTU), N,N,N',N'-Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate, O-[N-Succinimidyl)-1, 1,3,3- tetramethyluronium tetrafluoroborate (TSTU), l,l,3,3-Tetramethyl-2-(4,5,6,7-tetrachloro-l,3- dioxoisoindolin-2-yl)isouronium hexafluorophosphate(V) (CITU), hydroxybenzotriazole (HOBt), dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N'- diisopropylcarbodiimide (DIC), l-hydroxy-7-azabenzotriazole (HOAt), and 4-dimethylaminopyridine (DMAP). In some embodiments, the agent comprises hydroxybenzotriazole (HOBt), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC), N,N'-diisopropylcarbodiimide (DIC), l-hydroxy-7- azabenzotriazole (HOAt), or 4-dimethylaminopyridine (DMAP), or any combination thereof.

[0266] In some embodiments, the agent comprises hydroxybenzotriazole (HOBt), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC), N,N'-diisopropylcarbodiimide (DIC), l-hydroxy-7- azabenzotriazole (HOAt), or 4-dimethylaminopyridine (DMAP), or any combination thereof.

[0267] In some embodiments, the first fragment can comprise a sequence as set forth in ILA, IGV, AVP, VCC, SCG, GGV, GSC, CQPV (SEQ ID NO.: 251), GGTN (SEQ ID NO.: 252), VGAS (SEQ ID NO.: 260), GGCQ (SEQ ID NO.: 264), GSVSS (SEQ ID NO.: 266), CAPVY (SEQ ID NO.: 277), CFQPT (SEQ ID NO.: 269), CGGSG (SEQ ID NO.: 270), ASCGV (SEQ ID NO.: 273), LLGNP (SEQ ID NO.: 279), CGYGSG (SEQ ID NO.: 298), SCGCSQ (SEQ ID NO.: 305), GGVCLP (SEQ ID NO.: 306), GCISSS (SEQ ID NO.: 309), GGCQCS (SEQ ID NO.: 312), LCEPAIG (SEQ ID NO.: 316), ASECGSG (SEQ ID NO.: 320), GSCVTNP (SEQ ID NO.: 326), VCCCVPA (SEQ ID NO.: 328), GCISSSC (SEQ ID NO.: 333), GGCQCSC (SEQ ID NO.: 336), ILACAPIY (SEQ ID NO.: 337), CGYGSGCG(SEQ ID NO.: 346), SCGCSQCN (SEQ ID NO.: 353), LLCEPAIG (SEQ ID NO.: 358), GSVSSCQPS (SEQ ID NO.: 362), CAPVYCRRT (SEQ ID NO.: 363), CFQPTCVYS (SEQ ID NO.: 365), CGGSGCGGS (SEQ ID NO.: 366), IGVCGPSPP (SEQ ID NO.: 367), CQPVCPTPT (SEQ ID NO.: 371), AVPCVPSVP (SEQ ID NO.: 373), VCCCVPACS (SEQ ID NO.: 376), SCGCSQCNC (SEQ ID NO.: 377), GGVCGPSPP (SEQ ID NO.: 379), VGASCVSLL (SEQ ID NO.: 380), GSCCAPPVY (SEQ ID NO.: 383), ASCGVCLPST (SEQ ID NO.: 393), GGTNCSPRPI (SEQ ID NO.: 396), LLGNPCSTPS (SEQ ID NO.: 399), GCISSSCCPS (SEQ ID NO.: 405), GSCCAPPVYC (SEQ ID NO.: 407), LCEPAIGCEPS (SEQ ID NO.: 412), GCISSSCCPSC (SEQ ID NO.: 429), GGCQCSCCKPY (SEQ ID NO.:432), ILACAPIYCRRT (SEQ ID NO.: 433), ASECGSGCGVPV (SEQ ID NO.: 440), GGVCLPCLPAAS (SEQ ID NO.: 450), GCISSSCCPSCC (SEQ ID NO.: 453), LLCEPAIGCEPS (SEQ ID NO.: 454), or any combination thereof. In some instances, the C-terminal residue of the first fragment (i.e., CA) is covalently bound to a thioester group having the formula -SRa. In some cases, Ra is a substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl group.

[0268] In some embodiments, the second fragment can comprise a sequence as set forth in CEPAIGCEPSCG (SEQ ID NO.: 28), CCCVPACSCSVG (SEQ ID NO.: 40), CGCSQCNCCKGG (SEQ ID NO.: 41), CGVCLPSTCPL (SEQ ID NO.: 57), CVTNPCGPIIG (SEQ ID NO.: 62), CCVPACSCSVG (SEQ ID NO.: 64), CISSSCCPSCC (SEQ ID NO.: 69), CEPAIGCEPSC (SEQ ID NO.: 70), CCAPPVYCCKL (SEQ ID NO.: 71), CQCSCCKPYCS (SEQ ID NO.: 72), CAPIYCRRTC (SEQ ID NO.: 73), CGPSPPCITS (SEQ ID NO.: 79), CGSGCGVPVC (SEQ ID NO.: 80), CVPSVPCTPG (SEQ ID NO.: 85), CVPACSCSVG (SEQ ID NO.: 88), CSQCNCCKGG (SEQ ID NO.: 89), CLPCLPAASC (SEQ ID NO.: 90), CGPSPPCITT (SEQ ID NO.: 91), CAPPVYCCKL (SEQ ID NO.: 95), CPTPTCGVG (SEQ ID NO.: 107), CSPRPICVG (SEQ ID NO.: 108), CSTPSCTTG (SEQ ID NO.: Ill), CSCCKPYCS (SEQ ID NO.: 120), CQPSCSEA (SEQ ID NO.: 122), CRRTCGGV (SEQ ID NO.: 123), CVYSCHHG (SEQ ID NO.: 125), CLPSTCPL (SEQ ID NO.: 129), CVSLLCRP (SEQ ID NO.: 140), CGCGIIL (SEQ ID NO.: 154), CNCCKGG (SEQ ID NO.: 161), CLPAASC (SEQ ID NO.: 162), CCKPYCS (SEQ ID NO.: 168), CEPSCG (SEQ ID NO.: 172), CGVPVC (SEQ ID NO.: 176), CGPIIG (SEQ ID NO.: 182), CSCSVG (SEQ ID NO.: 184), CCPSCC (SEQ ID NO.: 189), CKPYCS (SEQ ID NO.: 192), CRRTC (SEQ ID NO.: 193), CGIIL (SEQ ID NO.: 202), CCKGG (SEQ ID NO.: 209), CPSCC (SEQ ID NO.:213), CEPSC (SEQ ID NO.: 214), CSEA (SEQ ID NO.: 218), CGGV (SEQ ID NO.: 219), CHHG (SEQ ID NO.: 221), CHSL (SEQ ID NO.: 222), CITS (SEQ ID NO.: 223), CGVG (SEQ ID NO.: 227), CTPG (SEQ ID NO.: 229), CTTG (SEQ ID NO.: 231), CSVG (SEQ ID NO.: 232), CKGG (SEQ ID NO.: 233), CITT (SEQ ID NO.: 235), CCKL (SEQ ID NO.: 239), or any combination thereof.COMPOSITIONS

[0269] In some aspects, the present disclosure provides a composition comprising a peptide, wherein the peptide is present with a purity of about 85%. In some embodiments, the peptide is present in the composition with a purity of at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at leastabout 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, at least about 99.9%, or greater than about 99.9%. In some embodiments, the peptide in the composition comprises an amino acid sequence having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity to a sequence as set forth in SEQ ID NOs: 1-1368. In some embodiments, the peptide in the composition comprises an amino acid sequence having at most about 99.9%, at most about 99.5%, at most about 99%, at most about 98.5%, at most about 98%, at most about 97%, at most about 96%, at most about 95%, at most about 94%, at most about 93%, at most about 92%, at most about 91%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 65%, at most about 60%, or less than about 60% sequence identity to a sequence as set forth in SEQ. ID NOs: 1-1368. In some embodiments, the peptide in the composition comprises an amino acid sequence as set forth in SEQ ID NOs: 1-1368. In some embodiments, the peptide in the composition comprises an amino acid sequence as set forth in Table 2.Table 2. Exemplary amino acid peptide sequences

[0270] In some embodiments, the composition can comprise a peptide with a purity of about 85% and an amino acid sequence having at least about 70% sequence identity to any one of SEQ. ID NOs: 1-1368.

[0271] In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 75% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 80% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 85% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 86% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 87% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 88% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 89% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 90% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 91% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 92% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 93% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 94% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 95% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 96% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 97% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 98% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 98.5% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 99% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 99.5% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of greater than 99.9% wt. In some embodiments, the composition described herein comprises a peptide present with a purity of 100% wt.

[0272] In some embodiments, the composition described herein comprises a peptide present with a purity between about 85% wt to about 100% wt. In some embodiments, the composition described herein comprises a peptide present with a purity between about 85% wt to about 90% wt, about 85% wt to about 91% wt, about 85% wt to about 92% wt, about 85% wt to about 93% wt, about 85% wt to about 94% wt, about 85% wt to about 95% wt, about 85% wt to about 96% wt, about 85% wt to about 97% wt, about 85% wt to about 98% wt, about 85% wt to about 99% wt, about 85% wt to about 100% wt, about 90% wt to about 91% wt, about 90% wt to about 92% wt, about 90% wt to about 93% wt, about 90% wt to about 94% wt, about 90% wt to about 95% wt, about 90% wt to about 96% wt, about 90% wt to about 97% wt,about 90% wt to about 98% wt, about 90% wt to about 99% wt, about 90% wt to about 100% wt, about 91% wt to about 92% wt, about 91% wt to about 93% wt, about 91% wt to about 94% wt, about 91% wt to about 95% wt, about 91% wt to about 96% wt, about 91% wt to about 97% wt, about 91% wt to about 98% wt, about 91% wt to about 99% wt, about 91% wt to about 100% wt, about 92% wt to about 93% wt, about 92% wt to about 94% wt, about 92% wt to about 95% wt, about 92% wt to about 96% wt, about 92% wt to about 97% wt, about 92% wt to about 98% wt, about 92% wt to about 99% wt, about 92% wt to about 100% wt, about 93% wt to about 94% wt, about 93% wt to about 95% wt, about 93% wt to about 96% wt, about 93% wt to about 97% wt, about 93% wt to about 98% wt, about 93% wt to about 99% wt, about 93% wt to about 100% wt, about 94% wt to about 95% wt, about 94% wt to about 96% wt, about 94% wt to about 97% wt, about 94% wt to about 98% wt, about 94% wt to about 99% wt, about 94% wt to about 100% wt, about 95% wt to about 96% wt, about 95% wt to about 97% wt, about 95% wt to about 98% wt, about 95% wt to about 99% wt, about 95% wt to about 100% wt, about 96% wt to about 97% wt, about 96% wt to about 98% wt, about 96% wt to about 99% wt, about 96% wt to about 100% wt, about 97% wt to about 98% wt, about 97% wt to about 99% wt, about 97% wt to about 100% wt, about 98% wt to about 99% wt, about 98% wt to about 100% wt, or about 99% wt to about 100% wt.

[0273] In some embodiments, a composition described herein comprises at least about 1% wt ethanol, at least about 2% wt ethanol, at least about 3% wt ethanol, at least about 4% wt ethanol, at least about 5% wt ethanol, at least about 10% wt ethanol, at least about 15% wt ethanol, at least about 20% wt ethanol, at least about 25% wt ethanol, at least about 30% wt ethanol, at least about 35% wt ethanol, at least about 40% wt ethanol, or greater than about 40% wt ethanol. In some embodiments, a composition described herein comprises at most about 40% wt ethanol, at most about 35% wt, at most about 30% wt ethanol, at most about 25% wt, at most about 20% wt, at most about 15% wt, at most about 10% wt, at most about 5% wt, at most about 4% wt, at most about 3% wt, at most about 2% wt, or less than about 2% wt ethanol. In some embodiments, a composition described herein comprises 0% wt ethanol. In some embodiments, a composition described herein comprises between about 1% wt ethanol to about 40% wt ethanol. In some embodiments, a composition described herein comprises between about 1% wt ethanol to about 2% wt ethanol, about 1% wt ethanol to about 3% wt ethanol, about 1% wt ethanol to about 4% wt ethanol, about 1% wt ethanol to about 5% wt ethanol, about 1% wt ethanol to about 10% wt ethanol, about 1% wt ethanol to about 15% wt ethanol, about 1% wt ethanol to about 20% wt ethanol, about 1% wt ethanol to about 25% wt ethanol, about 1% wt ethanol to about 30% wt ethanol, about 1% wt ethanol to about 35% wt ethanol, about 1% wt ethanol to about 40% wt ethanol, about 2% wt ethanol to about 3% wt ethanol, about 2% wt ethanol to about 4% wt ethanol, about 2% wt ethanol to about 5% wt ethanol, about 2% wt ethanol to about 10% wt ethanol, about 2% wt ethanol to about 15% wt ethanol, about 2% wt ethanol to about 20% wt ethanol, about 2% wt ethanol to about 25% wt ethanol, about 2% wt ethanol to about 30% wt ethanol, about 2% wt ethanol to about 35% wt ethanol, about 2% wt ethanol to about 40% wt ethanol, about 3% wt ethanol to about 4% wt ethanol, about 3% wt ethanol to about 5% wtethanol, about 3% wt ethanol to about 10% wt ethanol, about 3% wt ethanol to about 15% wt ethanol, about 3% wt ethanol to about 20% wt ethanol, about 3% wt ethanol to about 25% wt ethanol, about 3% wt ethanol to about 30% wt ethanol, about 3% wt ethanol to about 35% wt ethanol, about 3% wt ethanol to about 40% wt ethanol, about 4% wt ethanol to about 5% wt ethanol, about 4% wt ethanol to about 10% wt ethanol, about 4% wt ethanol to about 15% wt ethanol, about 4% wt ethanol to about 20% wt ethanol, about 4% wt ethanol to about 25% wt ethanol, about 4% wt ethanol to about 30% wt ethanol, about 4% wt ethanol to about 35% wt ethanol, about 4% wt ethanol to about 40% wt ethanol, about 5% wt ethanol to about 10% wt ethanol, about 5% wt ethanol to about 15% wt ethanol, about 5% wt ethanol to about 20% wt ethanol, about 5% wt ethanol to about 25% wt ethanol, about 5% wt ethanol to about 30% wt ethanol, about 5% wt ethanol to about 35% wt ethanol, about 5% wt ethanol to about 40% wt ethanol, about 10% wt ethanol to about 15% wt ethanol, about 10% wt ethanol to about 20% wt ethanol, about 10% wt ethanol to about 25% wt ethanol, about 10% wt ethanol to about 30% wt ethanol, about 10% wt ethanol to about 35% wt ethanol, about 10% wt ethanol to about 40% wt ethanol, about 15% wt ethanol to about 20% wt ethanol, about 15% wt ethanol to about 25% wt ethanol, about 15% wt ethanol to about 30% wt ethanol, about 15% wt ethanol to about 35% wt ethanol, about 15% wt ethanol to about 40% wt ethanol, about 20% wt ethanol to about 25% wt ethanol, about 20% wt ethanol to about 30% wt ethanol, about 20% wt ethanol to about 35% wt ethanol, about 20% wt ethanol to about 40% wt ethanol, about 25% wt ethanol to about 30% wt ethanol, about 25% wt ethanol to about 35% wt ethanol, about 25% wt ethanol to about 40% wt ethanol, about 30% wt ethanol to about 35% wt ethanol, about 30% wt ethanol to about 40% wt ethanol, or about 35% wt ethanol to about 40% wt ethanol.

[0274] In some embodiments, a composition described herein comprises at least about 0.1% wt benzylic alcohol, at least about 0.2% wt benzylic alcohol, at least about 0.3% wt benzylic alcohol, at least about 0.4% wt benzylic alcohol, at least about 0.5% wt benzylic alcohol, at least about 0.6% wt benzylic alcohol, at least about 0.7% wt benzylic alcohol, at least about 0.8% wt benzylic alcohol, at least about 0.9% wt benzylic alcohol, at least about 1% wt benzylic alcohol, at least about 1.5% wt benzylic alcohol, at least about 2% wt benzylic alcohol, at least about 2.5 benzylic alcohol, at least about 3% wt benzylic alcohol, at least about 3.5% wt benzylic alcohol, at least about 4% wt benzylic alcohol, at least about 4.5% wt benzylic alcohol, at least about 5% wt benzylic alcohol, or greater than about 5% wt benzylic alcohol. In some embodiments, a composition described herein comprises at most about 5% wt benzylic alcohol, at most about 4.5% wt benzylic alcohol, at most about 4% wt benzylic alcohol, at most about 3.5% wt benzylic alcohol, at most about 3% wt benzylic alcohol, at most about 2.5% wt benzylic alcohol, at most about 2% wt benzylic alcohol, at most about 1.5% wt benzylic alcohol, at most about 1% wt benzylic alcohol, at most about 0.9% wt benzylic alcohol, at most about 0.8% wt benzylic alcohol, at most about 0.7% wt benzylic alcohol, at most about 0.6% wt benzylic alcohol, at most about 0.5% wt benzylic alcohol, at most about 0.4% wt benzylic alcohol, at most about 0.3% wt benzylic alcohol, at most about 0.2% wt benzylic alcohol,at most about 0.1% wt benzylic alcohol, or less than about 0.1% wt benzylic alcohol. In some embodiments, a composition described herein comprises 0% wt benzylic alcohol.

[0275] In some embodiments, a composition described herein comprises between about 0.1% wt benzylic alcohol to about 4% wt benzylic alcohol. In some embodiments, a composition described herein comprises between about 0.1% wt benzylic alcohol to about 0.2% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 0.3% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 0.4% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 0.5% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 1% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 1.5% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 2% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 3% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 0.1% wt benzylic alcohol to about 4% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 0.3% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 0.4% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 0.5% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 1% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 1.5% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 2% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 3% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 0.2% wt benzylic alcohol to about 4% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 0.4% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 0.5% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 1% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 1.5% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 2% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 3% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 0.3% wt benzylic alcohol to about 4% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 0.5% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 1% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 1.5% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 2% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 3% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 0.4% wt benzylic alcohol to about 4% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 1% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 1.5% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 2% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 3% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 0.5% wt benzylic alcohol to about 4% wt benzylic alcohol, about 1% wt benzylic alcohol to about 1.5% wt benzylic alcohol, about 1% wt benzylic alcohol to about 2% wt benzylic alcohol, about 1% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 1% wt benzylic alcohol to about 3% wt benzylic alcohol, about 1% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 1% wt benzylic alcohol to about 4% wt benzylic alcohol,about 1.5% wt benzylic alcohol to about 2% wt benzylic alcohol, about 1.5% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 1.5% wt benzylic alcohol to about 3% wt benzylic alcohol, about 1.5% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 1.5% wt benzylic alcohol to about 4% wt benzylic alcohol, about 2% wt benzylic alcohol to about 2.5% wt benzylic alcohol, about 2% wt benzylic alcohol to about 3% wt benzylic alcohol, about 2% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 2% wt benzylic alcohol to about 4% wt benzylic alcohol, about 2.5% wt benzylic alcohol to about 3% wt benzylic alcohol, about 2.5% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 2.5% wt benzylic alcohol to about 4% wt benzylic alcohol, about 3% wt benzylic alcohol to about 3.5% wt benzylic alcohol, about 3% wt benzylic alcohol to about 4% wt benzylic alcohol, or about 3.5% wt benzylic alcohol to about 4% wt benzylic alcohol.

[0276] In some embodiments, a composition described herein comprises at least about 0.1% wt of a diol molecule (e.g., ethylene glycol, propylene-l,3-diol, and / or 1,4-butanediol), at least about 0.2% wt of a diol molecule, at least about 0.3% wt of a diol molecule, at least about 0.4% wt of a diol molecule, at least about 0.5% wt of a diol molecule, at least about 1% wt of a diol molecule, at least about 5% wt of a diol molecule, at least about 10% wt of a diol molecule, at least about 15% wt of a diol molecule, at least about 20% wt of a diol molecule, at least about 25% wt of a diol molecule, at least about 30% wt of a diol molecule, or greater than about 30% wt of a diol molecule. In some embodiments, a composition described herein comprises at most about 30% wt of a diol molecule (e.g., ethylene glycol, propylene-1,3- diol, and / or 1,4-butanediol), at most about 25% wt of a diol molecule, at most about 20% wt of a diol molecule, at most about 15% wt of a diol molecule, at most about 10% wt of a diol molecule, at most about 5% wt of a diol molecule, at most about 1% wt of a diol molecule, at most about 0.5% wt of a diol molecule, at most about 0.4% wt of a diol molecule, at most about 0.3% wt of a diol molecule, at most about 0.2% wt of a diol molecule, at most about 0.1% wt of a diol molecule, or less than about 1% wt of a diol molecule. In some embodiments, a composition described herein comprises 0% wt of a diol molecule (e.g., ethylene glycol, propylene-l,3-diol, and / or 1,4-butanediol).

[0277] In some embodiments, a composition described herein comprises between about 0.1% wt of a diol molecule to about 30% wt of a diol molecule. In some embodiments, a composition described herein comprises between about 0.1% wt of a diol molecule to about 0.2% wt of a diol molecule, about 0.1% wt of a diol molecule to about 0.3% wt of a diol molecule, about 0.1% wt of a diol molecule to about 0.4% wt of a diol molecule, about 0.1% wt of a diol molecule to about 0.5% wt of a diol molecule, about 0.1% wt of a diol molecule to about 5% wt of a diol molecule, about 0.1% wt of a diol molecule to about 10% wt of a diol molecule, about 0.1% wt of a diol molecule to about 15% wt of a diol molecule, about 0.1% wt of a diol molecule to about 20% wt of a diol molecule, about 0.1% wt of a diol molecule to about 25% wt of a diol molecule, about 0.1% wt of a diol molecule to about 30% wt of a diol molecule, about 0.2% wt of a diol molecule to about 0.3% wt of a diol molecule, about 0.2% wt of a diol molecule to about 0.4% wt of a diol molecule, about 0.2% wt of a diol molecule to about 0.5% wt of a diol molecule, about 0.2% wt of adiol molecule to about 5% wt of a diol molecule, about 0.2% wt of a diol molecule to about 10% wt of a diol molecule, about 0.2% wt of a diol molecule to about 15% wt of a diol molecule, about 0.2% wt of a diol molecule to about 20% wt of a diol molecule, about 0.2% wt of a diol molecule to about 25% wt of a diol molecule, about 0.2% wt of a diol molecule to about 30% wt of a diol molecule, about 0.3% wt of a diol molecule to about 0.4% wt of a diol molecule, about 0.3% wt of a diol molecule to about 0.5% wt of a diol molecule, about 0.3% wt of a diol molecule to about 5% wt of a diol molecule, about 0.3% wt of a diol molecule to about 10% wt of a diol molecule, about 0.3% wt of a diol molecule to about 15% wt of a diol molecule, about 0.3% wt of a diol molecule to about 20% wt of a diol molecule, about 0.3% wt of a diol molecule to about 25% wt of a diol molecule, about 0.3% wt of a diol molecule to about 30% wt of a diol molecule, about 0.4% wt of a diol molecule to about 0.5% wt of a diol molecule, about 0.4% wt of a diol molecule to about 5% wt of a diol molecule, about 0.4% wt of a diol molecule to about 10% wt of a diol molecule, about 0.4% wt of a diol molecule to about 15% wt of a diol molecule, about 0.4% wt of a diol molecule to about 20% wt of a diol molecule, about 0.4% wt of a diol molecule to about 25% wt of a diol molecule, about 0.4% wt of a diol molecule to about 30% wt of a diol molecule, about 0.5% wt of a diol molecule to about 5% wt of a diol molecule, about 0.5% wt of a diol molecule to about 10% wt of a diol molecule, about 0.5% wt of a diol molecule to about 15% wt of a diol molecule, about 0.5% wt of a diol molecule to about 20% wt of a diol molecule, about 0.5% wt of a diol molecule to about 25% wt of a diol molecule, about 0.5% wt of a diol molecule to about 30% wt of a diol molecule, about 5% wt of a diol molecule to about 10% wt of a diol molecule, about 5% wt of a diol molecule to about 15% wt of a diol molecule, about 5% wt of a diol molecule to about 20% wt of a diol molecule, about 5% wt of a diol molecule to about 25% wt of a diol molecule, about 5% wt of a diol molecule to about 30% wt of a diol molecule, about 10% wt of a diol molecule to about 15% wt of a diol molecule, about 10% wt of a diol molecule to about 20% wt of a diol molecule, about 10% wt of a diol molecule to about 25% wt of a diol molecule, about 10% wt of a diol molecule to about 30% wt of a diol molecule, about 15% wt of a diol molecule to about 20% wt of a diol molecule, about 15% wt of a diol molecule to about 25% wt of a diol molecule, about 15% wt of a diol molecule to about 30% wt of a diol molecule, about 20% wt of a diol molecule to about 25% wt of a diol molecule, about 20% wt of a diol molecule to about 30% wt of a diol molecule, or about 25% wt of a diol molecule to about 30% wt of a diol molecule.

[0278] In some embodiments, the peptide and / or composition described herein may be used for cosmetic treatment. In some embodiments, the composition can be formulated as a hair care product, body wash, shampoo, conditioner, moisturizer, deodorant, anti-aging / skin repair preparation, cleanser, toner, eye care composition, lip care composition, fingernail care composition, toenail care composition, scalp care composition, sun care composition, hand care composition, or body care. In some embodiments, the compositions described herein may be used for various cosmetic purposes on the exterior of a mammalian body. In some embodiments, the compositions may be used for the treatment of keratin-comprising structures and tissues. In some embodiments, the compositions described hereinmay be used for the treatment of hair, nails, or skin or any combination thereof. In some embodiments, the compositions described herein may be utilized to strengthen or improve the overall appearance and health of a subject's hair, nails, or skin, or any combination thereof. In some embodiments, the compositions described herein may be used to prevent breakage of a subject's hair, nails, or skin, or any combination thereof. In some embodiments, the compositions described herein may be used to reduce or prevent split or frayed ends of a subject's hair. In some embodiments, the compositions described herein may be used to enhance the color or color vibrancy of a subject's hair. In some embodiments, the composition and / or peptide described herein may be used for a hair treatment including, but not limited to, a shampoo, a conditioner, a foam, an elixir, an oil, an aerosol, a moisturizer, a serum, a mask, and a lotion. In some embodiments, the composition can be used in a cosmetic. In some embodiments, the cosmetic is a hair care product, body wash, shampoo, conditioner, moisturizer, deodorant, anti-aging / skin repair preparation, cleanser, toner, eye care composition, lip care composition, fingernail care composition, toenail care composition, scalp care composition, sun care composition, hand care composition, or body care.RECOMBINANT SYNTHESIS

[0279] Disclosed herein are methods for providing a peptide provided herein. The method for providing a peptide may comprise expressing a gene encoding for the peptide. The method for providing a peptide may further comprise providing a composition comprising the peptide.

[0280] In some embodiments, the peptide may comprise a sequence having at least 60% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 65% identity to any one of SEQ. ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 70% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 75% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 80% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 85% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 90% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 92% identity to any one of SEQ ID NOS: 1-1368. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 1. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 1. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 1. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 1. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 1. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 1. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 1. In some embodiments,the peptide may comprise a sequence having at least 65% identity to SEQ ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ. ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO 2. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO 3. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO 4. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO 5. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO 6. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO 7. In some embodiments,the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 7. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ. ID NO: 7. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 7. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 7. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 7. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 7. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 8. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 9. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 10. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 11. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 12. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 12. In some embodiments,the peptide may comprise a sequence having at least 75% identity toSEQIDNO 12. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 12. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 12. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 12. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 12. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 13. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 14. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 15. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 16. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 17. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 17. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 17. In some embodiments,the peptide may comprise a sequence having at least 80% identity toSEQIDNO 17. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 17. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 17. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 17. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 18. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 19. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 20. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 85% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 90% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 92% identity toSEQIDNO 21. In some embodiments, the peptide may comprise a sequence having at least 65% identity toSEQIDNO 22. In some embodiments, the peptide may comprise a sequence having at least 70% identity toSEQIDNO 22. In some embodiments, the peptide may comprise a sequence having at least 75% identity toSEQIDNO 22. In some embodiments, the peptide may comprise a sequence having at least 80% identity toSEQIDNO 22. In some embodiments,the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 22. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 22. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 22. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 23. In some embodiments, the peptide may comprise a sequence having at least 65% identity to SEQ ID NO: 24. In some embodiments, the peptide may comprise a sequence having at least 70% identity to SEQ ID NO: 24. In some embodiments, the peptide may comprise a sequence having at least 75% identity to SEQ ID NO: 24. In some embodiments, the peptide may comprise a sequence having at least 80% identity to SEQ ID NO: 24. In some embodiments, the peptide may comprise a sequence having at least 85% identity to SEQ ID NO: 24. In some embodiments, the peptide may comprise a sequence having at least 90% identity to SEQ ID NO: 24. In some embodiments, the peptide may comprise a sequence having at least 92% identity to SEQ ID NO: 24.

[0281] In some embodiments, the peptide may comprise a sequence X1X2X3X4X5X6X7X8X9X10X11X12X13, where XI and X2 are selected from the group consisting of V, S, G, C, and L, X3 is an aliphatic residue or a hydrophobic residue, X4 is a sulfur-containing residue or a polar uncharged residue, X5 is any amino acid, X6 and X7 are selected from the group consisting of C, P, Q, S, I and A, X8 and X9 are any amino acid, X10 is selected from the group consisting of S, C, A, E, and P, Xll is any amino acid, and X12 and X13 are an aliphatic residue or a hydrophobic residue. In some embodiments, the peptide does not comprise a basic amino acid (e.g., a R, H, K, or N residue). In some embodiments, the peptide does not comprise an aromatic residue. In some embodiments, the peptide comprises at least two sulfur-containing residues. In some embodiments, X5, X8, and X9 are aliphatic residues. In some embodiments, the peptide comprises no acidic residue. In some embodiments, the peptide comprises one acidic residue.

[0282] In some embodiments, the composition comprises a tag. In some embodiments, the tag enables purification of the peptide. In some embodiments, the tag comprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof. In some embodiments, the tag is MBP. In some embodiments, the tag is a (His)x. In some embodiments, x is an integer from 1 to 10. In some embodiments, x is 1. In some embodiments, x is 2. In some embodiments, x is 3. In some embodiments, x is 4. In some embodiments, x is 5. In some embodiments, x is 6. In some embodiments, x is 7. In some embodiments, x is 8. In some embodiments, x is 9. In some embodiments, x is 10. In someembodiments, the tag is a glutathione S-transferase (GST). In some embodiments, the tag is a chitin binding protein (CBP). In some embodiments, the tag is a ubiquitin. In some embodiments, the tag is a small ubiquitin-like modifier (SUMO). In some embodiments, the tag is a flag-acidic target tag (FATT).

[0283] In some embodiments, the gene encoding for the peptide comprises an expression regulating element. In some embodiments, the expression regulating element comprises a promoter. In some embodiments, the sequence of the promoter provides the binding of RNA polymerases and transcription factors to the gene. In some embodiments, the promoter is from about 50 to about 1000, from about 100 to about 1000, from about 200 to about 1000, from about 400 to about 1000, from about 600 to about 1000, from about 800 to about 1000, from about 50 to about 800, from about 100 to about 800, from about 200 to about 800, from about 400 to about 800, from about 600 to about 800, from about 50 to about 600, from about 100 to about 600, from about 200 to about 600, from about 400 to about 600, from about 50 to about 400, from about 100 to about 400, from about 200 to about 400, from about 50 to about 200, from about 100 to about 200, from about 50 to about 100, from about 100 to about 400, from about 200 to about 600, from about 400 to about 800 base pair long. In some embodiments, the promoter comprises a prokaryotic promoter, a eukaryotic promoter, or a combination thereof. In some embodiments, the promoter comprises a prokaryotic promoter. In some embodiments, the promoter comprises a eukaryotic promoter. In some embodiments, the promoter comprises a prokaryotic promoter and a eukaryotic promoter. In some embodiments, the prokaryotic promoter comprises T7, Sp6, lac, araBad, trp, or Ptac, or a combination or two or more thereof. In some embodiments, the eukaryotic promoter is a promoter in mammalian cells, yeast cells, or plant cells. In some embodiments, the eukaryotic promoter comprises CMV, EFla, CAG, PGK, TRE, SV40, TEF, U6, or UAS, or a combination or two or more thereof. In some embodiments, the promoter is constitutively active. In some embodiments, the promoter is conditionally active. In some embodiments, the promoter is regulated by a second expression regulating element. In some embodiments, second expression regulating element is an enhancer, a boundary element, an insulator, or a silencer. In some embodiments, the promoter is regulated by another gene. In some embodiments, the promoter is turned on or off with a chemical, heat, or light.

[0284] In some embodiments, the peptide is adjacent to a cleavage region. In some embodiments, cleavage region provides one or more sites of action of one or more proteases. In some embodiments, the cleavage region provides removal of the tag after the purification of the peptide. In some embodiments, the one of more proteases comprise enterokinase, Factor X, TEV, thrombin, or any combination thereof. In some embodiments, the one of more proteases comprise enterokinase. In some embodiments, the one of more proteases comprise Factor X. In some embodiments, the one of more proteases comprise TEV. In some embodiments, the one of more proteases comprise thrombin. In some embodiments, the one of more proteases comprise enterokinase and Factor X. In some embodiments, the one of more proteases comprise enterokinase and TEV. In some embodiments, the one of moreproteases comprise enterokinase and thrombin. In some embodiments, the one of more proteases comprise Factor X and TEV. In some embodiments, the one of more proteases comprise Factor X and thrombin. In some embodiments, the one of more proteases comprise TEV and thrombin. In some embodiments, the one of more proteases comprise enterokinase, Factor X, and TEV. In some embodiments, the one of more proteases comprise enterokinase, Factor X, and thrombin. In some embodiments, the one of more proteases comprise enterokinase, TEV, and thrombin. In some embodiments, the one of more proteases comprise Factor X, TEV, and thrombin. In some embodiments, the one of more proteases comprise enterokinase, Factor X, TEV, and thrombin.

[0285] In some embodiments, the cleavage region is interspaced between the peptide and the tag. In some embodiments, the cleavage region is adjacentto a N-terminus of the peptide. In some embodiments, the cleavage region is at least about 100 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 80 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 60 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 50 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 40 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 30 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 20 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 10 base pairs to the N-terminus of the peptide. In some embodiments, the cleavage region is at least about 0 base pair to the N-terminus of the peptide. In some embodiments, the cleavage region is adjacent to a C-terminus of the peptide. In some embodiments, the cleavage region is at least about 100 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 80 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 60 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 50 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 40 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 30 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 20 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 10 base pairs to the C-terminus of the peptide. In some embodiments, the cleavage region is at least about 0 base pair to the C-terminus of the peptide.

[0286] In some embodiments, the peptide comprises tag-cleavable region-peptide. In some embodiments, the peptide comprises peptide-cleavable region-tag.

[0287] In some embodiments, the peptide comprises a reporter protein. In some embodiments, the reporter protein comprises green fluorescent protein (GFP), yellow fluorescent protein (YFP), luciferase, or a fragment thereof, or a combination thereof. In some embodiments, the reporter protein comprises GFP. In some embodiments, the reporter protein comprises YFP. In some embodiments, the reporter protein comprises luciferase. In some embodiments, the reporter protein comprises GFP and luciferase.In some embodiments, the reporter protein comprises YFP and luciferase. In some embodiments, the reporter protein comprises GFP and YFP. In some embodiments, the reporter protein comprises GFP, YFP, and luciferase. In some embodiments, the reporter protein comprises a fragment or a variant of GPF. In some embodiments, the reporter protein comprises a fragment or a variant of YPF. In some embodiments, the reporter protein comprises a fragment or a variant of luciferase. In some embodiments, the reporter protein is adjacent to the cleavable tag. In some embodiments, upon cleavage the reporter protein and the gene encoding for the peptide are separated. In some embodiments, upon cleavage the reporter protein and the sequence having at least 70% identity to any one of SEQ ID NOS: 1-24 are separated.

[0288] The expressing a gene of the method provided herein may comprise expressing a first gene and a second gene. In some embodiments, the gene further comprises an additional element between the first gene and the second gene. In some embodiments, the additional element allows expressing the first gene and the second gene at the same time. In some embodiments, the additional element is an Internal Ribosome Entry Site (IRES). In some embodiments, the additional element is a 2A peptide.

[0289] In some embodiments, the first gene encodes for a first peptide. In some embodiments, the second gene encodes for a second peptide. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 60% identity to any one of SEQ. ID NOs: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 65% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 75% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 80% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 85% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 90% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 92% identity to any one of SEQ ID NOS: 1-24. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 60% identity to any one of SEQ ID NOs: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 65% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 75% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 80% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 85% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 90% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 92% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 60% identity to any one of SEQ ID NOs: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 65% identity to any one of SEQ. ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 75% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 80% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 85% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 90% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 92% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 60% identity to any one of SEQ ID NOs: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 65% identity to any one of SEQ ID NOS: 457- 912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOS: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 75% identity to any one of SEQ ID NOS: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 80% identity to any one of SEQ ID NOS: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 85% identity to any one of SEQ ID NOS: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 90% identity to any one of SEQ ID NOS: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 92% identity to any one of SEQ ID NOS: 457-912. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 60% identity to any one of SEQ ID NOs: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 65% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 70% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 75% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 80% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 85% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 90% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the gene encodes for a peptide comprising a sequence having at least 92% identity to any one of SEQ ID NOS: 913-1368. In some embodiments, the first peptide comprises a sequence having at least 60% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 65% identity to any one of SEQ IDNOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 70% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 75% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 80% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 85% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 90% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the first peptide comprises a sequence having at least 92% identity to any one of SEQ ID NOS: 25-240. In some embodiments, the second peptide comprises a sequence having at least 60% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 65% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 70% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 75% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 80% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 85% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 90% identity to any one of SEQ ID NOS: 241-456. In some embodiments, the second peptide comprises a sequence having at least 92% identity to any one of SEQ ID NOS: 241-456.

[0290] In some embodiments, the first gene comprises a first region encoding a first tag. In some embodiments, the second gene comprises a second region encoding a second tag. In some embodiments, the first tag comprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof. In some embodiments, the first tag is MBP. In some embodiments, the first tag is a (His)x. In some embodiments, the first tag is a glutathione S-transferase (GST). In some embodiments, the first tag is a chitin binding protein (CBP). In some embodiments, the first tag is a ubiquitin. In some embodiments, the first tag is a small ubiquitin-like modifier (SUMO). In some embodiments, the second tag comprises a maltose-binding protein (MBP), a (His)x, a glutathione S-transferase (GST), a chitin binding protein (CBP), a ubiquitin, a small ubiquitin-like modifier (SUMO), a flag-acidic target tag (FATT), or a combination thereof. In some embodiments, the second tag is MBP. In some embodiments, the second tag is a (His)x. In some embodiments, x is an integer from 1 to 10. In some embodiments, x is 1. In some embodiments, x is 2. In some embodiments, x is 3. In some embodiments, x is 4. In some embodiments, x is 5. In some embodiments, x is 6. In some embodiments, x is 7. In some embodiments, x is 8. In some embodiments, x is 9. In some embodiments, x is 10. In some embodiments, the first tag and the second tag are the same. In some embodiments, the second tag is a glutathione S-transferase (GST). In some embodiments, the second tag is a chitin binding protein (CBP). In some embodiments, the second tag is a ubiquitin. In some embodiments, the second tag is a small ubiquitin-like modifier (SUMO). In someembodiments, the second tag is a flag-acidic target tag (FATT). In some embodiments, the first tag and the second tag are different.

[0291] In some embodiments, the first gene comprises a region encoding for a first cleavable region. In some embodiments, the first cleavage region is interspaced between the first peptide and the first tag. In some embodiments, the first cleavage region is adjacent to a N-terminus of the first peptide. In some embodiments, the first cleavage region is adjacent to a C-terminus of the peptide. In some embodiments, the first peptide comprises tag- first cleavable region- first peptide. In some embodiments, the first peptide comprises first peptide-first cleavable region-tag. In some embodiments, the second gene comprises a region encoding for a second cleavable region. In some embodiments, the second cleavage region is interspaced between the second peptide and the second tag. In some embodiments, the second cleavage region is adjacent to a N-terminus of the second peptide. In some embodiments, the second cleavage region is adjacent to a C-terminus of the peptide. In some embodiments, the second peptide comprises tag- second cleavable region- second peptide. In some embodiments, the second peptide comprises second peptide-second cleavable region-tag. In some embodiments, the first peptide and the second peptide are joined.

[0292] In some embodiments, the method comprises expressing the gene in a microorganism. In some embodiments, the microorganism is a bacterium or a yeast. In some embodiments, the bacterium is E. coli. In some embodiments, the yeast is S. cerevisiae. In some embodiments, the method comprises transforming or transfecting a nucleic acid comprising the gene into the microorganism.DEFINITIONS

[0293] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, "consist of" or "consist essentially of" the described features.

[0294] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.

[0295] "Alkyl" refers to a straight or branched chain hydrocarbon monoradical, which may be fully saturated or unsaturated, having from one to about ten carbon atoms, or from one to six carbon atoms, wherein a sp3-hybridized carbon of the alkyl residue is attached to the rest of the molecule by a single bond. Examples of saturated hydrocarbon monoradical include, but are not limited to, methyl, ethyl, n- propyl, isopropyl, 2-methyl-l-propyl, 2-methyl-2-propyl, 2-methyl-l-butyl, 3-methyl-l-butyl, 2-methyl-3- butyl, 2,2-dimethyl-l-propyl, 2-methyl-l-pentyl, 3-methyl-l-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl, and the like. Whenever it appears herein, a numerical range such as "C1-C6 alkyl" means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated. In some embodiments, the alkyl is a C1-C10 alkyl, a Cl- C9 alkyl, a C1-C8 alkyl, a C1-C7 alkyl, a C1-C6 alkyl, a C1-C5 alkyl, a C1-C4 alkyl, a C1-C3 alkyl, a C1-C2 alkyl, or a Cl alkyl. When the alkyl refers to an unsaturated straight or branched chain hydrocarbon monoradical it is known as an "alkenyl" or an "alkynyl". The alkenyl may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers. Examples of alkenyls include, but are not limited to ethenyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as "C2-C6 alkenyl" means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl" where no numerical range is designated. In some embodiments, the alkenyl is a C2-C10 alkenyl, a C2-C9 alkenyl, a C2-C8 alkenyl, a C2-C7 alkenyl, a C2-C6 alkenyl, a C2-C5 alkenyl, a C2-C4 alkenyl, a C2-C3 alkenyl, or a C2 alkenyl. Examples of alkynyl include, but are not limited to ethynyl, 2-propynyl, 2- and the like. Whenever it appears herein, a numerical range such as "C2-C6 alkynyl" means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl" where no numerical range is designated. In some embodiments, the alkynyl is a C2-C10 alkynyl, a C2-C9 alkynyl, a C2-C8 alkynyl, a C2- C7 alkynyl, a C2-C6 alkynyl, a C2-C5 alkynyl, a C2-C4 alkynyl, a C2-C3 alkynyl, or a C2 alkynyl. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -N02. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.

[0296] "Aryl" refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic ortetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl. Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.In some embodiments, the aryl is phenyl. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.

[0297] "Cycloalkyl" refers to a stable, partially or fully saturated, monocyclic or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl), from three to ten carbon atoms (C3-C10 cycloalkyl), from three to eight carbon atoms (C3-C8 cycloalkyl), from three to six carbon atoms (C3-C6 cycloalkyl), from three to five carbon atoms (C3-C5 cycloalkyl), or three to four carbon atoms(C3-C4 cycloalkyl). In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls or carbocycles include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl is optionally substituted with halogen.

[0298] "Heterocycloalkyl" refers to a stable 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl), from two to tencarbon atoms (C2-C10 heterocycloalkyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl), from two to six carbon atoms (C2-C6 heterocycloalkyl), from two to five carbon atoms (C2-C5 heterocycloalkyl), or two to four carbon atoms (C2-C4 heterocycloalkyl). In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl [l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-l-yl, 3-oxo-l,3-dihydroisobenzofuran-l-yl, methyl- 2-oxo-l,3-dioxol-4-yl, and 2-oxo-l,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Partially saturated heterocycloalkyls include, for example dihydropyrrolyl or tetrahydropyridine. Unless stated otherwise specifically in the specification, a heterocycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -N02. In some embodiments, a heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.

[0299] "Heteroaryl" refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur, and at least one aromatic ring. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, the heteroaryl isa 5-membered heteroaryl. In some embodiments, the heteroaryl is a 6-membered heteroaryl. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1- oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-lH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl is optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.

[0300] The term "percent identity" refers to a comparison between two nucleic acid or amino acid sequences. Such comparisons are measured using any number of alignment methods known in the art, including but not limited to global (e.g., Needleman-Wunsch algorithm) or local alignments (e.g., Smith- Waterman, Sellers, or other algorithm). Percent identity often refers to the percentage of matching positions of two sequences for a contiguous section of positions, wherein the two sequences are aligned in such a way to maximize matching positions and minimize gaps of non-matching positions. In some instances, alignments are conducted wherein there are no gaps between the two sequences. In some instances, the alignment results in less than 5% gaps, less than 3% gaps, or less than 1% gaps. Additional methods of sequence comparison or alignment are also consistent with the disclosure.

[0301] Percent (%) sequence identity with respect to a reference polypeptide sequence is the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences are able to be determined, including algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acidsequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN- 2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons, the% amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain% amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the% amino acid sequence identity of A to B will not equal the% amino acid sequence identity of B to A. Unless specifically stated otherwise, all% amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0302] "Amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, gamma-carboxyglutamate, and O-phosphoserine. "Amino acid analogs" refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an alpha carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs can have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

[0303] The term "peptide" can refer to two or more amino acids joined to each other by peptide bonds or modified peptide bonds, such as amide bonds.

[0304] The term "about" or "approximately" can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, per the practice in the given value. Where particular values are described in the application and claims, unless otherwise stated the term "about" should beassumed to mean an acceptable error range for the particular value, such as ± 15% of the value modified by the term "about".

[0305] "Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl group may or may not be substituted and that the description includes both substituted aryl groups and aryl groups having no substitution.

[0306] "Pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye, colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[0307] Ranges: throughout this disclosure, various aspects of the present disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the pre-sent disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.EXAMPLESExample 1: Chemical Synthesis of Peptides

[0308] A peptide having a sequence of any one of SEQ. ID NOs: 1-1368 are synthesized using the method described below.

[0309] Step 1: Resin Preparation: The peptide is synthesized using fmoc chemistry. The resin is prepared using 9H-fluoren-9-ylmethyl N-[(2,4-dimethoxyphenyl)-[4-[2-oxo-2-[[phenyl(p- tolyl)methyl]amino]ethoxy]phenyl]methyl]carbamate (5.00 mmol, 1.00 eq) (Sub: 0.28 mmol / g) in DMF (300 mL) and is agitated with N2 for 2 hrs at 20 °C. The mixture is filtered to provide the resin.

[0310] Step 2: Deprotection: 20% piperidine in DMF is added and the resin is agitated with N2. The resin is washed with DMF and filtered to provide the resin.

[0311] Step 3: Coupling: A solution of fmoc-AA(tBu)-OH (15.0 mmol, 5.75 g, 3.00 eq), DIEA (30.0 mmol, 5.20 mL, 6.00 eq) in DMF (100 mL), then HBTU (5.41 g, 14.2 mmol, 2.85 eq) was added to the resin and agitated with N2 for 20 mins at 20 °C. The resin was then washed with DMF (450 mL * 5), where fmoc- AA(tBu)-OH corresponds to the C-terminal residue of any one of the sequences of Table 2.

[0312] Repeat above steps 2 to 3 for the coupling of following amino acids in Table 3.Table 3. fmoc-protected amino acids.

[0313] A solution of 20% piperidine in DMF is used for fmoc deprotection for 15 mins. The coupling reaction is monitored by ninhydrin test, and the resin is washed with DMF for 5 times.

[0314] Peptide Cleavage and Purification. After coupling, the resin is washed with DMF at least three times. After last step, the resin is washed with MeOH at least three times and dried under vacuum. Then the peptide resin is treated with the cleavage cocktail (92.5%TFA / 2.5%TIS / 2.5%Mpr / 2.5%H2O) for 2.5 hours. The mixture is filtered to remove the cleavage cocktail. The peptide is precipitated with cold isopropyl ether, filtered and concentrated under reduced pressure to give a residue. LCMS (EW33512-1- P1A1, Rt = 1.539 min). The product is purified by HPLC.Example 2: Native Chemical Ligation Synthesis of PeptidesPeptides of Table 2 are synthesized using native chemical ligation (NCL).

[0315] Example 2A: Synthesis of SEQ ID NO: 12 (GGTNCSPRPICVG)

[0316] Peptide fragments are synthesized using the SPPS method as outlined in Example 1. A first fragment comprising SEQ. ID NO: 252, a 6x-His tag, and an enterokinase cleavage sequence is prepared using SPPS and has the sequence: NH2-His-His-His-His-His-His-Asp(OtBu)-Asp(OtBu)-Asp(OtBu)- Asp(OtBu)-Lys(fmoc)-Gly-Gly-Thr(Bzl)-Asn(Xan)-thioester (SEQ ID NO: 1369). A second fragment is prepared using SPPS and has the sequence: NH2-Cys-Ser(Bzl)-Pro-Arg(Tos)-Pro-lle-Cys(Trt)-Val-Gly-OH (SEQ ID NO: 108). The second fragment is generated using a rink amide resin.

[0317] Ligation buffer (6 M guanidine HCI, 20 mM NaHPO4, pH 8.5) is prepared. About 1:1 molar equivalent of the first fragment and the second fragment are dissolved in the ligation buffer with a final concentration of ImM-lOmM of the first fragment, and ImM-lOmM of the second fragment. Thiophenol (2% (v / v)) is added to the mixture. The pH of the mixture is confirmed with a pH meter and decreases from the initial pH of about 8.5. The pH of the mixture is maintained at roughly pH 7.1. The mixture is left at room temperature for 4 hours to 24 hours. The reaction is monitored by taking aliquots of the reaction mixture, diluted in a solution of 0.05% TFA (v / v) in 1:1 MeCN:H2O, quenched with TCEP HCI (tris(2- carboxyethyl)phosphine hydrochloride), and analyzed by HPLC. When the reaction is at least 90% complete, as determined by HPLC, the reaction is quenched with 15 molar equivalents TCEP HCI and diluted lOx in 0.05% TFA in 1:1 MeCN:H2O to provide the reaction produ...

Claims

AMENDED CLAIMS received by the International Bureau on 21 August 2025 (21.08.025)1. A method for providing a peptide wherein the method comprises the following steps: joining a first fragment of the peptide and a second fragment of the peptide in a solution or resin; wherein the first fragment is represented by the Formula (l-A):(NA-A-CA)m(Formula l-A), wherein the second fragment is represented by the Formula (l-B):(NB-B-CB)P(Formula l-B), wherein:NAis the N-terminus of the first fragment,A is one or more amino acids and up to 32 amino acids,CAis the C -terminus of the first fragment,NBis the N-terminus of the second fragment,B is one or more amino acids and up to 32 amino acids,CBis the C -terminus of the second fragment, m is an integer from 1 to 32, p is an integer from 1 to 32, and the peptide is represented by the Formula (l-C') or ( l-C") :NA-A-CA-NB-B-CBFormula l-C', or NB-B-CB-NA-A-CAFormula l-C", and separating the obtained peptide from the solution, thereby providing the peptide with a purity of at least about 80% wt.; wherein 1-5 amino acids of the obtained peptide are cysteine amino acids, and about 15% to about 50% of the amino acids of the peptide are cysteine amino acids; wherein the first fragment comprises a sequence of about 10% to about 90% the length of the peptide; wherein the second fragment comprises a sequence of about 10% to about 90% the length of the peptide; wherein the peptide comprises at least one hydrophobic amino acid residue and wherein each of the at least one hydrophobic amino acid residues is independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan; wherein the peptide comprises the sequence of any one of SEQ. ID NOs: 1-1368; wherein the peptide has a length that ranges from 1-32 amino acid residues; wherein the second fragment has a length that ranges from 4-13 amino acids.

2. The method according to any of the previous claims, wherein the first fragment has 7-30 amino acids; preferably wherein the first fragment has 15-30 amino acids, more preferably wherein the first fragment has 20-30 amino acids.

3. The method according to any of the previous claims, wherein the second fragment has 4-9 amino acids.

4. The method according to any of the previous claims, wherein the first fragment comprises a sequence of at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% the length of the peptide.

5. The method according to any of the previous claims, wherein the second fragment comprises a sequence of at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% the length of the peptide.

5. The method according to any of the previous claims, wherein the peptide has a general hydrophobic amino acid content of about 5% to about 80%.

7. The method according to any of the previous claims, wherein the peptide comprises the sequence of any one of the sequences SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20,SEQ ID NO: 22, or SEQ ID NO: 23, SEQ ID NO: 98, SEQ ID NO: 230, SEQ ID NO: 450, SEQ ID NO: 467, SEQ IDNO: 506, SEQ ID NO: 691, SEQ ID NO: 718.

8. The method according to any of the previous claims, wherein the peptide comprises a protecting group, preferably wherein an amino acid side chain of at least one of the first or the second fragments comprises a protecting group.

9. The method according to any of the previous claims, wherein the protecting group is benzyloxy carboyl (Cbz), allyloxycarbonyl (Alloc), tert-butyloxycarbonyl (Boc), 9-Fluorenylmethyloxycarbonyl (Fmoc), trityl (Trt), 2,2,4,6,-7-pentamethyl-2,3-dihydrobenzofuran-5- sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl(TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl (Acm), preferably the protecting group is Fmoc, Cbz, Trt, or Boc.

10. The method according to any of the previous claims, wherein each of NAand NBcomprises a protecting group, wherein each protecting group is 9-fluorenylmethoxycarbonyl (Fmoc) or tertbutyloxycarbonyl (Boc), and / or wherein each of CAand CBcomprises a protecting group, wherein each protecting group is t-butyl (tBu), Trt, 2,4-dimethoxybenzyl (Dmb), 9-fluorenylmethyl (Fm), or benzyl (Bn).

11. The method according to any of the previous claims, comprising contacting the peptide with an acidic solution to provide a deprotected peptide.

12. The method according to any of the previous claims wherein the first fragment has 1-2 cysteine residues, and an amino acid content of about 10% to about 85% cysteine, or wherein the first fragment has 1-5 cysteine residues, and an amino acid content of about 15% to about 45% cysteine.

13. The method according to any of the previous claims, wherein the first fragment has at least about70% sequence identity to any one of SEQ ID Nos: 25-456; preferably 90% sequence identity; more preferably 95% sequence identity; even more preferably identical.

14. The method according to any of the previous claims, wherein the first fragment comprises at least one hydrophobic amino acid residue, preferably wherein each of the at least one hydrophobic amino acid residues is independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan.

15. The method according to any of the previous claims, wherein a side chain of an amino acid residue of the first fragment comprises a protecting group.

16. The method according to any of the previous claims, wherein the first fragment has 4 amino acids and any one of SEQ ID Nos: 217-240, or wherein the first fragment has 5 amino acids and any one of SEQID Nos: 193-216, or wherein the first fragment has 6 amino acids and any one of SEQ. ID Nos: 169-192, or wherein the first fragment has 7 amino acids and any one of SEQ ID Nos: 145-168, or wherein the first fragment has 8 amino acids and any one of SEQ ID Nos: 121-144, or wherein the first fragment has 9 amino acids and any one of SEQ ID Nos: 97-120, or wherein the first fragment has 10 amino acids and any one of SEQ ID Nos: 73-96, or wherein the first fragment has 11 amino acids and any one of SEQ ID Nos:49-72, or wherein the first fragment has 12 amino acids and any one of SEQ ID Nos: 25-48.

17. The method according to any of the previous claims, wherein the second fragment has 1 or 2 cysteine residues, and an amino acid content of about 10% to about 85% cysteine.

18. The method according to any of the previous claims, wherein the second fragment has at least about70% sequence identity to any one of SEQ ID NOs: 25-456; preferably 90% sequence identity; more preferably 95% sequence identity; even more preferably identical.

19. The method according to any of the previous claims, wherein the second fragment comprises at least one hydrophobic amino acid residue, preferably wherein the second fragment has about 5% to about 85% hydrophobic amino acid content; more preferably wherein each of the at least one hydrophobic aminoacid residues is independently glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, or tryptophan.

20. The method according to any of the previous claims, wherein the second fragment has 4 amino acids and any one of SEQ ID Nos: 217-240, or wherein the second fragment has 5 amino acids and any one ofSEQ ID Nos: 193-216, or wherein the second fragment has 6 amino acids and any one of SEQ ID Nos: 169-192, or wherein the second fragment has 7 amino acids and any one of SEQ ID Nos: 145-168, or wherein the second fragment has 8 amino acids and any one of SEQ. ID Nos: 121-144, or wherein the second fragment has 9 amino acids and any one of SEQ ID Nos: 97-120, or wherein the second fragment has 10 amino acids and any one of SEQ ID Nos: 73-96, or wherein the second fragment has 11 amino acids and any one of SEQ ID Nos: 49-72, or wherein the second fragment has 12 amino acids and any one of SEQ IDNos: 25-48.

21. The method according to any of the previous claims, wherein the side chain of an amino acid residue of the second fragment comprises a protecting group, preferably wherein the protecting group is benzyloxycarboyl (Cbz), allyloxycarbonyl (Alloc), Boc, Fmoc, trityl (Trt), 2,2,4,6,-7-pentamethyl-2,3- dihydrobenzofuran-5-sulfonyl (Pbf), 9-xanthenyl (Xan), tosyl (Tos), benzyloxymethyl (Bom), formyl (For), t-butyldimethylsilyl (TBDMS), allyl (Al), o-nitrobenzyl (PNB), p-methylbenzyl (Meb), or acetoamidomethyl(Acm).

22. The method according to any of the previous claims, wherein when NAcomprises a protecting group, then NB comprises a free thiol of a cysteine and CAcomprises a thioether, or wherein when NBcomprises a protecting group, then NAcomprises a free thiol of a cysteine and CBcomprises a thioether.

23. The method according to any of the previous claims, wherein the first fragment comprises the sequence: ILA, IGV, AVP, VCC, SCG, GGV, GSC, CQPV (SEQ ID NO.: 251), GGTN (SEQ ID NO.: 252), VGAS(SEQ ID NO.: 260), GGCQ (SEQ ID NO.: 264), GSVSS (SEQ ID NO.: 266), CAPVY (SEQ ID NO.: 277), CFQPT(SEQ ID NO.: 269), CGGSG (SEQ ID NO.: 270), ASCGV (SEQ ID NO.: 273), LLGNP (SEQ ID NO.: 279), CGYGSG(SEQ ID NO.: 298), SCGCSQ (SEQ ID NO.: 305), GGVCLP (SEQ ID NO.: 306), GCISSS (SEQ ID NO.: 309),GGCQCS (SEQ ID NO.: 312), LCEPAIG (SEQ ID NO.: 316), ASECGSG (SEQ ID NO.: 320), GSCVTNP (SEQ ID NO.:326), VCCCVPA (SEQ ID NO.: 328), GCISSSC (SEQ ID NO.: 333), GGCQCSC (SEQ ID NO.: 336), ILACAPIY (SEQID NO.: 337), CGYGSGCG (SEQ ID NO.: 346), SCGCSQCN (SEQ ID NO.: 353), LLCEPAIG (SEQ ID NO.: 358),GSVSSCQPS (SEQ ID NO.: 362), CAPVYCRRT (SEQ ID NO.: 363), CFQPTCVYS (SEQ ID NO.: 365), CGGSGCGGS(SEQ ID NO.: 366), IGVCGPSPP (SEQ ID NO.: 367), CQPVCPTPT (SEQ ID NO.: 371), AVPCVPSVP (SEQ ID NO.:373), VCCCVPACS (SEQ ID NO.: 376), SCGCSQCNC (SEQ ID NO.: 377), GGVCGPSPP (SEQ ID NO.: 379),VGASCVSLL (SEQ ID NO.: 380), GSCCAPPVY (SEQ ID NO.: 383), ASCGVCLPST (SEQID NO.: 393), GGTNCSPRPI(SEQ ID NO.: 396), LLGNPCSTPS (SEQ ID NO.: 399), GCISSSCCPS (SEQ ID NO.: 405), GSCCAPPVYC (SEQ IDNO.: 407), LCEPAIGCEPS (SEQ ID NO.: 412), GCISSSCCPSC (SEQ ID NO.: 429), GGCQCSCCKPY (SEQ IDNO.:432), ILACAPIYCRRT (SEQ ID NO.: 433), ASECGSGCGVPV (SEQ ID NO.: 440), GGVCLPCLPAAS (SEQ IDNO.: 450), GCISSSCCPSCC (SEQ ID NO.: 453), LLCEPAIGCEPS (SEQ ID NO.: 454), or any combination thereof.

24. The method according to any of the previous claims, wherein the second fragment comprises the sequence: CEPAIGCEPSCG (SEQ ID NO.: 28), CCCVPACSCSVG (SEQ ID NO.: 40), CGCSQCNCCKGG (SEQ IDNO.: 41), CGVCLPSTCPL (SEQ ID NO.: 57), CVTNPCGPIIG (SEQ ID NO.: 62), CCVPACSCSVG (SEQ ID NO.: 64),CISSSCCPSCC (SEQ ID NO.: 69), CEPAIGCEPSC (SEQ ID NO.: 70), CCAPPVYCCKL (SEQ ID NO.: 71),CQCSCCKPYCS (SEQ ID NO.: 72), CAPIYCRRTC (SEQ ID NO.: 73), CGPSPPCITS (SEQ ID NO.: 79), CGSGCGVPVC(SEQ ID NO.: 80), CVPSVPCTPG (SEQ ID NO.: 85), CVPACSCSVG (SEQ ID NO.: 88), CSQCNCCKGG (SEQ IDNO.: 89), CLPCLPAASC (SEQ ID NO.: 90), CGPSPPCITT (SEQ ID NO.: 91), CAPPVYCCKL (SEQ ID NO.: 95),CPTPTCGVG (SEQ ID NO.: 107), CSPRPICVG (SEQ ID NO.: 108), CSTPSCTTG (SEQ ID NO.: Ill), CSCCKPYCS(SEQ ID NO.: 120), CQPSCSEA (SEQ ID NO.: 122), CRRTCGGV (SEQ ID NO.: 123), CVYSCHHG (SEQ ID NO.:125), CLPSTCPL (SEQ ID NO.: 129), CVSLLCRP (SEQ ID NO.: 140), CGCGIIL (SEQ ID NO.: 154), CNCCKGG (SEQID NO.: 161), CLPAASC (SEQ ID NO.: 162), CCKPYCS (SEQ ID NO. : 168), CEPSCG (SEQ ID NO.: 172), CGVPVC(SEQ ID NO.: 176), CGPIIG (SEQ ID NO.: 182), CSCSVG (SEQ ID NO.: 184), CCPSCC (SEQ ID NO.: 189), CKPYCS(SEQ ID NO.: 192), CRRTC (SEQ ID NO.: 193), CGIIL (SEQ ID NO.: 202), CCKGG (SEQ ID NO.: 209), CPSCC(SEQ ID NO.:213), CEPSC (SEQ ID NO.: 214), CSEA (SEQ ID NO.: 218), CGGV (SEQ ID NO.: 219), CHHG (SEQID NO.: 221), CHSL (SEQ ID NO.: 222), CITS (SEQ ID NO.: 223), CGVG (SEQ ID NO.: 227), CTPG (SEQ ID NO.:229), CTTG (SEQ ID NO.: 231), CSVG (SEQ ID NO.: 232), CKGG (SEQ ID NO.: 233), CITT (SEQ ID NO.: 235),CCKL (SEQ ID NO.: 239), or any combination thereof.

25. The method according to any of the previous claims, wherein when NAcomprises a protecting group, then CBis bound to a resin, or wherein when NBcomprises a protecting group, then CAis bound to a resin.

26. The method according to any of the previous claims, wherein when NBcomprises a selenocysteine, then CAcomprises a thioester or selenoester, or wherein when NAcomprises a selenocysteine, then CBcomprises a thioester or selenoester.TJ. The method according to any of the previous claims, wherein joining the first fragment and the second fragment comprises contacting the NBof the second fragment and the CAof the first fragment to provide a selenium-containing peptide, or wherein joining the first fragment and the second fragment comprises contacting the NAof the first fragment and the CBof the second fragment to provide a selenium- containing peptide.

28. The method according to any of the previous claims 26-27, further comprising reacting the selenium- containing peptide with a phosphine to provide a serine-containing peptide, and / or further comprising reacting the selenium-containing peptide with a phosphine to provide an alanine-containing peptide,and / or further comprising reacting the selenium-containing peptide with a phosphine and a radical initiator to provide an alanine-containing peptide.

29. The method according to claim 29, wherein the phosphine is tris(2-carboxyethyl)phosphine (TCEP) and / or wherein CAcomprises an acyl halide, preferably wherein CAcomprises a C-terminal acyl chloride.

30. The method according to any of the previous claims, wherein the first fragment comprises a sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 241-456 and / or wherein the second fragment comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 25-240.

31. The method according to any of the previous claims, wherein NBcomprises an unprotected N- terminal amine.

32. The method according to any of the previous claims, wherein joining the first fragment and the second fragment comprises contacting the NBof the second fragment and the CAof the first fragment; preferably wherein CAcomprises an unprotected C-terminal carboxylate group.

33. The method according to any of the previous claims, comprising contacting the first fragment comprising the unprotected C -terminal carboxylate group with an agent to provide an activated ester, preferably wherein the agent comprises a carbodiimide, wherein the carbodiimide comprises dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), or N,N'- diisopropylcarbodiimide (DIG), or a combination or two or more thereof, or wherein the agent comprises hydroxybenzotriazole (HOBt), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N'- diisopropylcarbodiimide (DIG), l-hydroxy-7-azabenzotriazole (HOAt), or 4-dimethylaminopyridine(DMAP), or a combination of two or more thereof.

34. The method according to any of the previous claims, wherein NB is an unprotected N-terminal amine; preferably comprising contacting the unprotected N-terminal amine of the second fragment with the activated ester to provide the peptide.

35. A composition comprising a peptide obtained by the method described in any of the claims, wherein the peptide comprises a sequence having at least about 85% sequence identity to any one of SEQ ID NOs:1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 95% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 97% sequence identity to any one of SEQ ID NOs: 1-18 and20-1368, or wherein the peptide comprises a sequence having at least about 98% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at leastabout 99% sequence identity to any one of SEQ ID NOs: 1-18 and 20-1368, or wherein the peptide comprises a sequence having at least about 100% sequence identity to any one of SEQ ID NOs: 1-18 and20-1368.

36. The composition according to the previous claim, wherein the peptide is present in the composition with a purity of about 85% or more and the peptide comprises a sequence having at least about 90% sequence identity to any one of SEQ. ID NOs: 1-18 and 20-456, preferably wherein the peptide is present in the composition with a purity of about 90% or more; more preferably wherein the peptide is present in the composition with a purity of about 95% to about 100%.

37. The composition according to any of the previous claims 35-36, further comprises at least one excipient suitable for dermatological use, preferably wherein at least one excipient suitable for dermatological use is selected from ethanol, benzylic alcohol, diol molecule, e.g., ethyleneglycol, propylene diol, butylenodiol, among other.

38. The composition according to any of the previous claims 35-37, comprising:0-30% by weight (% wt.) ethanol;0-3% wt. benzylic alcohol; and0-20% wt. of a diol molecule.

39. The composition according to any of the previous claims 35-38, for use in a cosmetic; namely as a cosmetic for hair, nails, skin or scalp; preferably wherein the cosmetic is a shampoo, a lotion, a serum, a cream, a conditioner, a foam, an elixir, an oil, an aerosol, or a mask.STATEMENT UNDER ARTICLE 19 (1)D1 discloses methods for preparing peptides by conventional methods of peptide synthesis.D3 discloses peptide compositions and cosmetic applications but does not disclose a peptide production method involving two specific fragments— each representing10-90% of the final peptide length— and the defined amino acid profiles or hydrophobic residues required by amended Claim 1.D4 relates to bioactive peptides with antimicrobial properties. Although D4 does not disclosed a fragment-based joining method, defined cysteine percentages, or purity thresholds of at least 80%.D5 discloses a method for preparation of peptide, but not the ranges of amino acids per fragment, nor the percentage of cysteine residues or hydrophobic content as now claimed.D2 discloses peptides for cosmetic use, including sequences containing cysteine, and compositions comprising said peptides. D2 refers to solid-phase synthesis and fragments but does not disclose a method comprising the specific joining of two fragments with defined lengths and structural features to form a stable peptide of up to 32 residues, having a high cysteine content and a high purity level.Documents D1 -D5 fail to disclose a peptide synthesis method involving: joining of two peptide fragments in solution or resin, specific lengths for each fragment (first: 7-30 amino acid residues; second: 4-13 amino acid residues], defined overall sequence length (1 -32 amino acid residues I, sequence selection from SEQ ID NOs: 1 -1368, at least 15-50% cysteine content (1 -5 residues], inclusion of hydrophobic residues from a defined group, and purification to at least 80% wt.D2 can be considered the closest prior art. The technical difference between the claimed subject matter and D2 is the method of synthesis: specifically, the construction of a peptide via fragment coupling using fragments of precise lengthsand sequences, with specified amino acid content (namely, cysteine and hydrophobic residues), and achieving a defined purity threshold.The technical effect conferred by the fragment-based synthesis approach of Claim 1 is the controlled assembly of short, cysteine-rich peptides with increased yield, structural integrity, and scalability, enabling synthesis of otherwise unstable or difficult-to-produce sequences.Thus, the objective technical problem is how to develop an efficient and scalable method for producing short, cysteine-rich peptides with defined purity and structure, avoiding aggregation or degradation.The above objective problem is solved by the joining of two carefully designed peptide fragments in solution or resin, using sequences enriched in cysteine and optionally hydrophobic residues, followed by purification to a defined level.The prior art document D5 provides no suggestion or indication that fragment joining strategies with specific amino acid content and purification thresholds could be used to produce cysteine-rich peptides with high purity, stability, avoiding aggregation and purification issues, mitigating these problems.D1 -D5 do not suggest the claimed synthesis approach, nor do they combine the concept of controlled fragment coupling and the specific technical effect of enhancing production of defined peptides with challenging sequences (e.g . , disulfide-rich, aggregation-prone).There is no incentive for the skilled person to combine the teachings of D2 with D1 , D3-D5 and arrive at the new Claim 1 , which uniquely integrates structural, sequence-based, and process parameters to overcome prior art limitations.